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ABSTRACT 
A school of literature has shown that Annexin-A1 (Anx-A1) is an 
endogenous anti-inflammatory protein that exerts a regulatory 
control over the innate immune system in order to restore 
homeostasis after an inflammatory reaction. Surprisingly, recent 
published works have highlighted that Anx-A1 has an alternate role in 
the adaptive immune system by positively modulating the strength of 
TCR signalling and biasing helper-subset differentiation. 
Dendritic cells are a class of innate leukocytes, poised at the 
environmental interface, that are the essential immune cells 
responsible in the initiation of T-cell driven responses. These findings 
provided the foundation for this PhD project, the principal aim of 
which is to provide a link between the disparate effects of Annexin-A1 
in innate and adaptive immunity by investigating the role of 
endogenous Annexin-A1 in dendritic cell biology and its effector 
function as an antigen-presenting cell towards T cell activation and 
differentiation. To address this hypothesis, I cultured bone marrow-
derived dendritic cells from AnxA1-deficient mice or control 
littermates and stimulated with LPS (100ng/ml) then compared 
phenotypic and functional characteristics. 
My results demonstrate that Anx-A1-/- bone marrow derived dendritic 
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cells show an increased number of CD11c+ cells expressing high 
levels of some maturation markers such as CD40, CD54 and CD80 
and a decreased capacity to take up antigen compared to control 
Anx-A1+/+ cells. However, analysis of LPS-treated dendritic cells from 
Anx-A1-/- mice demonstrated a diminished up-regulation of 
maturation markers, a decreased migratory activity in vivo and an 
attenuated production of the inflammatory cytokines Interleukin (IL)-
1β, Tumour Necrosis Factor (TNF)-α and IL-12.  
This defect was resultant of an impaired Nuclear Factor (NF)-κB/DNA-
binding activity due to lack of Anx-A1 signalling as demonstrated by 
the reduced activation of Extracellular-signal Regulated Kinase (ERK) 
1/2 and protein kinase B (PKB)/Akt compared to cells from control 
littermates. 
As a consequence of these defects, I assessed the antigen-
presenting/T-cell activating capabilities of these DC. Anx-A1-/- DC 
showed an impaired capacity to stimulate T cell proliferation and 
differentiation in allogeneic mixed leukocyte reaction. To dissect this 
biologically relevant phenomenon further, I employed an antigen-
specific, T-cell restricted model; a co-culture system of chicken 
ovalbumin peptide-pulsed, LPS-matured bone marrow-derived DC 
incubated with transgenic TCR T cells from OT-I/RAG-1-/- (OT-I, OT-
I/CD8+) or OT-II/ RAG-1-/- (OT-II, OT-II/CD4+) mice. Peptide-pulsed, 
LPS-matured AnxA1-/- DC failed to initiate an appropriate T cell 
activation in both OT-I and OT-II T cells indicated by reduced cell 
proliferation when compared to T cells co-cultured with peptide-
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pulsed, LPS-matured AnxA1+/+ DC. Additionally, comparison of 
peptide-pulsed, LPS-matured AnxA1-/- DC with AnxA1+/+ DC 
counterparts detected severely diminished levels of IL-2 from co-
cultures with OT-I T cells and ablated IFN-γ production from co-
cultures with both OT-I and OT-II T cells. 
In conclusion, AnxA1 seems to act as a positive modulator of 
immunogenic activation of DC, whereby the AnxA1 signal pathway 
has a probable synergism with the TLR4 signalling cascade. DC-
derived AxnA1 appears to contribute in promoting T cell activation 
with a larger influence on OT-I/CD8+ T cells than OT-II/CD4+ T cells. 
Altogether these findings suggest that inhibition of Anx-A1 expression 
or function in dendritic cells might represent a useful way to 
modulate the adaptive immune response and pathogen-induced T 
cell-driven immune diseases. 
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1. INTRODUCTION 
1.1. THE INFLAMMATORY RESPONSE 
Inflammation is an adaptable response that is sparked by nocuous 
conditions such as tissue injury and infections. It is generally thought 
to be a beneficial, controlled process but can become detrimental if 
dysregulated resulting in patho-physiological events and death. 
Despite the aetiology, the inflammatory response supposedly evolved 
as a flexible reaction for restoring homeostasis. Therefore, a 
successful inflammatory response involves the elimination of the 
pernicious agents followed by a resolution and repair phase 
(Medzhitov, 2008). 
 
This process is achieved by the immune system fulfilling its four main 
duties. Firstly, there is immunological recognition; that is the 
presence of an infection must be detected, which is performed by 
leukocytes of innate immune system and lymphocytes of the adaptive 
immune system. The second task is the involvement of immune 
effector functions to contain and possibly eliminate the infection by 
employing the coordination of complement proteins in the blood, 
antibodies and the killing capacities of lymphocytes and some 
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leukocytes. Whilst the destructive nature of these cells is in play, the 
immune response must be managed as not to cause unnecessary 
damage to the body. This is the third undertaking referred to as 
immune regulation; the ability of the immune system to self-
regulate and thus a very important feature of immunity. Our 
environment is inundated by microorganisms, many of which cause 
disease. Yet despite this incessant exposure metazoan hosts only 
rarely become ill. The fourth facet is to protect against recurring 
disease due to the same pathogen. This unique feature is 
immunological memory and it is the capability of the adaptive 
immune system to execute this course of action so once exposed to 
an infection, an individual will formulate stronger and more 
immediate response to subsequent exposures creating protective 
immunity (Murphy et al., 2008). 
 
The inflammatory process, which eradicates pathogens or repairs 
tissue damage, broadly involves both divisions of the immune 
system: innate immunity and adaptive immunity to effectively 
complete its course. 
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1.1.1. Innate Immunity 
The innate immune system is present, in comparable forms, in all 
organisms of the Eukaryotic domain. From the single-celled 
Amoebozoa kingdom to the complex multi-cellular Animalia kingdom, 
this system is a phylogenetically preserved mechanism that provides 
rapid, generalised (i.e. antigen non-specific) host defence against 
noxious agents - hence its name. The innate immune system of 
metazoan hosts consists of several elements, some of which would 
not traditionally, in an immunological sense, be considered part of the 
immune system. These elements include anatomical barriers, 
secretory molecules and cellular components. 
 
There are three aspects to the anatomical barriers (Brodell and 
Rosenthal, 2008). Firstly, the mechanical wall that include the 
external epithelial layers, i.e. the skin (Burtenshaw, 1945, 
Burtenshaw, 1942), and the internal epithelial layer that are 
armoured with mucosal linings, i.e. the mouth, intestines and anus, 
as well as equipped with the specialized feature of motile cilia to 
deflect debris and bacteria, i.e. the broncho-pulmonary tract 
(Knowles and Boucher, 2002). The second aspect comprises of 
chemical factors; fatty acids in sweat and its low pH inhibit bacterial 
growth (Wille and Kydonieus, 2003, Fluhr et al., 2001, Kabara et al., 
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1977, Nieman, 1954), lysozyme and phospholipases present in tears, 
saliva and nasal secretions weaken bacterial membranes (Boman, 
1995), and low molecular weight proteins with antimicrobial activity 
known as defensins (Ganz, 2003, Fellermann and Stange, 2001). 
Thirdly are the biological factors that originate from the cooperation 
between beneficial organisms and their host. The normal flora of 
commensals living in host skin and gastrointestinal tract prevent 
colonisation of opportunistic pathogens by competitive survival for 
resources and by secreting toxic substances (Cheesman and 
Guillemin, 2007). 
 
Another constituent of innate immunity are secretory molecules, 
often triggered when the anatomical barriers are compromised and 
pathogen incursion or tissue abrasion occurs. It entails the 
complement system, the coagulation system and other molecules. 
The complement system is a group of small pro-proteins mainly 
produced and secreted by the liver into the circulation. They are the 
major non-specific humoral defence mechanism and once activated 
can lead to increased vascular permeability (oedema), recruitment of 
phagocytes (Jose, 1987) and lysis and opsonisation of bacteria and 
parasites (Jose, 1987, Mackay et al., 2001). The inflammatory 
relevance of the coagulation system’s involvement chiefly depends on 
the severity of the tissue damage (Cicala and Cirino, 1998, McGilvray 
and Rotstein, 1998). Some products of coagulation contribute to 
increased vascular permeability (Lee et al., 1996) and as 
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chemoattractants for phagocytes (Bar-Shavit et al., 1984, Bar-Shavit 
et al., 1983a, Bar-Shavit et al., 1983b). Moreover, some coagulation 
products have direct antimicrobial activity such as platelet-derived β-
lysin, which acts as a cationic detergent in the killing of Gram-
positive bacteria (Donaldson and Tew, 1977, Donaldson et al., 1974). 
Other molecules include lactoferrin and transferrin that are 
responsible for chelating iron, an essential metal in bacterial nutrition 
and growth (Singh et al., 2002). 
 
The third facet of innate immunity is cellular agents. These immune 
cells offer a potent, rapid and broad first line of defence. Some are 
resident in tissues and organs such as macrophages and dendritic 
cells. Other are recruited to the site of inflammation such as 
neutrophils, eosinophils, monocytes and natural killer (NK) cells 
(Figure 1.1). 
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Figure 1.1. Cells and mediators of the innate and adaptive immune system. 
The innate immune response functions as the first line of defense against infection. It 
consists of soluble factors, such as complement proteins, and diverse cellular 
components including basophils, eosinophils, neutrophils, mast cells, macrophages, 
dendritic cells and natural killer cells. Natural killer T cells and γδ T cells are cytotoxic 
lymphocytes that straddle the interface of innate and adaptive immunity. 
 
Neutrophils and eosinophils are polymorphonuclear cells both of 
which possess granules containing highly reactive compounds that kill 
bacteria (Faurschou and Borregaard, 2003, Borregaard et al., 1993) 
and parasites (Molina et al., 1988, Hamann et al., 1987, Gleich et al., 
1979) respectively but in addition cause collateral tissue damage 
(Weissmann et al., 1978, Goldyne, 1975). Neutrophils also 
phagocytose foreign organisms and kill them intracellularly (Dale et 
al., 2008). Resident macrophages and dendritic cells, and migratory 
inflammatory monocytes that differentiate primarily into dendritic 
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cells but also macrophages at sites of inflammation (Banchereau et 
al., 2000), function to phagocytose and kill microorganisms 
intracellularly (Nagl et al., 2002, Banchereau et al., 2000). 
Furthermore, macrophages contribute to inflammation resolution and 
tissue repair (Serhan et al., 2006, Serhan and Savill, 2005) and 
dendritic cells, and to a much lesser extent macrophages, act as 
antigen-presenting cells (APC) that are crucial for the initiation of the 
adaptive immune responses (Banchereau and Steinman, 1998, 
Steinman and Hemmi, 2006). NK cells, although not usually involved 
in the classical inflammatory response, are important innate immune 
cells required for the detection and eradication of virally infected cells 
and tumour cells (Cerwenka and Lanier, 2001, Lodoen and Lanier, 
2005). 
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1.1.2. Adaptive Immunity 
Antigen presenting cells (APC), like dendritic cells (Inaba et al., 
1990), are involved in innate immunity but also are a paramount link 
to the adaptive immune system by participating in the activation of 
both T and B lymphocytes (Jego et al., 2005, Ni and O'Neill, 1997). A 
characteristic feature of APC is the expression of cell surface 
molecules, class I and class II major histocompatibility complex 
(MHC), which forms a complex with antigens (components from 
foreign microbes processed when endocytosed) and is presented so 
that the appropriate lymphocytes can be activated. B cells also 
express class II MHC molecules and also function as APC. B cells are 
very effective in presenting antigen to memory T cells, especially 
when the antigen concentration is low because surface 
immunoglobulin on the B cells binds antigen with a high affinity 
(Rodríguez-Pinto, 2005). After exposure to antigen, naïve B and T 
cells differentiate into effector lymphocytes. B cells differentiate into 
effector B cells called plasma cells whose primary function is the 
production of antibodies.  Similarly, T cells can differentiate into 
either a single subset of T cytotoxic (Tc) cells that primarily operate 
to destroy tumour cells and virally infected cells or a single subset of 
T helper (Th) cells that largely provide help to cytotoxic T-
lymphocytes and B-lymphocytes by augmenting the roles of these 
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cells. 
 
Antigen specificity of T and B cells is accomplished through 
recognition by the T cell receptor (TCR) and the B cell receptor (BCR), 
respectively. The TCR and BCR are similar in that each receptor is 
specific for one antigenic determinant but they differ in that BCR are 
divalent and have their antigen receptors cross-linked by antigen 
while TCR are monovalent and do not require cross-linking (Weiss 
and Littman, 1994, Alberola-Ila et al., 1997). Each B and T cell has a 
receptor that is unique for a particular antigenic determinant and 
there is a vast array of different antigen receptors on both B and T 
cells (Janeway, 2005, Honjo et al., 1989). B cells utilise cell surface-
bound immunoglobulin as antigen receptor and the specificity of that 
receptor is the same as the immunoglobulin that it is able to secrete 
after activation. B cells recognize the following antigens in soluble 
form: proteins, nucleic acids, polysaccharides, lipids and haptens 
(Elgert, 2009). In contrast, the overwhelming majority of antigens for 
T cells are proteins, and these must be fragmented and recognized in 
association with MHC products expressed on the surface of APC, not 
in a soluble form. T cells are grouped functionally according to the 
class of MHC molecules that associate with the peptide fragments of 
the protein; helper T cells recognize only those peptides associated 
with class II MHC molecules, and cytotoxic T cells recognize only 
those peptides associated with class I MHC molecules. This 
constrained detection of peptides by T cells is established during T 
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cell development in the thymus and is termed self-MHC restriction. 
For T cells to recognize and respond to a foreign protein antigen, it 
must recognize the MHC on the APC as self-MHC. Helper T cells 
recognize antigen in context of class II self-MHC and cytotoxic T cells 
recognize antigen in context of class I self-MHC (Doyle and Mamula, 
2001, Koch and Stockinger, 1991). 
 
After Th cells recognize specific antigen presented by an APC, they 
initiate several key immune processes that include: 1) selection of 
appropriate effector mechanisms; 2) induction of proliferation of 
appropriate effector cells; and 3) enhancement of the functional 
activities of other leukocytes. Classically, Th effector subsets were 
categorised into two groups. But over the last decade, further insight 
into patho-physiological conditions has led to the discovery of new Th 
effector subsets, namely Th17 (Annunziato and Romagnani, 2009, 
Liew, 2002, Ma et al., 2010, Stockinger et al., 2007). When naïve T 
cells encounter antigen in secondary lymphoid tissues, they become 
activated; these activated, non-committed Th0 cells and are capable 
of differentiating into Th1 cells, Th2 cells, Th17 cells, which are 
distinguished by the cytokines they produce. Whether a Th0 cells 
becomes a Th1, a Th2 or a T17 cell depends upon the cytokine 
microenvironment, which is influenced by antigen-bearing APC (Feili-
Hariri et al., 2005, Gutcher and Becher, 2007, Steinman and Hemmi, 
2006). Some antigens stimulate IL-4 production that favours the 
generation of Th2 cells while other antigens stimulate IL-12 
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production, which favours the generation of Th1 cells. Equally 
important, each subset can exert inhibitory influences on the other; 
Th1-derived IFN-γ inhibits proliferation of Th2 cells and differentiation 
of Th17 cells, and Th2-derived IL-10 inhibits the production of IFN-γ 
by Th1 cells. In addition, IL-4 inhibits formation of Th1 cells and 
differentiation of Th17 cells (Farrar et al., 2002, Flavell et al., 1999, 
Male et al., 2006). Subsequently, the differentiating T cells initiate 
transcriptional pathways as well as activate production of cytokines in 
order to promote and propagate lineage commitment of the T helper 
cell subset (Figure 1.1.2.1). Thus, the immune response is adapted 
and directed to deal with the pathogen encountered – cell-mediated 
responses for intracellular pathogens or antibody responses for 
extracellular pathogens. 
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Figure 1.1.2.1. Intrinsic commitment and microenvironment signalling 
resulting in T helper cell subset differentiation. 
Naïve T cells become activated by APC and in the presence of a select APC-derived and 
T-cell-derived cytokine milieu initiate distinct transcription factors to drive the 
development of diverse T helper cell subsets. 
 
Th1, Th2 and Th17 cells affect different cells and influence the type of 
immune response; Th1 cytokines activate macrophages and 
participate in the generation of cytotoxic lymphocytes (CTL), resulting 
in a cell-mediated immune response. In contrast Th2 cytokines help 
to activate B cells, resulting in antibody production; Th2 cytokines 
also activate eosinophils, mast cells and basophils, which are central 
to immune responses to extracellular parasites such as helminths. 
The relatively recently identified Th17 cells constitute a group of T 
cells collectively termed neutrophil-regulatory T (Tn) cells that also 
 32 
include γδ T cells and NKT cells (Ley et al., 2006). All these cell types 
secrete IL-17A, which stimulate epithelial cells, endothelial cells and 
fibroblasts to secrete IL-8 (Fossiez et al., 1996), a potent neutrophil 
chemokine, which activates and recruits neutrophil to inflammatory 
sites. Th17 cells also produce IL-23, which has been reported to play 
a prominent role in the regulation of granulopoiesis (Figure 1.1.2.2) 
(Smith et al., 2007, Stark et al., 2005). 
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Figure 1.1.2.2. Main populations of CD4+ T helper cells and their effector 
functions. 
Effector T helper cell subsets and the biological significance of their effector functions in 
driving immunity against an array of pathogenic infections. Also their patho-physiological 
contributions to human diseases and different disease models. 
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1.2. DENDRITIC CELLS 
Dendritic cells (DC), a heterogeneous population of leukocytes, are 
unique antigen-presenting cells with the ability to induce primary 
immune responses. DC capture and transfer information from the 
external environment to the cells of the adaptive immune system 
(Steinman, 1991, Steinman et al., 1980). DC are not only critical for 
the induction of primary immune responses, thus permitting 
establishment of immunological memory; but may also be important 
for the induction of immunological tolerance, as well as for the 
regulation of the type of T cell–mediated immune response (Steinman 
et al., 2000). 
 
The identification of dendritic cells by Steinman and Cohn (Steinman 
and Cohn, 1973) and the elucidation of their crucial role as antigen-
presenting cells (Steinman, 1991) was a major advancement in 
immunology. DC are the central policing leukocytes of the immune 
system, which initiate innate as well as adaptive immune responses; 
they begin in an immature form as sentinels constantly sampling 
antigens at peripheral sites. On encountering microbial products or 
danger signals they migrate to lymphoid organs and mature into an 
antigen-presenting entity now capable of activating T cells. 
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To detect pathogens or other forms of danger, DC are equipped with 
a variety of pattern recognitions receptors (PRR). Amongst the PRR, 
the Toll-like receptors (TLR) are a family of highly conserved, 
germline-encoded transmembrane receptors (Medzhitov and 
Janeway, 2000, Mogensen, 2009). Structurally, TLR are typical type I 
receptors with an extracellular domain consisting of leucine-rich 
repeats (LRR), one short transmembrane region and an intracellular 
domain. The latter is highly homologous with the respective 
counterparts of the IL-1 receptor and Toll and thus named the Toll-
IL-1R (TIR) domain (Akira, 2004). The LRR domains of the TLR 
directly bind invariant “pathogen associated molecular patterns” 
(PAMPs) that are conserved products of microbial metabolism 
expressed by virtually all classes of microorganisms, including 
bacteria, viruses fungi and parasites. One characteristic common to 
all PAMPS is that they are produced by microorganisms but not by 
host cells (Bianchi, 2007). 
 
At present, thirteen mammalian TLR motifs have been identified, 
ten in human and twelve in mice, as well as their co-receptors, 
accessory molecules and each individual signal transduction. TLR2 in 
combination (heterodimerisation) with TLR1 or TLR6 recognises a 
variety of lipoproteins, lipopeptides or polysaccharides of bacterial, 
viral or fungal origin (Akira and Hemmi, 2003, Into et al., 2004, 
Takeda and Akira, 2004, van der Aar et al., 2007, Zeuthen et al., 
2008). TLR3 seems to be highly specific for double-stranded (ds)RNA, 
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which might be either genomic viral RNA or dsRNA intermediates 
produced during viral replication. TLR4, the first mammalian TLR 
identified, is the main receptor for bacterial derived 
lipopolysaccharides and in addition senses some viral envelope 
proteins. TLR4 may also act as a receptor for stress-induced 
molecules such as heat shock proteins (HSP) (Vabulas et al., 2002). 
TLR5 recognises flagellin. TLR7 and TLR8 represents receptors for 
single stranded RNA (ssRNA) from RNA viruses like influenza or HIV 
(Diebold et al., 2004, Heil et al., 2004). Synthetic ligands for TLR7 
have also been identified, which include guanosine analogs like 
loxoribrine, imiquimod and resiquimod (also acts through human 
TLR8). TLR9 originally was described as a receptor for CpG motif 
containing unmethylated bacterial or synthetic DNA but recently the 
spectrum was broadened to include viral DNA from viruses of the 
herpes family including HSV-1, HSV-2 and MCMV-5 (Lund et al., 
2003, Krug et al., 2004, Hochrein et al., 2004). Hemozoin, a 
digestion product of haemoglobin by the malaria parasite has been 
recently added to the list of TLR9 ligands. Hemozoin is until now the 
only non-nucleic acid ligand for TLR9 (Coban et al., 2005). 
TLRs can be classified using several categories: cellular localisation, 
amino acid homology, nature of their specific ligands or use of 
adaptor molecules. TLR7, -8, -9 are grouped together into the TLR9 
subfamily based on their high amino acid sequence similarity, 
localisation in endosomes, the requirement for endosomal 
acidification for ligand binding and their structurally related ligands: 
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nucleic acids (Wagner, 2004). At least in DC, location and ligand 
recognition of nucleic acids are also attributes of TLR3 however 
sequence homology to the TLR9 subfamily is comparatively poor. 
TLR2 family members (TLR1, -2, -6), TLR4 and TLR5 are localised to 
the extracellular membrane and thus recognise extracellular PAMPs 
and TLR ligands. 
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1.3. DENDRITIC CELLS AS ANTIGEN-PRESENTING CELLS 
Upon pathogenic encounter or tissue insult, DC initiate a maturation 
process into highly specialised antigen-presenting cells (APC), 
thereby activating cellular mechanisms in order to decrease antigen 
(Ag)-processing capacities, to enhance expression of MHC Class I or 
II and co-stimulatory molecules and migrate to secondary lymph 
nodes, where they trigger naïve T cells. The fate of naive T cells is 
determined by three stimulatory signals that are provided by 
pathogen-primed mature DC (Ni and O'Neill, 1997). Signal 1 results 
from the ligation of the T-cell receptor (TCR) to pathogen-derived 
peptides, presented on MHC class I or II molecules on the cell surface 
of DC, and determines the antigen-specificity of the response (Nel 
and Slaughter, 2002). However, the initiation of protective immunity 
also requires T-cell co-stimulation. Signal 2 is the co-stimulatory 
signal, which involves a balanced combination of signals to T-cell via 
the binding of the DC co-stimulatory surface molecules particularly 
butyrophilin family members B7-1 (cluster of differentiation (CD) 80) 
and B7-2 (CD86) to their T-cell cell surface counterparts CD28 or 
cytotoxic T lymphocyte antigen 4 (CTLA-4/CD152) on naïve T cells as 
well as reciprocal signalling from the T-cell to the DC via CD40 on DC 
ligating to CD40L on activated T cells (Chambers and Allison, 1997).  
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The affinities of the B7 molecules and their interactions with CD28 or 
CTLA-4 differ substantially. B7-1 binds to CTLA-4 with highest affinity 
(Kd = 0.2µM); B7-1-CD28 and B7-2-CTLA-4 bind with intermediate 
affinities (Kd = 4µM and 2.6µM respectively); and B7-2 binds to CD28 
with lowest affinity (Kd = 20µM) (Bhatia et al., 2006). In addition, 
these molecules have differential expression and regulation profiles 
on APC. B7-2 is constitutively expressed and rapidly up-regulated 
upon stimulation; in contrast, B7-1 is generally absent on immature 
cells and is induced upon activation with slower expression kinetics 
(Coyle and Gutierrez-Ramos, 2001). These observations have led to 
the hypothesis that B7-2 interactions are required for initial T cell co-
stimulation, whereas B7-1-CD28 interactions are more involved in the 
sustained T cell activation; however this model remains to be 
corroborated. 
 
Recently, intense research in the field of co-stimulation was to dissect 
whether B7-1 and B7-2 have overlapping and redundant roles in 
determining polarisation of Th effector cells. Ligation of CD28 and 
CTLA-4 may directly regulate non-polarised T helper (Th) 
differentiation because CD28 activation facilitates Th2 responses, 
whereas CTLA-4 inhibits Th2 responses. Furthermore, these findings 
suggest a model that the engagement of either CD28 or CTLA-4 is 
more critical in the differentiation fate of non-polarised Th cells rather 
than the B7 molecules themselves (Khattri et al., 1999, Oosterwegel 
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et al., 1999b). Although, emerging evidence strongly support the 
importance of B7 molecules in signalling to regulatory T cells. Mice 
lacking B7-1 and B7-2 have a profound decrease in the CD4+ CD25+ 
regulatory T cell subset population (Salomon et al., 2000). In the 
absence of signal 2, Th cells become anergic (Gimmi et al., 1993); 
this is important when DC present self-antigens to naïve Th cells. 
 
TCR stimulation and co-stimulation allow naive Th cells to develop 
into effector Th cells, undoubtedly accompanied by high-level 
expression of selective sets of cytokines (Curtsinger et al., 1999). 
The balance of these cytokines and the resulting class of immune 
response strongly depend on the conditions under which DC are 
primed for the expression of the T-cell-polarizing molecules, which 
constitute signal 3. Indeed, bioactive pathogen-derived compounds 
that polarize DC for their expression of these Th-polarizing cytokines 
largely tune the adaptive immune response to pathogens. These DC-
derived cytokines with Th-cell-polarizing capacity have been well 
documented and are integral to T-cell polarisation (Figure 1.3.1). 
Several Th1-cell-polarizing cytokines are interleukin (IL)-12 and its 
family members IL-23 and IL-27, and Type 1 IFN; whereas Th2-cell-
polarizing cytokines are monocytic chemotactic protein 1 (MCP-
1)/CCL2; and the regulatory T-cell-polarizing factors IL-10 and 
transforming-growth factor-β (TGF-β) (de Jong et al., 2005, 
Kapsenberg, 2003). DC activation also triggers production of pro-
inflammatory cytokines including TNF-α, IL-1β and IL-6 (Blanco et al., 
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2008), which are suspect in the initial inflammatory scenario. 
 
Figure 1.3.1. The three signals required for activating naïve T cells. 
The three signalling events necessary for T cell activation: 1. T-cell receptor engagement 
and the activation events signalling through the TCR and the co-receptor, CD3. 2. Co-
stimulatory molecule ligation and the signalling cascades through their counterparts. 3. 
Cytokine receptor signalling acting either in an autocrine manner, such as DC-derived 
TNF-α inducing itself and IL-1β, or in a paracrine manner, for instance the polarising 
cytokines IL-12 and CCL2. 
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1.4. DENDRITIC CELL SUBSETS 
The development of culture systems for the production of DC from 
monocytes or from myeloid precursors under the influence of 
granulocyte-macrophage colony stimulating factor (GM-CSF) has 
provided a readily available model for detailed study (Caux et al., 
1996, Inaba et al., 1992). This unifying theory of an experimentally 
practical culture model has also lead to the discovery of DC with 
distinctive phenotypes within lymphoid tissue. 
 
All DC subsets possess the fundamental functionalities: capture 
foreign and host entities and then process them into antigens for 
MHC presentation to T cells, which, in turn, become activated. But 
there are additional features of DC functions of immunological 
significance as well as many specialisations that provide biological 
rationale to justify the existence of multiple DC subtypes (Shortman, 
2000). 
 
The logic for the existence of different DC subsets is that DC are 
localised in various tissues and organs and consequentially these 
tissue-specific DC display differences in chemokine receptors, 
adhesion molecules and addressins to maintain their residency in 
their respective tissue sites. These distinct DC types also share 
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variation in their expression recognition and phagocytic-endocytic 
receptors, such as TLR, lectin receptors, allowing for recognition and 
response to different yet diverse ranges of insult and potential 
pathogens and also dictate functional differences. This possibly 
suggests that the actions of discrete DC subtypes streamline the 
initiation of the appropriate adaptive responses by influencing T cell 
activation and differentiation into unique effector T cell subsets to 
target the stimuli encountered (Manickasingham et al., 2003). DC are 
involved not only in inducing immunity, but also in regulating immune 
tolerance. Although these two central functions can be correlated to 
various developmental points of a single DC subset, it is plausible 
that further specialisation is required for inducing tolerogenic DC 
functional potential. 
 
The presence of microbial products or tissue damage in the sampling 
environment of the DC initiates a transition from antigen-capturing 
cells to antigen-presenting cells that correlate with decreased antigen 
uptake, increased half-life of surface MHC-peptide complexes, 
upregulation of co-stimulatory molecules, alteration in chemokine 
receptor expression and production of cytokine that are central to 
effector T cell differentiation. Despite the fact that the transition 
results in little phenotypic resemblance to its immature counterpart, 
the lifecycle of DC during an immune response is a very well defined 
process; but not all DC life cycles share this common fate (Wu and 
Dakic, 2004). 
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A DC lineage-specific marker has not yet been identified and the 
subsets of DC in humans and mice are therefore currently defined by 
lineage- (Lin-) MHC class II+ (MHC-II+) cells in combination with 
various cell surface markers. Although the development of murine DC 
from early haematopoietic precursors is currently a rapidly expanding 
field with intense intellectual dissection, there are five major DC 
subsets that have been identified, to date, in lymphoid tissues of 
uninfected mice. Phenotypically, all mouse DC are defined by a co-
expression of CD11c and MHC-II; high expression levels of these 
markers is characteristic of all mature DC in mice (Metlay et al., 
1990). Further characterisation is based on the expression four other 
surface markers that distinguishes the DC subsets; and these are 
CD4, CD8αα-homodimer, CD11b and DEC-205 (CD205). These 
murine DC subsets have loosely identifiable human DC equivalents 
(Figure 1.4.1). 
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Figure 1.4.1. Dendritic cell subsets and their major function in vivo. 
The different dendritic cell subtypes in human and mouse and their consequent influence 
on distinctive T cell responses. 
 
Anatomically, the thymus, spleen and lymph nodes (mesenteric and 
skin-draining) are DC-rich sites of the lymphoid environments. The 
subset populations that constitute thymic DC include mainly 
CD8α+CD4-CD205hiCD11b- cells (~70%) and to a minor extent 
CD8αlo/-CD4-CD205+CD11b- cells (~30%) (Crowley et al., 1989, Henri 
et al., 2001, Vremec et al., 2000). However in the spleen and lymph 
nodes, only about 20% of DC are CD8α+ phenotype. The mouse 
CD8α+ DC are non-migrating resident DC derived from a bone 
marrow precursor, distinct from monocytes that continuously 
propagate the subset populous in lymphoid organs. These cells vary 
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in a number of central functions from their CD8α- counterparts. In a 
homeostatic state, CD8α+ DC are in an immature state with high 
surface levels of MHC class II, low but detectable levels of co-
stimulatory molecules (Wilson et al., 2003) and produce TGF-β 
(Yamazaki et al., 2008). The CD8α+CD205+ DC are mainly found in T-
cell rich areas of the peripheral lymphoid organs such as the 
periarteriolar lymphatic sheaths (PALS) of the spleen (Pulendran et 
al., 1997) and paracortical regions of the lymph nodes (Inaba et al., 
1997). Upon activation or during intracellular pathogenic infection, 
they are chief producers of IL-12 and become the main presenters of 
pathogen antigens including efficiently cross-presenting exogenous 
cell-bound and soluble antigens on MHC class I (den Haan et al., 
2000, Pooley et al., 2001). Therefore, promoting CD8α+ CTL and 
antibody responses. 
 
CD8α+ DC also have immunoregulatory properties and help maintain 
tolerance to self-tissues. In the thymus, CD8α+ DC are proposed to 
play a principal role in the purging of self-reactive T cells from the 
developing repertoire. Also, CD8α+ DC are believed to have a unique 
regulatory role in preventing self-reactive responses (Fazekas de St 
Groth, 1998). In vitro studies revealed that when immature splenic 
CD8α+ DC, isolated from mice, are co-cultured with primary CD4+ or 
CD8+ T cells, or secondary CD4+ T cells they produced reduced 
proliferative responses in all cases compared to CD8α- DC 
counterparts (Kronin et al., 2001, Winkel et al., 1994). Further 
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studies have shown that despite equivalent activation states between 
CD8α+ and CD8α- DC as well as similar initial T-cell activation events, 
CD8α+ DC induced a higher incidence of apoptotic T-cell death per 
division cycle (Rizzitelli et al., 2006). These early signals from CD8α+ 
DC to T cells control the extent of T-cell proliferation; the nature of 
the signals is unclear but it is apparent that it is not Fas-ligand 
dependent (Suss and Shortman, 1996, Winkel et al., 1997). 
 
All DC subsets express some members of the TLR family, for instance 
TLR9, but CD8α+ DC exclusively express TLR3 that equip these cells 
with the ability to mount potent immune responses against viral 
infections (Belz et al., 2004). In addition to being the instigators of 
robust CTL responses, in the periphery, CD8α+ DC are restricted to 
lymphoid organs therefore, these cells are highly capable of acquiring 
antigens transferred from migrating DC that enter lymph nodes 
(Carbone et al., 2004, Vermaelen et al., 2001) as well as cross-
presentation (den Haan et al., 2000). Consequently, CD8α+ DC are 
noteworthy in directing CTL immunity, recalling virus-specific memory 
CD8+ T cells (Belz et al., 2007) and priming T cells against 
intracellular infections such as Listeria monocytogenes (Belz et al., 
2005), Salmonella typhimurium (Kirby et al., 2002), Toxoplasma 
gondii (Yarovinsky et al., 2006, Yarovinsky et al., 2005) and malarial 
Plasmodium spp (Lundie et al., 2008, Sponaas et al., 2006). 
 
Although most characteristic DC surface markers, like CD4, are also 
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expressed on human DC, CD8α is not. But several recent reports 
described BDCA3+ (blood dendritic cell antigen 3 or thrombomodulin; 
CD141+) DC as the human DC equivalent to murine CD8α DC. 
Villadangos and Shortman reviewed this human equivalent to the 
CD8α+ DC and highlighted the similarities between the mouse and 
human counterparts (Villadangos and Shortman, 2010). BDCA3+ DC 
are a subset member of conventional human blood DC but also are 
well known to possess CD8α+ DC-like properties such as DNGR-1 
(ClecA9) expression. Similar to CD8α+ DC, BDCA3+ DC effectively 
phagocytose apoptotic and dead cells and are also efficient at cross-
presentation of antigens. Both BDCA3+ and CD8α+ DC subtypes 
exclusively express TLR3 that is crucial in viral recognition and are 
potent producers of IL-12, in concert, resulting in rigorous CTL 
responses. The DC subsets both require the transcription factors 
Baft3 and IRF-8 to drive their developmental pathways, but not IRF-4 
(Villadangos and Shortman, 2010). The ethical and logistical 
implications to purifying lymphoid-resident human DC limit such 
probable identification and characterisation of human CD8α+ DC. 
Although, one very compelling piece of evidence equating the 
myeloid-derived blood (BDCA3+) DC and the lymphoid-resident 
CD8α+ DC is the restricted expression of the chemokine receptor 
XCR1. Mouse CD8α+ DC are the only murine cells known to express 
this molecule. XCR1 is responsive to its ligand XCL1, also known as 
lymphotactin, an exceedingly specific and potent chemokine for 
CD8α+ DC subset. XCL1 is abundantly secreted chemoattractant by 
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activated CD8+ T cells allowing recruitment these DC subsets to CD8 
T cells after antigen recognition - increasing the pool of antigen-
specific CD8 T cells and their capacity to produce IFN-γ (Dorner et al., 
2009). 
 
The CD8α- DC subset can be delineated into three additional subtypes 
based on further characterisation. These are the CD4+CD8α-CD205-
CD11b+ population, which is predominately present in the spleen (50-
70% of splenic DC), and the CD4-CD8α-CD205+CD11b+ (‘double-
negative’) and the CD4-CD8α-CD205-CD11b+ (‘triple-negative’) 
populations, majority of which are found in the lymph nodes. In the 
mesenteric lymph nodes, the CD4-CD8α-CD205-CD11b+ subset 
comprise about 40% of the total LN DC whilst skin-draining LN DC 
constitute similar proportions (20-30%) of the CD4-CD8α-CD205+ and 
the CD4-CD8α-CD205- DC, and about 10-20% of the CD8α+CD205+ 
DC subsets (Shortman and Liu, 2002). Interestingly, also in skin-
draining lymph nodes of healthy mice, about 30% of DC are 
CD8αloCD205+ that express high levels of MHC class II and co-
stimulatory molecules as well as langerin (CD207). It is suggestive 
that these cells are post-migrating Langerhans cells (Pulendran et al., 
1997). 
 
The CD4+CD8α-CD205-CD11b+ DC, CD4-CD8α-CD205+CD11b+ DC and 
CD4-CD8α-CD205-CD11b+ DC from the spleen and lymph nodes all 
resemble cells of a myeloid lineage; furthermore, CD4+CD8α-CD205-
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CD11b+ DC and CD4-CD8α-CD205-CD11b+ DC even express myeloid 
markers like 33D1 and F4/80 (Vremec et al., 2000). They are 
localised to the marginal zone and migrate to T cell areas upon 
stimulation; both subsets are effective stimulators of CD4+ and CD8+ 
T cells and demonstrate efficient MHC class II presentation to 
antigen-specific CD4+ T cells (Pooley et al., 2001). CD4+CD8α- DC 
and CD4-CD8α- DC do differ phenotypically and biologically. The 
former has a greater adhesion capacity, higher levels of F4/80 
expression but lower cytokine production post-stimulation compared 
to the latter (Hochrein et al., 2001, Pulendran et al., 1997, Vremec et 
al., 2000). 
 
The relationship between these subsets in the spleen and LN was 
addressed using continuous BrdU labelling of DC precursors in vivo, 
which illustrated that all five DC subsets arise from independent, 
dividing, self-renewing precursors, i.e. one subset does not seem to 
mature into another subset. These populations are short lived in 
lymphoid tissues (3-5 days) (Kamath et al., 2002). It had been 
proposed that the different DC populations originated from lymphoid 
or myeloid cell lineages principally based on cell surface marker 
expression and the common development of CD8+ DC and 
lymphocytes from CD4lo early thymic precursors; further studies have 
either supported or contested this concept (Ardavin, 2003, Shortman 
and Liu, 2002). However, it is now apparent that the major classes of 
DC can be derived from either a common myeloid or common 
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lymphoid haematopoietic precursor, as well from a specific blood 
derived DC precursor (del Hoyo et al., 2002); in addition, CD8α+ and 
CD8α- DC may arise from peripheral blood monocytes upon 
extravasation into tissues (Leon et al., 2004), similar to DC 
differentiation from monocytes upon migration into the lymph in 
humans (Randolph et al., 1998, Randolph et al., 1999, Randolph et 
al., 2002). 
 
Research on murine DC has been vastly extensive in contrast to the 
relatively few studies on human DC due to the ease of accessibility of 
freshly isolated DC. Blood is the only readily available source of 
human DC with rare cases of lymphoid tissues such as tonsils, spleen 
and thymus as a source. As aforementioned, human DC are defined 
by Lin- MHC-II+ cells and, like mouse DC, consist of several subset 
populations of which, all express CD4. These subset differences might 
be a reflection of maturation status rather than distinct DC lineages 
(Sato and Fujita, 2007). 
 
Human DC are divided into two subsets of conventional CD11c+ DC of 
a myeloid origin and a CD11c- plasmacytoid DC of a lymphoid 
lineage. The two conventional myeloid DC are present in peripheral 
blood and express the blood dendritic cell antigens (BDCA). These are 
the CD4+CD11chighCD1c+/BDCA-1+CD1a+ DC comprising of 0.6% of 
PBMC and the CD4+CD11clowCD141+/BDCA-3+CD1a- DC, which are 
found only in trace numbers in blood (<0.05% of PBMC) (Narbutt et 
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al., 2004, Dzionek et al., 2000). Under appropriate culture conditions, 
BDCA-1+ DC give rise to cells with characteristic LC features of E-
cadherin and Langerin expression with typical Birbeck granules but 
not BDCA-3+ DC; therefore, BDCA-1+ DC and BDCA-3+ DC are 
probable direct precursors of LC and interstitial DC (intDC) in 
peripheral blood respectively (Ito et al., 1999). Both myeloid DC 
subsets are capable of stimulating T cells and their T-cell stimulatory 
capacity is enhanced with GM-CSF stimulation. These DC can also 
elicit Th1 or Th2 responses depending on the inflammatory 
environments (Eksioglu et al., 2007, Liu et al., 2001, Liu, 2001, Liu et 
al., 2007, Wang et al., 2006). 
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1.5. DENDRITIC CELL BIOLOGY 
1.5.1. Dendritic Cell Activation: Immature 
versus Mature DC 
In most tissues, DC are present in an immature state and are 
generally incapable of stimulating T cells. Although these DC lack the 
co-stimulatory molecules required for full T cell activation, they are 
very well equipped to capture antigen in the periphery. Once 
immature DC have encountered foreign antigens (soluble or 
processed from a pathogen), they initiate maturation and migrate to 
the T cell areas of secondary lymphoid organs where the mature DC 
activate the adaptive immune response. 
 
Immature DC have several means of antigen capture. Firstly, they 
can engulf particles and microbes via phagocytosis (Caux et al., 
1992, Svensson et al., 1997). Secondly, immature DC can perform a 
process called macropinocytosis whereby large pinocytic vesicles are 
formed that endocytose extracellular fluid and soluble particulates 
(Sallusto et al., 1995). The vesicular contents are then sampled by 
the DC for foreign antigens. The third method is via receptors that 
mediate adsorptive endocytosis, which include the carbohydrate 
receptors – C-type lectin receptors, mannose receptors and DEC-205, 
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as well as the immunoglobulin receptors Fcγ and Fcε receptors (Jiang 
et al., 1995, Sallusto and Lanzavecchia, 1994). 
 
In immature DC, macropinocytosis and receptor-mediated antigen 
uptake are exceedingly proficient processes, requiring picomolar and 
nanomolar concentrations of antigen, considerably lower levels 
typically required by other APC. However, once a non-domestic entity 
is encountered or a non-self antigen is captured, signals are 
transduced to mature DC and their ability for antigen sampling is 
rapidly lessened. 
 
The captured pathogen or antigens enter the endocytic pathway and 
are directed to specialised lysosomes containing large amounts of 
class II MHC molecules. These MHCII-rich compartments (MIIC), 
which are abundant in immature DC, make it possible for DC to 
display numerous cell surface class II MHC-antigen complexes 
(Nijman et al., 1995, Pierre et al., 1997, Winzler et al., 1997). During 
DC maturation, MIIC convert to non-lysosomal vesicles and release 
their MHCII-antigen complexes onto the cell surface (Cella et al., 
1997a, Pierre et al., 1997). 
Once activated, DC migrate to lymph nodes to present antigen on 
MHC complex to naïve lymphocytes, which become activated and 
differentiate into effector T and B cells and memory T and B cells. DC 
maturation is crucial for the initiation of antigen-specific immunity 
and this process is characterised by reduced antigen-capture 
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capacity, and increased surface MHCII expression and surface 
expression of co-stimulatory molecules. Full DC maturation is only 
achieved upon interaction with appropriate T cells, i.e. T cells with the 
TCR that recognise the antigen being presented. Expression of the 
co-stimulatory molecules on mature DC that interact with appropriate 
receptors on T cells to enhance adhesion and TCR signalling include 
CD54, CD58, CD40, CD80 and CD86. Dendritic cells are a major 
source of many cytokines, namely, IFN-α, IL-1, IL-6, IL-7, IL-12, IL-
15 and MIP-1γ, all of which are important in eliciting of a primary 
immune response (Cella et al., 1996, Grouard et al., 1996, Macatonia 
et al., 1995, Mohamadzadeh et al., 1996, Strobl et al., 1996, Zhou 
and Tedder, 1995). 
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1.5.2. TLR4 and other TLR Signalling Pathways 
Signalling via TLR expressed by DC results in an array of activation 
events including phenotypic and morphological alterations, cytokine 
production and migration. TLR4 signalling pathway is the best 
described of all TLR signalling pathways and selectively binds LPS but 
does not solely recognise LPS. LPS binding to TLR4 is aided by its co-
receptor, CD14, which forms as a complex with a membrane-bound 
molecule, myeloid differentiation protein 2 (MD-2 also know as 
lymphocyte antigen 96, LY96). LPS binds initially to CD14 and then to 
TLR4-MD-2 receptor complex. TLR4 undergoes a conformational 
change in the cytoplasmic domain in response to LPS binding. The 
intracellular signalling domain of each TLR is known as the 
Toll/Interleukin-1 (IL-1) receptor (TIR) domain, which confers the 
conformational change and signals the recruitment of the cytoplasmic 
protein, myeloid differentiation factor 88 (MyD88), which possesses a 
TIR binding motif, and binds to the TIR and acts as an adaptor for 
signal transduction. A central adaptor molecule required for TLR 
signalling, MyD88 becomes recruited by homophile TIR interactions to 
the corresponding TLRs (Medzhitov et al., 1998). Consequently, IL-
1R-assocated kinase (IRAK) 4 becomes recruited, which binds to 
IRAK1 and forms a complex with the tumour necrosis factor (TNF) 
associated factor (TRAF) 6. IRAK1 and TRAF6 dissociate from the TLR 
complex and TRAF6 then forms a complex with the transforming 
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growth factor (TGF)-β activated kinase 1 (TAK1) and the TAK1 
binding molecules TAB1 and TAB2. This leads to the activation of 
TAK1 which in turn results in activation of two signal transduction 
pathways the nuclear factor (NF)-κB pathway and the mitogen-
activated protein (MAP) kinase pathway which includes p38, c-Jun N-
terminal kinase (JNK) 1/2 and extracellular signal-regulated kinase 
(ERK) 1/2 (Akira and Takeda, 2004, Wagner, 2001). NF-κB and 
activator protein 1 (AP-1), a gene product of the Jun oncogene, 
transcriptionally activate several pro-inflammatory genes, particularly 
the cytokines, chemokines and other inflammatory mediators. 
 
TLR2 and TLR9 subfamilies as well as TLR5 are wholly dependent on 
MyD88 for signalling; during MyD88-dependent TLR2 and TLR4 
signalling, MyD88 heterodimerizes with the adaptor molecule TIR 
domain-containing adaptor protein (TIRAP also named Mal) (Horng et 
al., 2002). Knockout studies have confirmed that many, but not all, 
TLR signals are abolished by targeted deletion of MyD88 gene; thus 
defining alternative signalling pathways to LPS/TLR4 responses 
(Yamamoto and Akira, 2005). 
 
TLR3 and TLR4 exploit this additional signalling pathway, which is 
MyD88 independent. These signals utilize the adaptor molecule TIR 
domain-containing adaptor inducing interferon (IFN)-β (TRIF also 
named TICAM). With respect to TRIF-dependent TLR4 signalling, an 
auxiliary adaptor protein called TIR domain-containing adaptor (TRAM 
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also known as TICAM-2) is involved (Fitzgerald et al., 2003b, 
Yamamoto et al., 2003b). This pathway induces delayed activation of 
NF-κB and IFN regulatory factor (IRF)-3 that results in MyD88-
independent DC maturation and induction of IFN-β respectively. 
Collectively, these converging signalling cascades acting via distinct 
Toll-like receptors are graphically represented in the simple schematic 
below (Figure 1.5.2.1). 
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Figure 1.5.2.1. Schematic representation of the TLR post-receptor early 
signalling events. 
Illustration showing the adaptor proteins that directly associate with the Toll/IL-1 
receptor (TIR) domains and the early signalling molecules that lead to activation of 
individual transcription factors. 
 
The activation of NF-κB is initiated by either activation of TRAF6 or 
receptor interacting protein (RIP) 1 upon binding to TRIF (Meylan et 
al., 2004, Sato et al., 2003). The cascade resulting in the activation 
of IRF-3 depends on the non-canonical IκB kinase homologs, IκB 
kinase-epsilon (IKKε also known as IKKi) and TANK-binding kinase-1 
(TBK1) (Fitzgerald et al., 2003a, Sharma et al., 2003). Following an 
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initial NF-κB and IRF-3 activation, transcription factor-dependent 
induction of IFN-β and IFN-α4 occurs; these cytokines acting through 
their IFN-I receptors activate the Janus kinases (JAK) that then 
phosphorylate signal transducer and activator of transcription (STAT) 
family of transcription factor (TF) proteins. The STAT proteins, in 
turn, induce IRF-7 thus initiating transcription of multiple IFN-α genes 
such as the IFN-inducible protein (IP-10) gene and the inducible nitric 
oxide (NO) synthase (iNOS) gene (Levy et al., 2002, Takeda and 
Akira, 2005). 
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1.6. NUCLEAR FACTOR (NF)-κB: THE PLURIPOTENT 
TRANSCRIPTION FACTOR 
In nearly all nucleated cells, NF-κB serves as a comprehensive 
transcription factor that regulates numerous genes, which play 
significant roles in inter- and intra-cellular signalling, stress 
responses, cellular growth, survival and apoptosis (Baichwal and 
Baeuerle, 1997, Baldwin, 2001, Guttridge et al., 1999, Karin and Lin, 
2002). NF-κB is activated by a broad range of agents including 
cytokines, viruses, lipopolysaccharide, T cell mitogens and okadaic 
acid. It is surprising how all these assorted agents, which elicit 
different intracellular reactions, can cause the same event, that is, 
the release of IκB from NF-κB (Barnes, 1997, Schmidt et al., 1995a, 
Schmidt et al., 1995b, Traenckner et al., 1995, Thanos and Maniatis, 
1995). Control of NF-κB-responsive genes, in a selective and 
temporal manner, is of biological importance particularly in 
physiological and patho-physiological inflammatory scenarios 
(Hoffmann et al., 2006, Hoffmann et al., 2002). 
 
Five subunits partake in NF-κB functions: RelA/p65, cRel, RelB, p50 
and p52 that form various dimers with each other to produce 
biologically active species and virtually in all cells, the p65:p50 
heterodimer is the most prevalent complex (Hoffmann and Baltimore, 
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2006, Siebenlist et al., 1994). Genetic studies of NF-κB binding sites 
have shown that its binding to regulatory sequences (promoter 
and/or enhancer regions) is responsible for transcriptional activation 
of genes in response to stimulation of cells by IL-1, TNF-α, bacterial 
LPS, double-stranded RNA and active phorbol esters. Published works 
have shown that NF-κB is present in the cytosol in a sequestered 
form, of resting cells, by a family of inhibitors called IκB (inhibitor of 
κB), which when activated is released from its inhibitory proteins. 
This inhibitor of DNA binding selectively and reversibly inactivates NF-
κB (Baeuerle and Baltimore, 1989, Baeuerle and Baltimore, 1988b, 
Baeuerle and Baltimore, 1988a). Stimulated cells induce signalling 
cascades to activate IκB kinase (IKK) complex, which phosphorylates 
all three IκB isoforms (IκB-α, -β and -ε) followed by ubiquitination. 
The ubiquitinated IκB proteins enter the proteolytic pathway and are 
degraded allowing NF-κB to localise to the nucleus and bind DNA 
(Ghosh et al., 1998). 
 
Previous literature has highlighted that overexpression of the p65 
subunit, by transfection or retroviral infection, markedly increases 
endogenous IκB-α mRNA and protein but overproduction of p50 is 
unable to induce a transcriptional response of the IκB-α gene. Free 
IκB protein is unstable therefore at basal conditions IκB levels must 
continuously equate or exceed those of the transcription factor. 
However, interaction between the IκB and p65 stabilises the 
inhibitory protein allowing protein levels to increase rapidly. In 
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addition to protein stabilisation, p65 also enhances the induction of 
the IκB-α gene thus rapidly increasing mRNA and protein levels 
(Scott et al., 1993, Brown et al., 1993). Hence, activation of many 
cells types by specific stimuli such as LPS, phorbol 12-myristate 13-
acetate (PMA), or TNF-α would lead to dissociation of p65:p50 
heterodimer from IκB and IκB degradation. The free NF-κB binds to 
consensus sequences of DNA and helps promote the initiation of 
transcription of many genes, in particular the p65 subunit supports 
the transcription of IκB gene. The inhibitor protein levels, specifically 
IκB-α, accumulate and bind NF-κB, which becomes deactivated. To 
surmise, IκB-α synthesis is controlled by an exceedingly NF-κB-
responsive promoter causing autoregulation of NF-κB signalling 
(Figure 1.6.1) (Scott et al., 1993). 
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Figure 1.6.1. Negative feedback loop of the IκB-α–NF-κB signalling 
cascade. 
NF-κB is held as an inactive complex in the cytoplasm by the IκB protein isoform 
complex. Cells exposed to stimuli leads to IκB kinase (IKK) activation, which then 
phosphorylate the three IκB isoforms of the protein complex and results in their 
degradation; allowing for NF-κB nuclear translocation. Translocated NF-κB binds to 
responsive elements of promoter regions and transcribes inflammatory genes as well as 
the genes of IκB isoforms: IκB-α. IκB-β (not shown) and IκB-ε (not shown). IκB-α 
induction is the most predominant of the inhibitor proteins and is responsible for cytosolic 
sequestering of NF-κB and arresting NF-κB activity. 
 
 65 
Genetic analyses have further dissected the precise role of each IκB 
isoforms in regulating NF-κB. Deletional studies reveal that 
expression of only IκB-α results in an extremely oscillatory NF-κB 
response indicating that after NF-κB activation, there is a rapid and 
potent inhibition of NF-κB by newly synthesized IκB-α. Further 
stimulus signal results in a swift IκB-α degradation, releasing and 
activating NF-κB and thus creating a cycle of sinusoidal activation 
patterns of NF-κB. In contrast, solitary expression of the IκB-β or the 
IκB-ε isoforms lead to an uniform increase in nuclear NF-κB that 
eventually plateau without further suppression (Hoffmann et al., 
2002). Unlike IκB-α, neither IκB-β nor IκB-ε can completely inhibit 
NF-κB activity and also highlights redundancy of inhibitory activity 
between these two isoforms. 
 
Both IκB-α and IκB-β are inactivated via protein kinase A and C 
signalling pathways, but in contrast to IκB-α, IκB-β loses its inhibiting 
activity through a dephosphorylation process (Link et al., 1992). 
Therefore, IκB-β is only partially degraded in response to most 
extracellular signals. Unphosphorylated, resynthesized IκB-β forms a 
stable complex with NF-κB in the cytosol; however, this binding fails 
to mask the nuclear localization signal and DNA binding domain on 
NF-κB, and the IκB-β–NF-κB complex enters the nucleus allowing 
transcription of NF-κB-inducible genes (Chen et al., 2004, Suyang et 
al., 1996). 
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IκB-β exists in at least two different forms: one that is bound to the 
NF-κB dimer and the other bound to both NF-κB and κB-Ras, a Ras-
like small G protein. Removal of cellular κB-Ras augments induced 
IκB-β degradation whereas excess κB-Ras impedes induced IκB-β 
degradation and astonishingly, κB-Ras functions in both GDP- and 
GTP-bound states. While signal-induced degradation of IκB-α is 
responsible for rapid, oscillatory pattern of NF-κB activation; 
prolonged activation of NF-κB, which is fundamental for certain 
biological functions such as T-cell activation, requires IκB-β 
degradation (Chen et al., 2003, Chen et al., 2004). 
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1.7. IMMUNE TOLERANCE 
Immunological tolerance is the failure to mount an immune response 
to an antigen; it is not simply a failure to recognise an antigen but an 
active process of detection of a particular epitope with equal 
specificity as an immunogenic response. There are two main modes 
of tolerance: natural or self-tolerance and induced tolerance 
(Khurana, 2006, Miller et al., 2009, Stockinger, 1999). Self-tolerance 
is the recognition of self-antigens without eliciting an immune 
response against them. This mechanism is paramount to lymphocyte 
development especially T cells. The second type of tolerance is a 
deliberate manipulation of adaptive immunity to usually nontoxic 
environmental antigens. A break in this induced tolerance typically 
results in atypical allergic reactions to food, insect sting and plant 
pollen or abnormal host rejection reactions such as miscarriage of 
pregnancy (Nossal, 1993, Weiner et al., 2011, Munoz-Suano et al., 
2011, du Pré and Samsom, 2011, Guerin et al., 2009, Saito et al., 
2007, Mahnke et al., 2003) Both T and B cells can be tolerised but a 
greater emphasis is aimed towards T cell tolerance. Overall B cell 
tolerance is not a rigidly regulated system as T cell tolerance but 
tolerising B cells is still a noteworthy procedure to general 
immunoregulation. B cells require the aid of T cells to make 
antibodies to most antigens hence tolerising T cells in general 
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prevents B cell differentiation into antibody-secreting plasma cells 
(Janeway, 2005). T and B cell tolerance is subdivided into central 
tolerance and peripheral tolerance. 
 
Central tolerance of T cells is critical for their normal development in 
the thymus and usually occurs in tandem with the MHC restriction 
process. During sampling of self-peptides to determine class I or 
class II MHC recognition, developing T cells also must surpass the 
checkpoints that monitor the affinity and strength of TCR binding to 
these self-antigen/MHC complexes. T cells that recognise self-
antigens too strongly are prevented to proceed through development 
and receive signals to induce apoptosis. This mechanism is termed 
negative selection (McCaughtry and Hogquist, 2008). The APC of the 
thymus, thymic DC and thymic medullary epithelial cells (TEC), 
present peptide fragments derived from many housekeeping genes 
found in all cells but some proteins are only expressed in 
differentiated cells, such as insulin and the thyroxine pro-protein, 
thyroglobulin. Thus preventing maturation of reactive T cells against 
such proteins, thymic APC largely thymic DC express the transcription 
factor, autoimmune regulator (AIRE), which can initiate the 
transcription of numerous tissue-specific gene products that are 
presented during negative selection (Heino et al., 1999, Ramsey et 
al., 2006). This checkpoint affords the necessary signals to T cells to 
continue developing appropriately therefore, mature naïve T cells that 
emerge from the thymus are sufficiently equipped to mount immune 
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responses against non-self peptides and not self peptides (Palmer, 
2003, Prud'homme, 2004). 
 
Central tolerance of B cells occurs in a similar fashion as T cells that 
is, checkpoint controls during development into immature B 
lymphocytes. B cells are generated and differentiate in the bone 
marrow and a vast proportion of developing B cells construct a 
polyreactive BCR that are capable of binding self-antigens. Like T 
cells, B cells with a self reactive BCR that binds robustly to self-
antigens receive signals that halt their development. Instead these B 
cells suffer one of two fates: either induce cell death via BCR 
signalling upon self antigen ligation or instigate receptor editing 
program of the BCR, which induces rearrangement of the gene 
segments that encode the heavy and light chains of the BCR in order 
to construct a new BCR that is not self reactive. Additionally, B cells 
that bind antigens with lower avidity become anergic and induce 
developmental arrest due to lack of receptiveness for survival signals 
(Ferry et al., 2006, Goodnow, 1992). 
 
Mature naïve T and immature B cells that immigrate into the 
periphery are reasonably safe but despite central tolerance, some 
self-reactive lymphocytes do escape this strict system and enter the 
periphery. Activation of these lymphocytes may result in autoimmune 
or immunopathological diseases and thus they do need to be made 
tolerant in the periphery. 
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Peripheral tolerance, like central tolerance is heavily geared towards 
regulating T cell responses as apposed to B cell responses. Peripheral 
T cell tolerance is achieved via several mechanisms: these are 
characterised as immunological ignorance, deletion, regulation 
and suppression. Immunologic ignorance occurs when autoreactive 
T cells fail to encounter their self-antigen due to anatomical barriers 
preventing access to the particular tissue sites. Under physiological 
conditions, these immune privileged sites, such as the eye, testes 
and brain, restrict T cell entry. Therefore the resident DC in these 
tissues cannot present self antigens to possibly autoreactive T cells, 
thereby maintaining self tolerance (Butcher and Picker, 1996). 
 
Self-peptides presented to T cells by dendritic cells usually occur in 
the absence of co-stimulation and thereby fail to prime. These T cells 
commit to either of two fates; one of which is CD95- or Fas-mediated 
cell death. Engagement of the Fas receptor with its ligand (FasL) 
induces apoptosis in Fas-positive cells. The importance of this 
mechanism is illustrated by constitutive expression of FasL by DC and 
other cell types of immune privileged sites; T cells granted entry into 
such organs, for instance the eye, that are CD95-positive will 
undergo apoptosis without compromising tissue homeostasis (Griffith 
and Ferguson, 1997, Griffith et al., 1995). 
 
Regulation of T cell responses is another process of maintaining self-
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tolerance in the periphery and it broadly occurs by two means: 
anergy or inhibition. Anergy is the alternative outcome to deletion 
when presentation of antigens occurs in the absence of co-
stimulation. Instead of T cell apoptosis in a Fas-dependent manner, 
insufficiently primed T cells fail to produce IL-2, the quintessential 
cytokine required for complete T cell activation, and thus regulating 
the action of T cells. The other approach to T cell regulation is 
inhibition; T cells that do encounter antigen in the presence of co-
stimulation must engage the co-stimulatory B7 ligands on DC with 
the co-stimulatory receptor CD28 instead of the co-inhibitory receptor 
CD152 (or CTLA-4) on T cells for full activation. In order to prevent 
aberrant T cell activation, CD152 preferentially binds the B7 ligands 
on DC and B cells inhibiting T cell activation or responses of activated 
T cells. Whilst this signalling path is not the only co-inhibitory system 
(another is PD-1 with PD-L1 and PD-L2 (Carter et al., 2002, Freeman 
et al., 2000)), the B7-CTLA-4 cascade is the most robust co-inhibitory 
signalling pathway (Brunner et al., 1999, Oosterwegel et al., 1999a, 
Rudd, 2009). 
 
Dysregulation or breach of either central or peripheral tolerance has 
been associated with the development of autoimmunity, and though 
adaptive immunity appears to be a central component of autoimmune 
pathogenesis, clearly a variety of cell types contribute to autoimmune 
diseases (Benson et al., 2010). It has recently been proposed that 
the progression to autoimmune pathologies is a four-step process, 
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which does not require antigen-specificity. These four hypothesized 
steps are: 
(1) T cell activation regardless of antigen specificity; 
(2) Local events inducing tissue-specific accumulation of activated T 
cells; 
(3) Enhanced sensitivity to T cell-derived cytokines in populations of 
cells in affected tissue; 
(4) Activation of a cytokine-dependent IL-6 amplification loop, 
triggered by CD4+ T cell-derived cytokines such as IL-17A (Ogura et 
al., 2008). 
 
In general, mechanistic understanding of human autoimmune 
diseases results from aberrant responses that were not centrally 
tolerised or are peripherally breached. Unlike many other conditions, 
animal models of autoimmune diseases have tended to focus on the 
later stages of disease pathogenesis. However, recent clinical studies 
tracking biomarkers associated with disease development revealed 
that the most critical checkpoint, breach of self-tolerance, occurs 
months or years prior to clinical presentation Therefore, little is 
known about the immunological processes that lead to the 
spontaneous loss of tolerance that is characteristic of human disease. 
This represents a bottleneck to the clinical development of prevention 
and early intervention strategies. (Benson et al., 2011, Rantapää-
Dahlqvist et al., 2003, Majka et al., 2008, Nielen et al., 2005) 
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Immunosuppression is the fourth form of T cell tolerance. Unlike the 
other means of T cell tolerance that involve the functionality of APC 
predominantly DC but on occasion B cells, this method is commonly 
employ a unique effector T cell – regulatory T cell (Treg), to 
immobilize activation of naïve and effector memory T cells. Originally 
called suppressor T cells (Ts cells), the significance of T-cell mediated 
immunosuppression had not been fully appreciated until recently and 
hindrance in the development or function of Tregs is a major cause of 
autoimmune and inflammatory diseases (Sakaguchi et al., 2008). 
Extensive animal studies of normal mice involving thymectomy at 
different life stages resulted in tissue-specific autoantibody 
production and autoimmune damage. These findings provide 
surprising evidence that normal mice harbour potentially pathogenic 
autoreactive T cells but also dominantly functional Tregs that 
suppress autoimmunity (Sakaguchi et al., 1982). Tregs are 
represented by three major cell populations: the naturally occurring 
Treg, Tr1 cells, Th3 cells, CD8+CD28- T cells and Qa-1 restricted T 
cells. 
 
The naturally occurring CD4+CD25+ Tregs was first described in mice 
as a population of cells consisting of about 5-10% of the T helper 
subset that demonstrated regulatory properties both in vivo and in 
vitro (Sakaguchi et al., 2001, Sakaguchi et al., 1995). Using a colitis 
model in severe combined immunodeficient mice, injection of 
CD4+CD25- T cells induced bowel disease while co-injection of these T 
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cells with CD4+CD25+ T cells prevented inflammation of the colon. 
Characteristically, naturally occurring Tregs are identified by their 
inability to proliferate upon TCR activation or stimulation via 
mitogenic antibodies.  
 
These Tregs require exogenous sources of IL-2, albeit autocrine or 
paracrine, for suppressive function that uniquely involves the 
inhibition of transcriptional induction of IL-2 in CD25- T cells 
(Shevach, 2002, Thornton et al., 2004). Treg suppressor effect has 
been shown, at least with in vitro culture models, to be dependent 
mainly on cell-cell contact and partially on granzyme B (Gondek et 
al., 2005). 
 
Animal investigations have highlighted that CD4+CD25+ Treg 
activation is antigen-specific and a requirement of their inhibitory 
function but these activated Tregs suppress T cell responses in a 
antigen-nonspecific manner; suggesting a broad spectrum regulatory 
role of these Tregs towards a variety of pathogen-specific effector T 
cells (Sakaguchi, 2003). 
 
The CD4+CD25+ T-cell population is heterogeneous and only a 
proportion of this population exerts regulatory functions, namely the 
CD4+CD25high T cells. Also, it is apparent that not all CD25+ T cells 
exercise a suppressive activity. Therefore, Tregs are typical 
characterised by expression of intracellular CTLA-4, neuropilin-1 
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(Npr-1), glucocorticoid-induced tumour necrosis factor family-related 
receptor, CCR4, CCR8, CD62L (L-selectin), lymphocyte activation 
gene-3 (LAG-3) and CD103 (integrin αεβ7). Naturally occurring Tregs 
specifically express the transcription factor forkhead box P3 (Foxp3), 
a master regulator of Treg development and function and a member 
of forkhead/winged-helix family of transcription factors. Foxp3 
expression in T cells is quite restricted; only peripheral CD4+CD25+ T 
cells and CD4+CD25+CD8- thymocytes express the gene. Studies 
employing ectopic retroviral transduction of the Foxp3 gene have 
shown that transduced CD4+CD25- T cells are converted to 
CD4+CD25+ Treg-like cells with suppressive activity towards other 
proliferating T cells. Moreover, Foxp3 transduction in naïve T cells 
upregulates the expression of CD25, CTLA-4 and the glucocorticoid-
induced TNF receptor family-related gene (GITR), whereas it 
represses the production of IL-2, IL-4 and IFN-γ (Hori et al., 2003, 
Hori and Sakaguchi, 2004). Naturally occurring Tregs, in mice, also 
regulate T cell responses by modulation tryptophan metabolism, an 
essential amino acid required for proliferation of effector T cells. CD4+ 
CD25+ cells constitutively express CTLA-4; this surface antigen binds 
the B7 molecules on DC and triggers a B7–dependent induction of 
indoleamine 2,3-dioxygenase (IDO) activation in DC. IDO catalyses 
the initial tryptophan degradation reaction; this is the rate-limiting 
step for the degradation process and thus results in tryptophan 
deficiency in the microenvironment. Consequently, in a tryptophan-
deprived environment, effector T cells undergo apoptosis. 
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1.8. TOLEROGENIC DENDRITIC CELLS 
Each DC subset has exceptional functional plasticity and thus it was 
proposed that a specific DC lineage determines the outcome of the T 
cell effector subset, that is, tolerance or immunity. Several studies 
suggest that tolerogenic DC represent a particular subtype. Kronin et 
al. demonstrated that splenic CD8α+ lymphoid DC induce a lesser 
proliferative response in CD4+ T cells than its CD8α- lymphoid 
counterparts (Kronin et al., 1997b). Furthermore, these DC 
preferentially induce Fas-dependent apoptosis of CD4+ T cells in vitro 
implicating their tolerogenic properties (Kronin et al., 1997b, Suss 
and Shortman, 1996, Kronin et al., 1997a). Conversely, numerous 
reports have counter argued this hypothesis by exhibiting that CD8α+ 
DC are also high producers of IL-12 that can stimulate cytotoxic CD8+ 
T cells during antiviral immunity (Dalod et al., 2002). In humans and 
mice, plasmacytoid DC (pDC) are the most potent producers of type I 
interferon and are the key effector cells in early antiviral innate 
immunity (Barchet et al., 2005, Kadowaki et al., 2001). pDC-derived 
type I IFN might have a significant role in driving myeloid DC 
maturation with an immunogenic nature (Kadowaki and Liu, 2002). 
During homeostasis, both myeloid and plasmacytoid immature DC 
efficiently capture apoptotic cells and non-pathogenic bodies from the 
environment by phagocytosis, macropinocytosis or endocytosis, but 
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these DC are unable to present antigens from these sources 
effectively and thus induce T cell anergy or a regulatory T cell 
phenotype (Dhodapkar and Steinman, 2002, Hawiger et al., 2001). 
This is due to low-level expression of MHC class II and undetectable 
levels of co-stimulatory molecules by immature DC – the surface 
receptors required for T cell activation. On the other hand, under 
steady-state conditions, DC that patrol periphery must undergo some 
spontaneous maturation indicative of CCR7 up-regulation (Ip and 
Lau, 2004), which is crucial for migration to lymphoid organs, thus 
supporting the hypothesis that maturing DC, not immature DC, are 
involved in triggering T cell tolerance (Huang et al., 2000, 
Scheinecker et al., 2002). 
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Figure 1.8.1. Dendritic cells are the homeostatic mediators in the balance 
between immunity and tolerance. 
Schematic illustrating signals mediated to the adaptive immune arm by DC based on 
external stimuli and DC microenvironment that leads to either immunity or tolerance. 
 
The phenotypical and morphological changes that occur when DC 
encounter tissue antigens and/or non-infectious material is a 
maturation process, which steady-state migrating DC evidently 
undergo (Figure 1.8.1). These steady-state migrating DC do not 
terminally differentiate into fully mature immunogenic DC but appear 
to arrest in a semi-mature state of maturation (Voigtlander et al., 
2006, Lutz and Schuler, 2002). Therefore, the degree of maturation 
causes them to lose their ability to capture foreign matter efficiently, 
to up-regulate class I and II MHC and co-stimulatory molecules, to 
some extent or in a few cases not at all dependent on the stimuli. 
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These DC do proficiently process and present the antigens from non-
immunogenic origin and accordingly possess antigen-presenting 
properties capable of engaging T cells. Typically, mature DC are also 
characterised by IL-12 production and this is apparently absent in 
these semi-mature DC; in addition, these DC may or may not secrete 
IL-10 as their major cytokine. All of the qualities of these semi-
mature DC are noticeable in tolerogenic DC (Lutz and Schuler, 2002). 
For these reasons, the activation or maturation status of dendritic 
cells determines the immunogenicity or tolerogenicity of dendritic 
cells. Therefore, tolerogenicity of DC is not a characteristic feature of 
a specific subset but rather an adapted consequence on DC due to 
environmental pressures. A more encompassing model is that 
discrete DC developmental and activation phases are responsible for 
the induction of either immunity or tolerance. 
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Figure 1.8.2. Simplified scheme summarising the contrasting features in 
phenotype and function between immunogenic (mature) and tolerogenic DC. 
A basic illustrative drawing highlighting the phenotypic differences between immunogenic 
and tolerogenic DC. 
 
Despite corresponding to a functional phenotype, tolerogenic DC do 
loosely display particular characteristics; the expression of inhibitory 
molecules such as signalling lymphocyte activation molecule (SLAM), 
programmed cell death ligand (PDL)-1 and -2 (PDL-1 and PDL-2), 
DEC-205 (CD205) and immunoglobulin-like transcript (ILT) family 
(ILT3/ILT4) are highly associated with these DC. Also, tolerogenic DC 
may express high levels of IL-10 and IDO (Figure 1.8.2) (Smits et al., 
2005). The myriad of co-signalling to augment or inhibit TCR-
mediated T cell activation is pictured below (Figure 1.8.3). It is 
noteworthy to emphasize that the co-inhibitory signals supersede co-
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stimulatory signals thus stressing the importance of stringently 
regulating T cell activation. 
 
Figure 1.8.3. Schematic representation of co-stimulatory molecules 
expressed on T cells and DC, with a focus on inhibitory pathways. 
Green arrows represent positive co-stimulatory signals and the red arrows represent 
negative or inhibitory signals transduced to T cells. 
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Dendritic cells can be tolerised by a range of cytokines and 
endogenous mediators as well as some invading pathogens, primarily 
parasites, greatly exploit these negative regulatory mechanisms to 
benefit their own survival. Conventionally, IL-10 and/or TGF-β have 
been heavily implicated in the in vitro differentiation of tolerogenic 
DC. More recently, new and uncategorised functions of single 
cytokines and hormones, such as vasoactive intestinal peptide (VIP), 
have been highlighted in the development of tolerogenic DC (Table 
1.8.1) (Rutella et al., 2006). Plasmodium-infected erythrocytes bind 
CD36 on human monocyte-derived DC (moDC) and inhibit the LPS-
induced maturation of moDC and subsequent T cell stimulation. 
Plasmodium utilises this method of immune evasion by inducing 
immature regulatory DC (Urban et al., 1999, Pain et al., 2001). 
Alternatively, in a TLR2-dependent manner, Schistosoma-derived 
lysophosphatidylserine (lyso-PS), primes DC maturation that initiate 
high IL-10 production and low IL-12 production and also drive the 
generation of IL-10-producing regulatory T cells (Rutella et al., 2006, 
Smits et al., 2005). Plasmodium falciparum in the asexual, 
erythrocytic stages of infection impair the ability of human DC to 
mature in vitro (Urban et al., 1999). P. falciparum-infected children 
showed reduced levels of the MHC molecule, HLA-DR, on peripheral 
blood DC compared with DC counterparts of uninfected children, 
suggesting a reduced state of activation (Urban et al., 2001). 
Subsequent to presentation of heterologous antigen by parasitized 
erythrocytes (pRBC)-exposed DC, activation of DC is drastically 
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altered partly because of deposition of the malarial pigment hemozoin 
(HZ) within these cells. These DC trigger an abrogated expansion of 
CD4+ T-helper cells and thus defective B-cell expansion and 
differentiation and a failure of the antibody response. Thus, the ability 
of malarial parasites to inhibit DC maturation could be involved not 
only in parasite-specific immunosuppression but also in the 
suppression of responses to heterologous antigens and unrelated 
pathogens (Millington et al., 2007, Millington et al., 2006) 
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Table 1.8.1 Endogenous mediators implicated in the in vitro or in vivo 
differentiation of tolerogenic DC. 
Table showing the cytokines and mediators involved in tolerogenic DC development. 
Excerpt taken from (Rutella et al., 2006). 
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A number of studies describing tolerogenic DC, particularly in models 
of infection, have either focussed on the regulatory effects on T cell 
responses or the modulating effects on DC without addressing the 
eventual outcome for effector T cell responses. In this respect, it is 
important to note the production of anti-inflammatory mediators by 
immature or mature tolerogenic DC that in turn induce Treg 
responses. This is crucial for the resolution process (Smits et al., 
2005). Some actions of tolerogenic DC are tabulated below (Table 
1.8.2). 
 
Table 1.8.2. Different regulatory DC subsets categorized by their phenotypic 
characteristics, putative function and site of action. 
Phenotype and functionality of the individual tolerogenic DC subtypes in tolerance and/or 
homeostasis. Excerpt taken from (Smits et al., 2005). 
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1.9. ANNEXINS 
The annexins are a superfamily of proteins consisting of 13 
members and are composed of an evolutionarily conserved carboxyl 
terminal protein core of four (Annexin-A1) or eight (Annexin-A6) 
repeats of five α-helices of 70 amino acids and a distinctive N-
terminal domain for each family member. The annexins are a family 
of phospholipid binding proteins characterised by the ability of their 
conserved core to bind negatively charged membrane phospholipids 
in a Ca2+-regulated manner. The unique N-terminal segment of 
annexins accounts for the diversified roles of each family member; 
these include controlled organisation of membrane domains, 
membrane-cytoskeleton scaffolding, certain endocytic and exocytic 
transport, regulation of ion fluxes, and growth control (Gerke et al., 
2005, Gerke and Moss, 2002). 
 
Annexins binding to phospholipid matrices is reversible process such 
that removal of Ca2+ ions results in the release of these membrane-
bound annexins. As a result, annexins are involved in exocytosis, 
endocytosis, macropinocytosis, phagocytosis and vesicle trafficking 
(Raynal and Pollard, 1994). Annexins can also mediate clustering of 
phospholipids and the stabilisation of the plasmalemma and organelle 
membrane microdomains and lipid rafts (Hu et al., 2008, Menke et 
 87 
al., 2005). 
 
In addition to lipids and lipid structures, annexins form complexes 
with a number of other molecules that include proteins like EF-hand 
family of Ca2+-binding proteins such as the S100 subfamily (Mailliard 
et al., 1996), cytoskeletal proteins such as F-actin and profilin 
(Alvarez-Martinez et al., 1996, Alvarez-Martinez et al., 1997, 
Filipenko and Waisman, 2001, Hayes et al., 2004); and 
macromolecules such as large polymer molecules like 
glycosaminogylcans (GAG) (Ishitsuka et al., 1998) and ribonucleic 
acid (RNA) (Hirata and Hirata, 1999). 
 
Surprisingly, annexins do not possess a secretory consensus 
sequence (Christmas et al., 1991, Haigler and Christmas, 1990), 
considering most annexins are closely associated with the machinery 
involved with vesicle trafficking, vesicle fusion, regulated exocytosis 
and the classical (canonical) secretory pathway (Donnelly and Moss, 
1997). Despite the absence of secretory signal sequence, annexins 
are sequestered to the plasma membrane and/or secreted into the 
extracellular compartment where they elicit biological effects in both 
an autocrine and/or paracrine manner for example anti-inflammatory 
actions of Annexin-A1 (Hayhoe et al., 2006, Perretti and Flower, 
1995, Perretti and Flower, 2004, Perretti and Gavins, 2003) and the 
anti-thrombogenic actions of Annexin-A2 (Hajjar et al., 1994, Ling et 
al., 2004). 
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1.9.1. Glucocorticoids 
Glucocorticoids (GC) are a class of steroid hormones that derives 
their name from their role in the regulation of the metabolism of 
glucose and their synthesis in the adrenal cortex. As the name 
implies, glucocorticoids have long been well known for the 
stimulatory effects on gluconeogenesis in the liver and for the 
catabolic effects on such peripheral tissues as the skeletal muscle and 
thymus. For these actions, GC exert crucial homeostatic actions and 
may perhaps participate in regulation of carbohydrate, protein and fat 
metabolism of the body. In large doses, GC are known also to act as 
potent anti-inflammatory and immunosuppressive agents. For a 
family of compounds that can wield such profound effects on the 
immune system and that are so widely used therapeutically (Figure 
1.9.1.1), the mechanisms by which the glucocorticosteroids exert 
their immunosuppressive and anti-inflammatory effects are poorly 
understood (Yeager et al., 2004, Guyre et al., 1984, Guyre et al., 
1981, Goulding, 2004, Wilckens and De Rijk, 1997). Early studies 
concentrated on the inhibitory effects of these hormones on cell 
trafficking patterns and cell functions, such as plasma cell Ig 
production, T-cell activities, and most functions of monocytes and 
macrophages (Rose et al., 2010, Newton, 2000). 
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GC cause their effects by binding to the glucocorticoid receptor (GR), 
which is a type of nuclear receptor found in practically all cells. The 
activated GR complex directly binds distinct segments of DNA called 
glucocorticoid response elements (GRE) and up-regulates the 
expression of anti-inflammatory and immunosuppressive agents (a 
process known as transactivation) and represses the expression of 
pro-inflammatory proteins in the cytosol by preventing nuclear 
translocation of transcription factors, principally NF-κB and AP-1, in 
the cytosol (transrepression) as well as down-regulates the 
transcriptional and post-transcriptional events of cytokine genes 
including IL-1, IL-6, TNF-α, MIP-1α and IL-10 (Franchimont et al., 
1999, John et al., 1998). Generally, endogenous GC play a prominent 
part of the feedback mechanism in the immune system by dampening 
down the inflammatory response but GC actions on the immune 
system are in fact complex by both suppressing and inducing several 
pro- and anti-inflammatory mediators (Goulding, 2004, Rhen and 
Cidlowski, 2005). GC depress the inflammatory cascade by enhancing 
certain events of the resolution phase (Heasman et al., 2003). 
 
Glucocorticoids also modulate the formation and the action of several 
growth factors and other mediators. At physiological concentrations 
GC favour the synthesis and release of these growth factors. GC also 
favours their effect by increasing the expression of specific receptors. 
All these actions contribute to the hormonal effect of GC (Wilckens, 
1995). At higher concentrations, natural and synthetic GC inhibit the 
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synthesis of cytokines and other factors and this is of major 
importance for bringing about their effect on the immune system. 
Several of the anti-inflammatory actions exerted by potent 
glucocorticoids are mediated by the endogenous protein, Annexin-A1 
(Goulding and Guyre, 1992, D'Acquisto et al., 2008b, Perretti and 
D'Acquisto, 2009). 
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Figure 1.9.1.1. Partial Signalling Network of the Glucocorticoid-Induced 
Antagonism of Inflammation. 
Interplay of positive pathways of inflammation (green arrows) and anti-inflammation (red 
blocked arrows) are highlighted above. The glucocorticoid receptor act at multiple points 
by directly inhibiting inflammatory mediators by inducing anti-inflammatory proteins. 
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1.9.2. Annexin-A1 
Formerly termed lipocortin 1, Annexin-A1 (Anx-A1 or AnxA1) was 
originally identified as a glucocorticoid-inducible 37-kDa protein, 
which inhibits phospholipase A2 (PLA2) activity and thus prostaglandin 
production (Di Rosa et al., 1984, Flower, 1988). The human Annexin 
A1 (ANXA1) gene is located on the q arm of chromosome 9 at locus 
q12-21.2 and transcribes three protein-encoding gene transcripts; 
and murine annexin 1 gene (Anxa1), found on chromosome 19q19, 
transcribes two gene transcripts that encode proteins. The conserved 
core of Anx-A1 contains four 70-amino acid repeating domains, which 
include the Ca2+ binding sites (Figure 1.9.2.1) and phospholipid 
binding sites (Rosengarth and Luecke, 2003). 
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Figure 1.9.2.1. Tertiary structure of Annexin-A1 monomer. 
The ribbon diagrams of one monomer of full-length annexin-A1 in comparison with full-
length annexin-A1 in the absence (top cartoon) and presence (bottom cartoon) of 
calcium. Image excerpted from (Rosengarth and Luecke, 2003) 
 
The 49-amino acid N-terminal domain of the protein is buried in 
groove of the α-helices of the 3rd repeat of the protein core. In the 
presence of Ca2+ (≥ 1mM), a conformational change occurs within the 
protein and exposes N-terminal tail (Figure 1.9.2.2) (Rosengarth and 
Luecke, 2003), which is responsible for the biological activity of 
Annexin-A1 (Cirino et al., 1993). The N-terminus contains 
phosphorylation and proteolysis sites whereby the revealed N-
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terminus undergoes proteolytic cleavage, which inactivates the anti-
inflammatory actions of the full-length protein (Vong et al., 2007). 
 
Figure 1.9.2.2. Tertiary structure of the N-terminus in the pocket of third α-
helical loop of Annexin-A1. 
The diagrams of conformational change in the third α-helical loop full-length annexin-A1 
in the presence (right image) of calcium from the native annexin-A1 in the absence (left 
image) of calcium. Image excerpted from (Rosengarth and Luecke, 2003) 
 
Annexin-A1 is present in many cell types and tissues and is 
detectable intracellularly in all leukocyte populations (Morand et al., 
1995, Spurr et al., 2011). In neutrophils, Anx-A1 is 
compartmentalised in gelatinase granules (Perretti et al., 2000) and 
generally the Anx-A1 protein expression tends to be greater in 
differentiated cells compared to precursor cells, for instance, higher 
levels of Anx-A1 expression in macrophages compared to their 
monocyte precursors (Ambrose et al., 1992). Neutrophils, monocytes 
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and NK cells express higher levels of Anx-A1 and compared to T or B 
cells. Furthermore, specific T cell subsets revealed higher Anx-A1 
levels in activated CD25+ and memory CD45RO+ CD4 T cells 
compared to resting CD25- or naïve CD45RA+ CD4 T cells. (Spurr et 
al., 2011) 
 
After treatment with GC, cytosolic Anx-A1 is mobilised to the 
plasmalemma, where by a mechanism not fully elucidated, the 
protein is secreted (Perretti et al., 1996) and it has been reported 
that after exogenous administration of corticosteroids resulted in 
changes in Anx-A1 distribution as well as  concentration in human 
peripheral blood leukocytes (Goulding et al., 1990c, Goulding et al., 
1990b, Goulding et al., 1990a). There is even evidence of a paracrine 
role of Anx-A1 in the hypothalamo-hypophysial system and a further 
endocrine involvement in the hypothalamo-pituitary-adrenocortical 
(HPA) axis (Traverso et al., 1999, Buckingham and Flower, 1997) as 
well as a relationship with serum cortisol levels (Mulla et al., 2005). 
 
T cells treated with glucocorticoids, particularly dexamethasone, 
decreased Anx-A1 mRNA and protein levels in a time-dependent 
fashion and almost abolished its expression after 12h of incubation. 
TCR-mediated activation of T cells, which were pre-incubated with 
dexamethasone for 12h, led to significant reduction of IL-2 
production. Moreover, addition of human recombinant Anx-A1 to 
dexamethasone-treated T cells reversed the inhibitory effects of the 
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steroids on the TCR-induced IL-2 production. Therefore, GC suppress 
Anx-A1 expression in T cells in vitro and also in vivo – the steroid 
treatment of rheumatic patients decreased Anx-A1 expression in T 
cells (D'Acquisto et al., 2008a). 
D’Acquisto et al proposed a novel pathway for regulating the adaptive 
immune response via steroids and suggest that Anx-A1 may 
represent a target for the treatment of autoimmune diseases 
(D'Acquisto, 2009, Paschalidis et al., 2009). 
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1.9.3. Annexin-A1 Receptor 
Human Anx-A1 is the endogenous ligand of the human formyl peptide 
receptor 2 (FPR2), also termed the ALX receptor because it is also the 
receptor for Lipoxin A4 (LXA4), formerly named formyl peptide 
receptor-like-1 (FPRL1). FPR2 is a member of a family of G-protein 
coupled seven transmembrane receptors constituting of two other 
family members: FPR1, previously known as FPR, and FPR3, formerly 
designated FPRL2 (Gavins et al., 2005, Ye et al., 2009, Perretti, 
2003). 
 
The FPR family classically recognise formyl peptides derived from 
bacterial and mitochondrial proteins and is involved in host defence 
against pathogens as well as sensing internal molecules that 
constitute signals of cellular dysfunction. In addition, peripheral blood 
mononuclear cells (PBMC) treated with different glucocorticoids in 
vitro demonstrated an up-regulation of the FPR1/ALX receptor 
(Sawmynaden and Perretti, 2006). Peptides derived from the N-
terminus of Anx-A1 are agonists for all three receptors of the human 
FPR family in vitro (Dahlgren et al., 2000, Gavins et al., 2005, 
Perretti et al., 2002). 
 
The FPR family vary markedly in their gene expression between 
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different mammalian species; the mouse FPR gene family has at least 
eight known members including related sequences (Fpr1, Fpr-rs1 – 
Fpr-rs8) clustered on chromosome 17 whilst only three human genes 
cluster on chromosome 19. Fpr1 gene product is the mouse 
orthologue of human FPR1 and Fpr-rs1 and Fpr-rs2 are both 
structurally related to human FPR2/ALX gene product with mouse 
Fpr-rs2 gene product being a low affinity receptor fMLF. There are no 
known mouse orthologues for human FPR3/FPRL2 (Ernst et al., 2004, 
Migeotte et al., 2006). 
 
A recent study performed by Spurr et al addressed the differential 
expression of FPR2 and Anx-A1 in leukocyte populations (Spurr et al., 
2011). Both PMN and PBMC express surface FPR2 with the latter 
showing a bifurcation within the population: a FPR2+ subset (~12%) 
and a FPR2− subset (~78%). However, these differences were 
masked when examining total FPR2 expression (surface and cytosolic 
FPR2) suggesting that FPR2 is localised intracellularly in the majority 
of PBMC while a small PBMC subpopulation readily expressed FPR2 on 
the cell membrane. Overall, the FPR2 expression pattern appeared to 
mirror AnxA1 expression, with PMN expressing about 3 times more 
FPR2 compared to PBMC (Spurr et al., 2011). 
 
In analysing CD3+ T cell subsets: CD4+ and CD8+ T cells virtually do 
not display membrane FPR expression however, intracellular 
expression of FPR was found to express slightly higher levels (~25–
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30% more) in CD4+ T cells compared to CD8+ T cells. Previous 
reports have shown that the AnxA1/FPR2 system is engaged upon 
TCR-mediated activation of naïve T cells (D'Acquisto et al., 2007a, 
D'Acquisto et al., 2007b). Analysis on activated, naïve or memory T 
cells revealed surface FPR2/ALX was about 30% higher in CD4+CD25+ 
T cells compared to CD4+CD25- T cells, while there were no 
differences in the intracellular levels of FPR2. Comparison between 
naïve and memory T cells highlighted that CD4+CD45RA+ naïve T 
cells expressed slightly higher levels of surface FPR2/ALX compared 
to CD4+CD45RO+ memory T cells. Meanwhile, intracellular FPR2/ALX 
was equally expressed in these subsets. These findings are 
summarised in the table below (Table 1.9.3.1) (Spurr et al., 2011). 
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Table 1.9.3.1. Analysis of the AnxA1/FPR2 system in human leukocyte 
subsets. 
Table indicate expression of Anx-A1 and FPR2 in human leukocyte populations. Numbers 
indicate the Mean Fluorescence Intensity (MFI)±S.E.M. obtained from n=5 different 
donors (Spurr et al., 2011). 
 
Human DC express functional FPR and FPRL2 in an immature state 
and lose expression of FPR upon maturation whilst FPRL2 expression 
is maintained; FPRL1 is not expressed in human DC (Yang et al., 
2002). Therefore it is believed that the action of Anx-A1 on DC is 
mediated by binding these two receptors in man. 
 
After binding of their agonists, like Anx-A1, the FPR family of 
receptors activate the receptor-coupled heterotrimeric Gi protein 
resulting in dissociation of the respective α and βγ subunits, 
activating signalling molecules and pathways shared with most 
chemoattractant receptors. The α and βγ subunits initiate a series of 
signal transduction events via phosphoinositide 3-kinase γ (PI3Kγ) 
and phospholipase Cβ (PLCβ). PLCβ hydrolyses phosphatidylinositol 
4,5-bisphosphate into inositol 1,4,5-triphosphate (IP3) and 
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diacylgylcerol (DAG), intermediatory second messengers that 
releases endoplasmic calcium stores and activates protein kinase C 
(PKC) isoforms respectively. PKC activation induces heterologous 
desensitization of unrelated chemotactic receptors; PI3Kγ induces the 
mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. 
Other signal mediators include phospholipase A2 and D, and tyrosine 
kinases such as lyn and p125FAK. ERK1/2 play a role in FPR-mediated 
phospholipase D activity (Gripentrog and Miettinen, 2008, Gripentrog 
and Miettinen, 2005, Lopez-Ilasaca et al., 1997, Migeotte et al., 
2006). 
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1.9.4. Annexin-A1 in Innate Immunity 
Anx-A1 is expressed highly and predominately in differentiated cells 
and cells of the haematopoietic lineage such as tissue-specific 
macrophages, monocytes, mast cells and particularly 
polymorphonuclear leukocytes, mainly in neutrophils. This expression 
has been widely documented to increase upon GC treatment in vitro 
(Ambrose et al., 1992) and in vivo (De Caterina et al., 1993). 
Localisation of Anx-A1 is varied amongst the immune cell types; for 
instance, neutrophils compartmentalise the protein in gelatinase 
granules (Perretti et al., 2000), likewise in or on α-granules within 
mast cells (Oliani et al., 2000). Whilst in most other cells including 
macrophages, Anx-A1 is localised chiefly in the cytosol as well as 
being associated with the phospholipid layers (plasmalemma and 
nuclear). Several studies with Anx-A1 and its related N-terminal 
peptide, Ac2-26 have shown pharmacological actions of inhibition of 
PMN adhesion to vascular beds and transmigration via induction of L-
selectin shedding, inhibition of trafficking of monocytes and 
phagocytic activity of macrophages in the zymosan-peritonitis mouse 
model (Getting et al., 1997, Harris et al., 1995). Anx-A1 has been 
revealed to mediate neutrophil apoptosis at inflammatory sites 
through dephosphorylation of the pro-apoptotic intermediary BAD 
(Solito et al., 2003). 
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Exploiting transgenic tools in the generation of the Annexin-1-null 
mouse has uncovered valuable information of the role of endogenous 
Anx-A1 in vivo as well as confirming prior evidence of the anti-
inflammatory role of this protein (Hannon et al., 2003). 
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1.9.5. Annexin-A1 in Adaptive Immunity 
The role of Anx-A1 in cells of the adaptive immune system is an 
emerging field and is not as well characterised as in innate immune 
responses. Both human and murine T lymphocytes express moderate 
levels of Anx-A1 (Morand et al., 1995). Expression profiles of Anx-A1 
in human and mouse leukocytes have shown that the protein is 
expressed at higher levels in PMN, monocyte/macrophages and other 
innate immune cells as compared with T and B lymphocytes (Kamal 
et al., 2005, Perretti and Flower, 2004, Perretti and Flower, 1996). In 
addition, extravasated lymphocytes all express Anx-A1 protein in 
contrast to peripheral blood T lymphocytes, which are about 50% 
positive for the protein (Perretti et al., 1999). 
 
Human recombinant (hr) Anx-A1 sensitises murine T lymphocytes to 
CD3/28 stimulation in a dose-dependent manner as manifested by 
increased cell proliferation and IL-2 production. Dissecting the T cell 
activation profile highlighted that high-levels of Anx-A1 (300nM, 
600nM) promote T cell activation with sub-optimal CD3/28 
stimulation (1.25 µg/ml) suggesting that Anx-A1 amplifies the TCR 
signalling. This finding was compounded by increased number of cells 
positive for the activation markers CD69 and CD25 in hrAnx-A1 
treated groups. Naive T cells stimulated with hrAnx-A1 in Th1 (IL-2, 
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IFN-γ and α-IL-4) conditions or Th2 (IL-2, IL-4 and α-IFN-γ) 
conditions and later restimulated with αCD3 produced higher levels of 
IL-2 and IFN-γ and lower levels of IL-4. Furthermore, analysis of the 
two major transcriptional switches in Th1 or Th2 differentiation, T-bet 
and GATA-3 (Glimcher and Murphy, 2000), showed that cells 
differentiated in the presence of hrAnx-A1 expressed a higher level of 
T-bet and a lower level of GATA-3 (D'Acquisto et al., 2007a). 
 
Conversely, in Annxein-A1-/- T cells stimulated with different stimuli 
such as αCD3 or αCD3/CD28 or PMA and ionomycin showed reduced 
IL-2 mRNA expression and protein production as well as reduced 
number of cells positive for the activation markers CD69 and CD25 
when stimulated with αCD3/CD28. Proliferation experiments were 
consistent with cytokine and surface activation molecules expression 
and exhibited significantly attenuated proliferation in Anx-A1-/- T 
cells. This lack of proliferation was not due to defective IL-2 signalling 
in these T cells since administration of recombinant IL-2 partially 
rescued the proliferative ability (D'Acquisto et al., 2007b). 
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THESIS AIM 
Published reports from our Centre have dogmatically shown the anti-
inflammatory role and the mechanism of action of Annexin-A1 in 
several immune cells indicating this protein is an effector of a pivotal 
pathway for the action of glucocorticoids in innate immunity. But 
more recently, annexin-A1 has been revealed as a positive 
immunomodulatory protein in the adaptive immune system, at least, 
in T lymphocytes. 
 
Is Annexin-A1 a positive or negative modulator of dendritic cell 
biology including their ability to instruct the adaptive immune 
response? 
  
The aims of my thesis are: 
To investigate the role of endogenous Anx-A1 in DC biology by 
characterising the phenotype of Anx-A1-/- DC and the biological 
response to TLR agonist, lipopolysaccharide (LPS); 
To examine the molecular determinants responsible for DC 
maturation;  
To study the consequential impact of AnxA1 deficiency in DC on their 
polarizing effect on T cells; 
To dissect the role of endogenous AnxA1 in governing DC responses 
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to CD4 or CD8 T cells. 
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2. MATERIALS AND METHODS 
2.1  MATERIALS 
2.1.1. Antibodies for Flow Cytometry 
Expression of DC surface antigens was quantified by flow cytometry 
using the following FITC-, PE- or biotin-conjugated, affinity-purified, 
rat or hamster IgG anti-mouse monoclonal antibodies: I-Ab,d,q/I-Ed,k 
(clone M5/114.15.2), CD16/32 (clone 93) CD80/B7-1 (clone 1G10), 
CD86/B7-2 (clone Gl-1), and CD40 (clone 1C10), CD197/CCR7 (clone 
4B12), CD54/ICAM-1 (clone YN1/1.7.4), CD34 (clone RAM34) 
(eBioscience, Middlesex, UK) and CD11c (clone HL3; BD Pharmingen, 
Oxford UK). 
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2.1.2. Antibodies for Western Blotting 
The mouse monoclonal antibody used to detect phosphorylated 
ERK1/2 (E-4) was purchased from Santa Cruz Biotechnology and 
recognises the short amino acid sequence containing phosphorylated 
tyrosine 204 of ERK1 and the correspondingly phosphorylated ERK2. 
The rabbit polyclonal antibodies used for recognition of the C-
terminus of total ERK1 (C-16) and total ERK2 (C-14) were also 
bought from Santa Cruz Biotechnology. Whereas the rabbit 
monoclonal antibodies against phosphorylated Akt recognise either 
phosphorylated serine residue 473 (clone 193H12) or phosphorylated 
threonine 308 (clone 244F9) were purchased from Cell Signaling 
Technology. In addition, detection of total Akt1/2/3 levels were 
performed using a rabbit polyclonal antibody also acquired from Cell 
Signaling Technology. 
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2.1.3. Mice 
BABL/c and C57BL/6 male mice were obtained from the B&K 
Universal Ltd (Hull, UK). Anx-A1 null mice on C57BL/6 background 
were generated in our lab and bred in pathogen free conditions in our 
animal facilities. OT-I (specific TCR for H-2Kb/OVA257-264) and OT-II 
(specific TCR for I-Ab/OVA323-339) transgenic mice on Rag-1-deficient 
background were kindly provided by Professor Hans Strauss (Royal 
Free Hospital, UCL, London, UK) and were also maintained in 
pathogen free conditions in our animal facilities. All mice were 6-8 
weeks old and had a body weight of 24-28g. Food and water were 
available ad libitum. Animals were kept under standard conditions 
and maintained in a 12-hr light/dark cycle at 22±1 0C. Wild type 
animals were used 7 days after arrival according to guidelines laid 
down by the Ethical Committee for the use of Animals, Barts and The 
London School of Medicine. Animal work was performed according to 
Home Office regulations (Guidance on the Operation of Animals, 
Scientific Procedures Act, 1986). All mice used in these studies were 
aged between 8 and 12 weeks. 
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2.1.4.  X63 Supernatant: Active 
Granulocyte-Macrophage Colony Stimulating 
Factor (GM-CSF) 
The mouse myeloma cell line P3-X63-Ag8 does not express 
immunoglobulin heavy or light chains. This clone X63-Ag8.653 can be 
used for efficient fusion with antibody-forming cells to obtain hybrid 
cell lines producing pure monoclonal antibodies (Kearney et al., 
1979). Culture supernatant from X63.Ag865 cell line stably 
transfected with the cDNA of murine granulocyte-macrophage colony 
stimulating factor (X63-GM-CSF) (kindly provided by Dr B. 
Stockinger, Molecular Immunology, National Institute for Medical 
Research, London, UK) was used as a biologically active source of 
GM-CSF (Volkmann et al., 1997, Volkmann et al., 1996). This 
supernatant was used to supplement complete Iscove’s Modified 
Dulbecco’s Media (IMDM) into a GM-CSF-rich media. 
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2.2. METHODOLOGY 
2.2.1. X63-GM-CSF Cell Line 
The murine GM-CSF-transfected X63.Ag8653 cell line is cultured in 
Iscove's Modified Dulbecco's Medium (IMDM) supplemented with 10% 
heat-inactivated Foetal Calf Serum (FCS), 50mg/ml gentamicin, 2mM 
L-glutamine and 1mg/ml geneticin on non-adherent plastic T175 
culture flasks. The P3-X63-Ag8.653-mGM-CSF gene construct 
contains a geneticin-resistance gene insert but the DNA vector is 
episomally expressed in the myeloma cells and therefore, it is 
essential that the cell line be maintained under antibiotic selection. 
 
The X63-GM-CSF cells, brought up from frozen stock, were washed 
free of Dimethyl Sulfoxide (DMSO) and then first cultured in the 
specific IMDM medium in non-adherent plastic T25 flasks until 
confluent. Cells were washed in the culture medium, counted, 
passaged by a dilution method with culture medium and then split 
into several T175 flasks at a 1:10 ratio. Maintaining episomal 
expression of the transfected cells, the cell cultures are split twice a 
week. 
 
For preparation of supernatant, the cells are grown to a cell density of 
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60 x 106 cells/ml. The cells are then resuspended at a cell density of 
60 x 106 cells/200ml in antibiotic-free IMDM medium in non-adherent 
plastic T175 culture flasks for 48hr. The supernatant is harvested and 
frozen at –20oC. It is important to note that the secreted GM-CSF 
protein forms aggregates in solution and filtering the supernatant will 
result in loss of most of the cytokine activity. 
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2.2.2. Cell Culture 
Bone marrow-derived DC were generated as previously described 
(Lutz et al., 1999). Bone marrow cells from tibias and femurs were 
flushed and cultured in IMDM (Sigma-Aldrich, Dorset, UK) 
supplemented with 10% heat-inactivated FCS, 2mM L-glutamine, 
100U/ml penicillin, 100mg/ml streptomycin: complete IMDM (all from 
Sigma-Aldrich) and 10% culture supernatant from X63-GM-CSF. Bone 
marrow-derived DC were generated by culturing 2x107 bone marrow 
cells in 10ml of medium in 100-mm Petri (Sterilin) dishes at 37oC 
under humidified 5% CO2. 
 
Cell density was calculated using a cell counting protocol and a 
haemocytometer. 50µl of freshly isolated bone marrow cells were 
transferred to a 1.5ml Eppendorf tube containing 200µl of Phosphate 
buffered saline (PBS) and 250µl of 0.4% Trypan Blue solution and the 
cell suspension is mixed thoroughly (dilution factor of 10). With a 
cover-slip placed onto the haemocytometer chamber, 10-20µl of 
diluted cell suspension is slowly and carefully pipetted at the edge of 
the cover-slip allowing the suspension to fill the chamber by capillary 
action (Figure 2.2.2.1). 
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Figure 2.2.2.1. Schematic diagram of the haemocytometer slide. (Image 
source: 
http://www.ruf.rice.edu/~bioslabs/methods/microscopy/cellcounting.
html.) 
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Figure 2.2.2.2. Schematic diagram of the counting grids of the 
haemocytometer chamber. (Image source: 
http://www.ruf.rice.edu/~bioslabs/methods/microscopy/cellcounting.
html.) 
 
All the viable cells are counted (non-viable cells take up the dye and 
stain blue, viable cells remain opaque) in the four corner squares. 
Each square of the haemocytometer (with the cover-slip in place) 
represents a total volume of 0.1mm3 or 10-4cm3 (Figure 2.2.2.2). 
Since 1cm3 is equivalent to 1ml, the subsequent concentration per 
ml, and the total number of cells, is determined using the following 
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formulae: 
 
Cells per ml = the average count per 4 squares x the dilution 
factor x 104 
 
Total cell number = cells per ml x the original volume of fluid 
from which cell sample was taken 
 
On day 2, an additional 10ml of medium was added. Starting on day 
4, 10ml of medium was replaced every 2 days for a total 
differentiation period of 6 days. On day 7 of culture, cells were 
harvested as immature dendritic cells (Figure 2.2.2.3) and phenotypic 
analysis was performed via flow cytometry to verify features of 
dendritic cells. 
 
Figure 2.2.2.3. Diagram showing the differentiation protocol of bone 
marrow progenitor cells into dendritic cells and maturation with LPS 
(lipopolysaccharide). 
 
The changes in phenotypical surface expression of the antigen-
presenting receptor and co-stimulatory ligands on wild-type bone 
marrow-derived dendritic cells were tracked to show the archetypal 
alterations during DC differentiation (Figure 2.2.2.4). 
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Figure 2.2.2.4. Dendritic Cell-Surface Receptor profiles of differentiating 
bone marrow progenitors into dendritic cells using a GM-CSF-rich medium. 
 119 
2.2.3. LPS Stimulation of BMDC 
Immature AnxA1+/+ and AnxA1-/- BMDC were collected from the 
bacteriological plates by scraping and aspirating adherent, semi-
adherent, and non-adherent cells. The cell cultures were washed free 
of dead and apoptotic cell with GM-CSF-free IMDM medium, counted 
and plated at a density of 1x106/well in triplicates in polystyrene-
treated (adherent) plastic 24-well plates. Thereafter, the cells were 
incubated with medium alone or with 100ng/ml lipopolysaccharide 
(LPS, S. minnesota; Alexis Biochemicals, Nottingham, UK) at 37oC 
under humidified 5% CO2 for various time-points before the cells and 
supernatants were used in assay analyses. 
 
In some cases, after incubation, cells and supernatants were 
harvested and frozen at –20oC prior to analysis by Western Blotting, 
immunoprecipitation, enzyme-linked immunosorbent assay (ELISA) 
and electrophoretic mobility shift assay (EMSA). Also, cells were 
frozen at –80oC prior to analysis by RNA extraction, cDNA synthesis 
and gene expression profiles (real-time PCR). 
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2.2.4. Flow Cytometry 
AnxA1+/+ and AnxA1-/- BMDC were treated as described in subheading 
2.2.3. The BMDC, in the 24-well culture plates, were centrifuged at 
2000rpm for 5min and subsequently cell-free supernatants were 
collected and stored at -200C; then the BMDC were first preincubated 
in FACS buffer (PBS containing 5% FCS and 0.02% NaN3) containing 
anti-CD16/32 monoclonal antibody (1:1000 dilution) for 30min at 
4oC, to avoid nonspecific binding of the reported monoclonal 
antibodies to the FcγII/IIIR. Thereafter, cells were washed and 
incubated with the appropriate concentration of the reported 
monoclonal antibodies (1:500 dilution for PE-conjugated antibodies 
and 1:250 dilution for FITC-conjugated antibodies) in FACS buffer for 
30min at 4oC. Cells were washed, resuspended in FACS buffer and 
subsequently analysed on the flow cytometer (FACSCalibur®; Becton 
& Dickinson, Oxford, UK). 
 
Forward and side scatters were calibrated to exclude erythrocytes 
and dead cells, and at least 2x104 DC were analysed per sample. 
Determination of positive and negative populations was performed 
based on the control staining with an irrelevant IgG isotype labelled 
with PE or FITC. 
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2.2.5. Endocytosis Assay 
Quantitative analysis of DC endocytic activity was performed as 
previously described (Sallusto et al., 1995) with minor modifications. 
AnxA1+/+ and AnxA1-/- BMDC previously treated as in subheading 
2.2.3 were washed free of GM-CSF-rich medium and diluted to a cell 
density of 0.5x106 cells/ml in GM-CSF-free IMDM medium. 2x106 
AnxA1+/+ and AnxA1-/- BMDC were incubated in complete medium 
with FITC-dextran (1mg/ml, MW 145000) on non-adherent plastic 
Falcon tubes at either 370C (water bath) or 40C (on ice) for 60 
minutes. Following the incubation, the cells were washed three times 
with cold FACS solution (PBS containing 5% FCS and 0.02% NaN3).  
 
The cells were stained with PE-conjugated CD11c as described in 
subheading 2.2.3 as a marker to identify DC and then analysed by 
flow cytometry. Forward and side scatters were calibrated to exclude 
erythrocytes and dead cells, and at least 5x104 DC were analysed per 
sample. BMDC treated with FITC-dextran at 40C was used as a 
background reference and MFI values for corresponding samples were 
always subtracted. 
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2.2.6. In Vivo Migration 
Following AnxA1+/+ and AnxA1-/- BMDC treatment described in 
subheading 2.2.3, the cells were washed twice in warm PBS (370C) 
and resuspended at cell density of 25-50x106 cells/ml in warm PBS 
solution containing free carrier protein (PBS/0.1%BSA). AnxA1+/+ and 
AnxA1-/- BMDC were resuspended in 1-5ml warm CFSE solution 
(PBS/1µM CFSE/0.1%BSA) at cell density of 25-50x106 cells/ml in 
non-adherent plastic Falcon tubes and incubated for 15 minutes in 
order for CFSE labelling to occur. Five times-volumes of cold PBS 
solution (PBS/1%BSA) were added to the cell suspension to cease the 
labelling; the cells were then washed at least three times in this cold 
PBS solution. The BMDC were resuspened in serum-free medium 
(IMDM medium, 50mg/ml gentamicin) at a concentration of 20x106 
cells/ml. 
 
100µl (2x106 DC) of CFSE-labelled cells were injected subcutaneously 
in the hind paws of C57BL/6 mice and 48h post-injection the draining 
inguinal and popliteal lymph nodes were harvested. Lymph nodes 
were isolated and processed into a single-cell suspension by crushing 
and homogenising the lymph nodes through a 70-µm cell strainer. 
Single-cell suspensions were washed and resuspended in FACS 
solution and then stained with PE-labelled CD11c as previously stated 
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in subheading 2.2.3 followed by analysis on the FACSCalibur™. 
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2.2.7. Enzyme-Linked Immunosorbent Assay 
(ELISA) 
AnxA1+/+ and AnxA1-/- BMDC culture supernatants post-incubation 
were collected and analysed for TNF-α, IL-1β and IL-12 content and 
the mixed leukocyte reaction (MLR) co-culture supernatants were 
also collected and tested for IL-2 and IFN-γ levels according to the 
manufacturer’s instructions (eBioscience). 96-well EIA/RIA high-
binding plates were coated with cytokine capture antibody and 
incubated overnight at 4oC. Protein cytokine of known concentration 
was diluted a 2-fold serial dilutions to make the standard curve. 
100µl/well protein cytokine and sample was added to the coated wells 
and incubated for 2 hours at room temperature or 37oC in order to 
allow the protein present in the cell free supernatants to bind to the 
immobilised antibody already bound to the plate. After the 
incubation, the plates were washed extensively with the wash buffer 
(1x PBS/0.05% Tween-20 (pH 7.4)) in order to remove any unbound 
sample. The bound protein to the antibody was detected by the 
addition of 100 µl of a detection antibody specific for the desired 
cytokine following incubation of 1-hour.  Thereafter, the plates were 
incubated for 30min with the enzyme Avidin-Horseradish Peroxidase 
(HRP), and after an extensive wash to remove unbound antibody-
enzyme reagent, 100 µl of substrate solution (tetramethylbenzidine 
TMB) was added to produce colour.  The reaction was terminated by 
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the addition of 50 µl of 1M H3PO4 turning the samples from blue to 
yellow and the absorbance was read at a wavelength of 450nm using 
a spectrophotometer (Labsystems Multiskan Bichromatic). The 
concentration was calculated from the standard curve using the 
software Graph Pad PrismTM. 
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2.2.8. Western Blotting (Immunoblotting) 
AnxA1+/+ and AnxA1-/- BMDC were lysed in ice-cold lysis buffer (1% 
Triton-X, 20mM Tris pH7.5, 150mM NaCl, 1mM DTT - 1, 4-Dithio-DL-
threitol) containing the protease and phosphatase inhibitors: 1mM 
MgCl2 (magnesium chloride), 1mM EGTA (ethylene glycol tetraacetic 
acid), 0.5mM PMSF (phenylmethylsulfonyl fluoride), 1mM Aprotinin, 
1mM Leupeptin, 1mM Pepstatin, 50mM NaF, 10mM Na4P2O7 
(tetrasodium phosphonatophosphate), and 1mM NaVO4 (sodium 
orthovanadate), 1mM β-glycerophosphate. The lysates were 
centrifuged at 14,000 rpm for 5min at 4°C and the supernatants 
collected and stored at -20°C. To immunoprecipitate extracellular 
released Anx-A1, 5µl of anti-Anx-A1 antibody (purified polyclonal 
rabbit IgG; Zymed, California, USA) and 35µl of protein A/G 
sepharose beads were added to 500µl of culture supernatants 
obtained from 1x106 DC. Samples were incubated overnight at 4°C 
under continuous rotation and thereafter, washed with PBS. Lysates 
and immunoprecipitates were denatured with hot 6x sample buffer 
and subjected to electrophoresis on SDS-12% polyacrylamide gel. 
After subsequent transfer onto nitrocellulose membranes, these were 
incubated overnight with antibodies diluted in Tris-buffered saline 
solution containing Tween-20 (TTBS: 130mM NaCl; 2.68mM KCl; 
19mM Tris-HCl; 0.001% v/v Tween-20; pH 7.4) with 5% non-fat dry 
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milk at 4ºC. For the experiments with anti-pERK1/2 and anti-pAkt, 
the antibodies were diluted in 5% milk/TTBS buffer supplemented 
with 50mM NaF and membrane washes post incubation with TTBS 
was adjusted to 500mM NaCl. For each condition, extract equivalents 
obtained from the same number of cells were used. Immunoblotting 
and visualization of proteins by enhanced chemiluminescence (ECL; 
Amersham Pharmacia Biotech) were performed according to 
manufacturer’s instructions. 
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2.2.9. Nuclear and Cytoplasmic Extraction 
Nuclear extracts were harvested from 3x106 cells according to a 
previously described protocol with modifications (Jorritsma et al., 
2003). 24h post-LPS stimulation of AnxA1+/+ and AnxA1-/- BMDC, 
viable cells were recovered and washed in ice-cold PBS and 
resuspended in 200µl of cold Buffer A (10mM HEPES pH 7.9, 2mM 
MgCl2, 10mM KCl, 10mM NaF, 0.1mM EDTA, 10mM Na4P2O7, 0.5mM 
DTT plus a mixture of protease/phosphatase inhibitors) then 
incubated on ice. After 10min on ice, cells were lysed by addition of 
Nonidet P-40 (NP-40) in a final concentration of 1% and allowed to 
incubate at room temperature for 4min. Lysates were centrifuged at 
5000rpm for 2min. Supernatants of cytoplasmic contents were 
aspirated, collected and stored at -200C. Pellets were washed with 
200µl of Buffer A and then 50µl of Buffer B (20mM HEPES pH 7.9, 
50mM MgCl2, 0.4M NaCl, 0.2mM EDTA, 0.5mM DTT plus 
protease/phosphatase inhibitors) was added without resuspension. 
The samples were then continuously vortexed for 45-60min then 
centrifuged for 5 min at 14,000 rpm under 40C conditions. 
Supernatants containing the nuclear fractions were stored at -80°C. 
Protein/nucleic acid concentrations of the nuclear extracts were 
determined by Bradford assay using the Bio-Rad Protein Dye Reagent 
(dye, H2SO4 and CH3OH) diluted 1:5 with H2O. 
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2.2.10. Electrophoretic Mobility Shift Assay 
(EMSA) 
NF-κB DNA binding was analysed by EMSA using 5µg of nuclear 
extracts were incubated with 2µg of poly(dI:dC) in 20µl of NF-κB 
binding buffer with 32P end-labelled, double–stranded NF-κB 
oligonucleotide probes (5x105 c.p.m). Following binding, the DNA-
protein complexes were fractionated from free probe by 
electrophoresis in a non-denaturing 4%-polyacrylamide gel (29:1 
cross-linking ratio) in 0.5% Tris-base/Borate/EDTA (TBE) buffer for 
3h at 150 volts. Gels were dried and exposed to autoradiography. 
 
The NF-κB binding buffer (10X) consists of 100mM Tris-HCl pH 7.5, 
500mM NaCl, 10mM EDTA, 10mg/ml BSA, 30mMGTP and 10mM DTT. 
The non-denaturing gel 4%-polyacrylamide gel is made up of 13.5ml 
30% Acrylamide:Bisacrylamide (29:1) solution, 2.5ml 10x TBE, 500µl 
10% Ammonium Persulphate (APS), 85µl TEMED (N,N,N',N'-
tetramethylenediamine) and water up to a total volume of 50ml. 
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2.2.11. RNA Extraction 
Total RNA was extracted from immature or LPS-matured AnxA1+/+ 
and AnxA1-/- BMDC using RNeasy mini-spin columns kit (Qiagen). 
Briefly, 5x106 cells were pelleted and lysed using buffer RLT, a lysis 
buffer that contains guanidine isothiocyanate and supplemented with 
1% β-mercaptoethanol (both responsible for the inactivation of 
RNAases). The samples were homogenized by passing the lysates at 
least 5 times through a 20-gauge needle and 70% (v/v) ethanol was 
added. The samples were loaded onto RNAeasy mini columns, and 
centrifuged to allow adsorption of RNA onto the column membrane.  
Following several washes with wash buffers RW1 (low-concentration 
guanidine isothiocyanate/ethanol buffer) and RPE (high salt/ethanol 
buffer) to remove contaminants, the RNA was eluted in TE buffer 
(Tris EDTA; 10 mM Tris, 1 mM EDTA, pH 7.5). 
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2.2.12. cDNA Synthesis 
cDNA synthesis was carried out using the AMV reverse transcriptase 
kit (Promega). Briefly, 5-10 µg of total RNA were mixed with 0.5 µg 
oligo (dT)15 and diethyl pyrocarbonate (DEPC)-treated H2O and 
incubated at 70°C for 10 min. Thereafter, the mix was transferred on 
ice and supplemented with 10 units AMV reverse transcriptase, 
40units RNase inhibitor, and 1.25mM each dNTPs and incubated at 
42°C for 45min, then at 70 C for 10 min. Thereafter, samples were 
stored at -20°C. DNA concentrations were determined by 
spectrophotometry using NanoDrop spectrophotometer 
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2.2.13. Real-time PCR 
Real-time PCR was carried out by using 5µl cDNA, ABsolute™ QPCR 
ROX Mix and the fluorescent QuantiTect primers for the following 
murine genes: Fpr1 (QT01165899), Fpr-rs1 (QT01063216), Fpr-rs2 
(QT00171514), Anx-A1 (QT00145915), TLR4 (QT00259042), IL-10 
(QT00106169), IDO (QT00103936), IDOL1 (QT01066345) and TGF-
β1 (QT00145250). 
 
Cycling conditions were set according to manufacturer’s instructions. 
Sequence specific fluorescent signal was detected by 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Warrington, Cheshire, 
UK). mRNA data was normalized relative to GAPDH or 18S RNA and 
then used to calculate expression levels. We used the comparative Ct 
method to measure the gene transcription in samples (Pfaffl, 2001). 
The results are expressed as relative units based on calculation of 2-
ΔΔCt, which gives the relative amount of gene normalized to 
endogenous control (GAPDH) and to the sample with the lowest 
expression set as one. 
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2.2.14. Mixed Leukocyte Reaction (MLR) 
Immature or LPS-matured AnxA1+/+ and AnxA1-/- BMDC (C57BL/6 
background) were treated with 50 ng/ml Mitomycin C in complete 
IMDM for 1h at 37°C. Thereafter, cells were washed with complete 
IMDM and incubated with 1x105 allogeneic naïve T cells from BALB/c 
mice at two ratios (1:1, 1:5) in 96-well U-bottom culture plates at 
37oC under humidified 5% CO2. T cells were obtained as previously 
described (Shankar et al., 2004). Briefly, the axillary, inguinal and 
mesenteric lymph nodes of BALB/c mice were isolated and processed 
into a single cell suspension; then naïve T cells were purified on a 
MACS column using a CD4+ CD62L+ T cell isolation kit (Miltenyi 
Biotec). After 3 days, T cell proliferation was measured by adding 
1mCi [3H]-thymidine in the final 12h of co-culture incubation 
thereafter, cells were harvested using a semi-automatic cell harvester 
(Skatron 7022). The incorporated radioactivity was measured by 
automated scintillation counter (Tri-Carb 1900TR, Packard, Berkshire, 
UK). 
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2.2.15. Antigen-specific Leukocyte Reactions 
of OT-I/RAG-1-/- and OT-II/RAG-1-/- Transgenic 
TCR T cells 
LPS-matured AnxA1+/+ and AnxA1-/- BMDC were treated as 
aforementioned under subheading 2.2.3 with the addition of the 
chicken ovalbumin peptides OVA323-339 (ISQAVHAAHAEINEAGR) and 
OVA257-264 (SIINFEKL) in 96-well U-bottom culture plates for 24h. The 
cervical, axillary, inguinal and mesenteric lymph nodes of OT-I/RAG-
1-/- and OT-II/RAG-1-/- mice were harvested, isolated and processed 
into a single cell suspension. Thereafter, 2x105 transgenic TCR T cells 
were appropriately added to the culture plates of OVA-pulsed, LPS-
matured AnxA1+/+ and AnxA1-/- BMDC at 37oC under humidified 5% 
CO2 for 5 and/or 7 days. After 4 days, 1mCi [3H]-thymidine in the 
final 18h of the 5-day co-culture incubations; this irradiation step was 
repeated on day 6 on the 7-day co-cultures. Thereafter, cells were 
harvested using a semi-automatic cell harvester (Skatron 7022). The 
incorporated radioactivity was measured by automated scintillation 
counter (Tri-Carb 1900TR, Packard, Berkshire, UK). 
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2.3. GRAPHICAL SOFTWARE AND STATISTICAL 
ANALYSIS 
All statistical analysis was performed with Prism software (GraphPad 
software). All values are expressed as mean ± S.E.M. Statistical 
analysis was assessed either by Student’s t test or one-way ANOVA 
where appropriate. A probability of P < 0.05 was considered 
significant. 
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3. RESULTS 
3.1. Anx-A1 Mobilisation and Modulation 
during DC Maturation 
Previous studies from our and other research groups have shown that 
activation of different cell types with inflammatory stimuli causes 
increased expression and release of endogenous Anx-A1 (Damazo et 
al., 2005, Rescher et al., 2006). To investigate if this phenomenon 
occurred also in DC, Anx-A1 expression was measured in immature 
and mature DC by Western blotting and real-time PCR. Immature DC 
express high levels of Anx-A1 that is localized mainly in the cytosol 
and constitutively released to a lower levels in the culture 
supernatant (Figure 3.1.1, Time 0, lower and upper panels, 
respectively). Stimulation with LPS over 24h induced a gradual and 
time-dependent release of Anx-A1 in the extracellular medium. The 
peak of the release occurs between 1 and 3h (Figure 3.1.1, top 
panel) and is paralleled by a depletion of the intracellular store 
followed by the resynthesis at later time points, between 12-24h 
(Figure 3.1.1, lower panel). 
 
This pattern of the protein expression was mirrored at the mRNA 
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level since a marked downregulation at 3 and 6h followed by 
resynthesis at 24h was observed (Figure 3.1.2). 
 
Figure 3.1.1. Anx-A1 protein modulation between immature and mature 
dendritic cells. 
Western blotting analysis of Anx-A1 protein expression in culture supernatants (upper 
panel) and whole cell lysates (lower panel) of bone marrow-derived DC stimulated with 
LPS (100ng/ml) for the indicated times. To measure Anx-A1 levels in the culture 
supernatants samples were immunoprecipitated as described in Materials and Methods. 
Data shown is from a single experiment of n=3 mice and is representative of n=5 
experiments. 
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Figure 3.1.2. Anx-A1 mRNA expression in immature and mature dendritic 
cells. 
Cumulative Real-time PCR analysis of Anx-A1 mRNA expression in Anx-A1+/+ bone 
marrow-derived DC incubated with LPS (100ng/ml) over the indicated time course. Data 
shown is the mean ΔΔCT values ± S.E.M. of n=3 mice per experiment from 4 separate 
experiments. P values were calculated using one-way ANOVA analysis and were 
determined from comparison of Control group vs. LPS-treated groups. *P<0.05. 
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3.2. Partial Maturation Status of Immature 
Anx-A1-/- DC 
To investigate the role of endogenous Anx-A1 in DC maturation we 
compared the phenotype of bone marrow derived Anx-A1+/+ and Anx-
A1-/- DC. The first difference we observed was a significant increase 
in the number of CD11c-high positive cells in Anx-A1-/- DC 
(98.3±5.6%; p< 0.001) compared to Anx-A1+/+ DC (56.2±4.6%; p< 
0.001) (Figure 3.2.1). Further phenotypic characterization of these 
CD11c+ populations showed a similar expression of CD86 and MHC II 
and an increased expression of CD80 in Anx-A1-/- DC compared to the 
Anx-A1+/+ (Figure 3.2.1). 
 
One key feature of immature DC is to endocytose foreign antigens 
before presenting on MHC II. This function is reduced upon 
maturation and hence it is used to distinguish the immature from 
mature DC (Steinman and Hemmi, 2006). Accordingly, the capability 
of immature and mature Anx-A1+/+ and Anx-A1-/- DC to endocytose 
FITC-dextran was compared as measure of antigen uptake. 
Consistent with the analysis shown in Figure 3.2.1, uptake of FITC-
dextran by immature Anx-A1-/- DC was significantly lower than 
immature Anx-A1+/+ DC while no differences were observed between 
mature Anx-A1+/+ and Anx-A1-/-DC (Figure 3.2.2 and 3.2.3). 
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Figure 3.2.1. Heightened maturation phenotype of Anx-A1-/- DC. 
Bone marrow-derived cells were differentiated in vitro with complete medium containing 
GMCSF for 6 days as described in Materials and Methods. Flow cytometric analysis of 
Anx-A1+/+ (white histograms) and Anx-A1-/- DC (black histograms) showing mean 
fluorescence intensity (MFI) for CD11c, CD80, CD86 and MHC class II in immature Anx-
A1-/- and Anx-A1+/+ DC. Histograms and MFI values shown for CD80, CD86, MHC class II 
are gated on CD11c+ DC and percentages of CD11c+ cells are shown in brackets. Data 
and values shown are from a single experiment of n=3 mice and representative of 4 
separate experiments. 
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Figure 3.2.2. Comparison of endocytosis in Anx-A1+/+ and Anx-A1-/- DC. 
Analysis of FITC-dextran uptake by immature (left histograms) or LPS-mature (right 
histograms) Anx-A1+/+ (white histograms) and Anx-A1-/- (black histograms) DC. Cells 
were incubated with FITC-dextran uptake at 37ºC (bold lines) as described under 
“Materials and Methods” and analysed by flow cytometry. FITC-dextran uptake at 4ºC 
served as negative control (dotted lines) Data shown is from a single experiment of n=3 
mice and is representative of 3 experiments. 
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Figure 3.2.3. Endocytic analysis between Anx-A1+/+ and Anx-A1-/- DC. 
Cumulative results of FITC-dextran uptake in immature and LPS-mature Anx-A1+/+ and 
Anx-A1-/- DC. Values represent the mean MFI ± S.E.M. of CD11c+/FSC high-gated 
populations obtained from DC cultures of n=3 mice. Data shown are cumulative from 3 
experiments and P values are calculated by Student’s T-test analysis and are determined 
from comparison between the Anx-A1+\+ data sets and their respective Anx-A1-\- data 
sets. **P<0.01. 
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3.3. Impaired Up-Regulation of Maturation 
Molecules on mature Anx-A1-/- DC 
Upregulation in cell surface levels of MHC class I and II and co-
stimulatory molecules characterise the transition of DC from the 
immature to the mature state. Escalated levels of these surface 
receptors in immature DC prompted us to further analyze the 
expression of phenotypical markers of DC maturation (Cella et al., 
1997b). Thus, immature Anx-A1+/+ and Anx-A1-/- DC were stimulated 
with LPS for 24h and thereafter we stained the cells with antibodies 
against CD40, CD54, CD80 and CD86, CCR7 and MHC II. Immature 
Anx-A1-/- DC expressed similar levels of CD86 and MHC II, higher 
levels of CD40, CD54 and CD80 and decreased levels of CCR7 
compared with Anx-A1+/+ DC. Stimulation with LPS caused an 
expected increase in expression of the maturation markers in Anx-
A1+/+ however, surprisingly, failed to remotely induce an increase in 
Anx-A1-/- DC (Figure 3.3.1). This pattern was conserved over several 
experiments and the cumulative results, expressed as percentage 
increase over basal mean fluorescence intensity (MFI), are 
summarised (Figure 3.3.2). 
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Figure 3.3.1. Expression of MHC class II and co-stimulatory molecules in 
Anx-A1-/- DC. 
Bone marrow-derived Anx-A1+/+ and Anx-A1-/- DC were incubated with culture medium 
or LPS for 24h and then analysed by FACS for the expression of MHC class II, CD40, 
CD80, CD86, CCR7 and CD54. Values in graphs are mean MFI of n=3 mice from a single 
experiment. Data shown are representative of 5 separate experiments and P values were 
calculated using one-way ANOVA and were determined from the comparison of the Anx-
A1+\+ sample groups with their respective Anx-A1-\- sample group counterparts. 
*P<0.05, **P<0.01, ***P<0.001. 
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Figure 3.3.2  Defective up-regulation of maturation markers in Anx-A1-/- DC. 
Cumulative analysis of LPS-induced MHC class II, CD40, CD80, CD86, CCR7 and CD54 
up-regulation in Anx-A1+/+ and Anx-A1-/- DC. Values are expressed as mean percentages 
of increase of MFI ± S.E.M. of mature vs. immature DC. Data shown are cumulative 
results from n=3 mice per experiment and a summation of 5 different experiments. P 
values were calculated using one-way ANOVA and were determined from the comparison 
of the Anx-A1+\+ data sets with their respective Anx-A1-\- data sets. *P<0.05, **P<0.01. 
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3.4. Abated Cytokine Production by Anx-A1-/- 
DC 
Stimulation of DC with LPS induced the production of pro-
inflammatory and T helper cell skewing cytokines. The fact that Anx-
A1-/- DC showed an altered phenotype even in the absence of LPS 
and a mediocre increase in the surface expression of maturation 
markers upon stimulation encouraged us to investigate whether this 
phenotype was also accompanied by an impaired cytokine production. 
 
To this aim, immature DC were stimulated with LPS over several time 
points and measured for the production of IL-1β, TNF-α and IL-12 in 
the culture supernatants. As shown in Figure 3.4.1, stimulation of 
Anx-A1+/+ DC with LPS induced a time dependent increase in IL-1β, 
TNF-α and IL-12 production that became significant after 3 or 6h of 
stimulation. Activation of Anx-A1-/- DC in the same conditions showed 
a decreased production of all cytokines compared to Anx-A1+/+ DC 
(Figure 3.4.1). 
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Figure 3.4.1. Impaired production of TNF-α, IL-1β and IL-12 in Anx-A1-/- 
DC. 
Bone marrow-derived Anx-A1+/+ and Anx-A1-/- DC were incubated with LPS (100ng/ml) 
for the indicated times and the supernatants collected and analysed for their content of 
IL-1β, TNF-α and IL-12. Values are mean ± S.E.M. of n=3 mice from a single experiment 
and are representative of 6 different experiments. P values were calculated using 
Student’s T-test and statistical analysis was determined from Anx-A1+\+ vs. Anx-A1-\- 
data within the same sample group. *P<0.05, **P<0.01. 
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3.5. Elevated IDO expression in Anx-A1-/- DC 
Immature Anx-A1-/- DC have an increased surface expression of the 
maturation markers: CD40 and CD80, and inhibited production of 
pro-inflammatory cytokines: IL-1β and TNF-α as well as T-cell 
skewing cytokine, IL-12 when stimulated. This phenotype, to some 
extent, resembles semi-mature, tolerogenic DC. These DC are usually 
characterized by production of TGF-β, IL-10 and/or indoleamine 2,3-
dioxygenase (IDO). Indoleamine 2,3-dioxygenase is a rate-limiting 
enzyme for tryptophan metabolism; tryptophan is an indispensable 
amino acid involved in T cell activation and proliferation. Hence, the 
expression of TGF-β, IL-10, indoleamine 2,3-dioxygenase and 
indoleamine 2,3-dioxygenase 2 (indoleamine 2,3-dioxygenase-like-1, 
IDOL1) mRNA was analyzed by real-time PCR in immature Anx-A1+/+ 
DC and Anx-A1-/- DC stimulated with LPS. TGF-β mRNA and protein 
levels were not detectable by real-time PCR and ELISA respectively.  
 
In Figure 3.5.1, Anx-A1-/- DC stimulated with LPS did not induce 
significant levels above basal expression of IL-10 mRNA whilst IL-10 
mRNA expression was downregulated upon LPS stimulation in Anx-
A1+/+ DC that became significant at 6h and 24h of stimulation. 
Alternatively, both IDO and IDOL1 mRNA expression were 
upregulated in Anx-A1-/- DC when stimulated with LPS within the first 
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6h followed by a homeostatic downregulation of IDOL1 mRNA to 
basal level but a sustained elevation IDO mRNA levels at 24h post-
LPS stimulation (Figure 3.5.2). 
 
Figure 3.5.1. IL-10 mRNA Expression between Anx-A1+/+ and Anx-A1-/- 
DC. 
Real Time PCR analysis of IL-10 expression in Anx-A1+/+ and Anx-A1-/- DC incubated with 
culture medium (Control) or LPS (LPS; 100ng/ml) for the indicated times. Values are 
mean ΔΔCT ± S.E.M. of n= 3 mice. Data shown are from a single experiment and P 
values are determined by Student’s T-test and calculated from Anx-A1+\+ vs. Anx-A1-\- 
data within the same sample group. *P<0.05. 
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Figure 3.5.2. IDO and IDOL1 mRNA Expression between Anx-A1+/+ and 
Anx-A1-/- DC. 
Real Time PCR analysis of IDO and IDOL1 expression in Anx-A1+/+ and Anx-A1-/- DC 
incubated with culture medium (Control) or LPS (LPS; 100ng/ml) for the indicated times. 
Values are mean ΔΔCT ± S.E.M. of n=3 mice. Data shown are from a single experiment 
and P values were determined by Student’s T-test and calculated from Anx-A1+\+ vs. 
Anx-A1-\- data within the same sample group. *P<0.05, **P<0.01 
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3.6. TLR4 Expression is Comparable in Anx-
A1-/- DC 
LPS is recognised by the TLR4 member of the PRR subfamily of 
receptors and upon LPS binding the receptor, signalling cascades are 
initiated. Pharmacologically, the frequency of a particular receptor 
expression effects cellular response to a specific stimulus; case in 
point, the co-stimulatory receptors expression and cytokine 
production. The expression of TLR4 on Anx-A1+/+ and Anx-A1-/- DC 
was analysed by real-time PCR to eliminate the level of TLR4 
expression as a factor accounting for poor activation status of Anx-
A1-/- DC. Surprisingly, as shown in Figure 3.6.1, Anx-A1-/- DC 
stimulated with LPS in a time-dependent manner portrayed a slightly 
greater but not significant expression of TLR4 in contrast to Anx-
A1+/+ DC. However, one may assume that TLR4 mRNA expression in 
BMDC was generally unmodulated by LPS stimulation. 
 
 152 
Figure 3.6.1. Paralleled TLR4 mRNA Expression between Anx-A1+/+ and 
Anx-A1-/- DC. 
Real Time PCR analysis of TLR4 expression in Anx-A1+/+ and Anx-A1-/- DC incubated with 
culture medium (Control) or LPS (LPS; 100ng/ml) for the indicated times. Values are 
mean ΔΔCT ± S.E.M. of n=3 mice. Data shown are from a single experiment and P values 
were determined by Student’s T-test and calculated from Anx-A1+\+ vs. Anx-A1-\- data 
within the same sample group. 
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3.7. Diminished NF-κB activation in Anx-A1-/- 
DC 
LPS activates TLR4 and induces a cascade of signalling events 
culminating in the activation of NF-κB and thus, the induction of 
numerous pro-inflammatory genes including the cytokines IL-1β and 
TNF-α. Given the attenuated production of these cytokines in Anx-A1-
/- DC, we investigated whether these differences were due to an 
impaired activation of this transcription factor. DC from Anx-A1+/+ or 
Anx-A1-/- mice were stimulated with LPS for various times and then 
analyzed for their NF-κB/DNA-binding activity by EMSA. Activation of 
Anx-A1+/+ DC with LPS induced a time-dependent increase and 
oscillatory pattern of NF-κB/DNA-binding activity. When we 
performed a similar analysis in Anx-A1-/- DC we observed a delayed 
onset of oscillatory pattern and a marked reduction in NF-κB/DNA-
binding activity (Figure 3.7.1). 
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Figure 3.7.1. Delayed and defective NF-κB activation in Anx-A1-/- DC. 
Electrophoretic mobility shift assay showing NF-κB/DNA-binding activity in nuclear 
extracts of Anx-A1+/+ and Anx-A1-/- DC stimulated with LPS (100ng/ml) for the indicated 
times. Autoradiogram shown is representative of n=5 experiments. 
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3.8. Waned Re-synthesis of IκBα in Anx-A1-/-
DC 
Activation of NF-κB occurs via the phosphorylation, ubiquitination and 
degradation of its inhibitory subunit IκBα. This process is followed by 
the resynthesis of IκBα promoted by activated NF-κB itself as a 
negative feedback mechanism to prevent prolonged NF-κB activation 
(Hoffmann et al., 2002). Analysis of LPS-induced IκBα degradation in 
Anx-A1+/+ and Anx-A1-/- DC showed a similar pattern with an almost 
complete degradation of the protein between 15 and 30min. 
However, at 60min post-stimulation (time when IκBα resynthesizes) 
Anx-A1-/- DC showed a virtually complete inability to regenerate 
protein as compared to Anx-A1+/+ cells (Figure 3.8.1). These findings 
are consistent with EMSA results (Figure 3.7.1), which suggest that 
the reduced activation of this transcription factor might be in turn 
responsible of the limited resynthesis of IκBα. 
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Figure 3.8.1. Impaired IκBα regeneration in Anx-A1-/- DC. 
Western blotting analysis of IκBα degradation profile in LPS-treated Anx-A1+/+ and Anx-
A1-/- DC. Autoradiograms and blots shown are representative of n=5 experiments. 
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3.9. Impaired FPR Signalling in Anx-A1-/- DC 
The binding of Anx-A1 to its receptor FPR induces a cascade of 
signalling events that contribute to cell activation. To investigate 
whether the exhausted phenotype of mature Anx-A1-/- DC was due to 
impaired FPR activation, we compared ERK1/2 and Akt 
phosphorylation in LPS-stimulated Anx-A1+/+ and Anx-A1-/- DC. 
Figure 3.9.1 highlights that stimulation of Anx-A1+/+ DC with LPS 
caused a rapid phosphorylation of both ERK1/2 and Akt whilst in Anx-
A1-/- DC there was minimal phosphorylation of all kinases; confirming 
the previous observation that the lack of endogenous Anx-A1 result in 
diminished FPR signalling (Alldridge et al., 1999). 
 
Physiologically, the absence of ligand may lead to modulation of its 
receptor expression, which can in turn be responsible for different 
extent of downstream signalling activation. To confirm the defect in 
ERK1/2 and Akt phosphorylation observed in the Anx-A1-/- DC was 
due to the absence of Anx-A1 and not to a differential expression of 
its receptor, Fpr1, FPR-rs1 and FPR-rs2 mRNA expression in mature 
and immature DC were analysed. Fpr1, FPR-rs1 and FPR-rs2 were 
expressed at similar levels in immature Anx-A1+/+ and Anx-A1-/- DC. 
Stimulation with LPS for 24h induced an upregulation of FPR and FPR-
rs2 but not FPR-rs1 with no significant differences being observed in 
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Anx-A1+/+ and Anx-A1-/- DC (Figure 3.9.2). 
 
Figure 3.9.1. Impaired FPR signalling in Anx-A1-/- DC. 
Western blot analysis of phosphorylated and total ERK1/2 and Akt of cell lysates of Anx-
A1+/+ and Anx-A1-/- DC stimulated with LPS (100ng/ml) for the indicated times. 
Autoradiograms and blots shown are representative of n=5 experiments. 
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Figure 3.9.2. Analysis of FPR expression in Anx-A1+/+ and Anx-A1-/- DC. 
Real Time PCR analysis of Fpr1, Fpr-rs1 and Fpr-rs2 expression in Anx-A1+/+ and Anx-A1-
/- DC incubated with culture medium (Control) or LPS (LPS; 100ng/ml) for 24h. Values 
and data are mean ΔΔCT ± S.E.M. of n=3 mice per experiment and are cumulative of 5 
separate experiments. P values were determined by one-way ANOVA and calculated from 
Anx-A1+\+ vs. Anx-A1-\- data within the same sample group. 
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3.10. Impaired Migratory Capacity of Anx-A1-/- 
DC In Vivo 
The maturation of DC at the site of infection is followed by their 
migration to the local draining lymph node where DC present the 
antigen to T cells. This process is mainly driven by the expression of 
the chemokine receptor CCR7 in mature DC and the high levels of its 
ligands CCL19 and CCL21 in the lymph nodes (Forster et al., 2008, 
Sanchez-Sanchez et al., 2006). Given the impaired ability of mature 
Anx-A1-/- DC to up-regulate CCR7 (as shown in Figure 3.3.1), the 
functional consequences of this impaired phenotype was investigated 
by evaluating their ability to migrate to the draining lymph nodes of 
host recipient mice. Therefore, we subcutaneously injected CSFE-
labelled mature Anx-A1+/+ and Anx-A1-/- DC into control C57BL/6 
mice as previously reported (de Noronha et al., 2005, Lammermann 
and Sixt, 2008, Sixt et al., 2005). FACS analysis of lymph node cells 
collected from mice injected with wild-type DC contained about 0.3 % 
of CD11c+ CFSE+ cells while about 40 % less cells could be recovered 
from mice injected with Anx-A1-/- DC (Figure 3.10.1). 
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Figure 3.10.1. Impaired migratory capacity in vivo of Anx-A1-/- DC. 
LPS-matured Anx-A1-/- and Anx-A1+/+ DC were labelled with CFSE and injected 
subcutaneously into the hind paws of C57BL/6 mice. DC migration to the draining lymph 
nodes was assessed as described in Materials and Methods 48 hours after the injection. 
The numbers in the dot plots indicate the percentage of CD11c+/CFSE+ DC recovered 
from a single mouse and are representative of 3 different experiments with similar 
results. The bar graph shows the mean number ± S.E.M. of CD11c+/CFSE+ DC recovered 
from n=3 mice and is representative of 3 different experiments with similar results. P 
values were determined by one-way ANOVA and calculated from Anx-A1+\+ vs. Anx-A1-\- 
data. *P<0.05. 
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3.11. Decreased T-cell Stimulatory Capacity of 
Anx-A1-/- DC 
The impaired capacity of Anx-A1-/- DC to fully mature prompted us to 
assess their ability to initiate T cell-driven responses. As a result, 
immature and mature Anx-A1+/+ and Anx-A1-/- DC from C57BL/6 
mice were co-cultured with allogeneic naïve T cells form BALB/c mice 
and T cell proliferation, IL-2 and IFN-γ production were recorded as a 
measure of T-cell stimulatory ability. Consistent with the findings 
showed thus far, mature Anx-A1+/+ DC induced a vigorous 
proliferative response and elevated IL-2 and IFN-γ production 
whereas Anx-A1-/- DC showed a significantly reduced ability to induce 
either cell proliferation or IL-2 and IFN-γ production. Surprisingly, 
incubation of naïve T cells with immature Anx-A1-/- DC showed 
increased but not significant levels of 3H-thymidine incorporation, IL-
2 and IFN-γ production compared to Anx-A1+/+ counterparts (Figure 
3.11.1). Together these results further demonstrate that, in absence 
of Anx-A1, DC lose their capacity to stimulate a robust T cell 
mediated effector response. 
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Figure 3.11.1. Abated stimulatory activity and Th1 skewing capacity of 
LPS-matured Anx-A1-/- DC. 
3H-thymidine incorporation, IL-2 and IFN- γ production from a mixed leukocyte reaction 
of naïve CD4+ T cells from BALB/c mice cultured with allogeneic immature or mature 
Anx-A1+/+ or Anx-A1-/- DC from C57BL/6 mice at two ratios (1:1 or 1:5) for 72h. Values 
are mean ± S.E.M. of cytokine concentration from n=3 mice and is representative of 4 
different experiments. P values were determined by Student’s T-test and calculated from 
Anx-A1+\+ vs. Anx-A1-\- comparison of the respective data sets. *P<0.05, **P<0.01. 
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3.12. Diminished Activation of Antigen-specific 
T cells by Anx-A1-/- DC 
Confirmation of the impaired ability of Anx-A1-/- DC to initiate T cell-
driven responses prompted further dissection of this poor APC 
function of Anx-A1-/- DC. Therefore, the use of transgenic TCR mouse 
models was employed to emphasize if the effect of Anx-A1 is more 
substantial in certain types of antigen-specific T-cell reactions; to 
perform this, the OT-I/RAG-1-/- and OT-II/RAG-1-/- transgenic mice 
were exploited to this end. OT-I/RAG-1-/- and OT-II/RAG-1-/- mice 
generate mature naïve T lymphocytes with a single functional TCR 
epitope that recognise the peptide sequences SIINFEKL (OVA257-264) 
and ISQAVHAAHAEINEAGR (OVA323-339) from chicken ovalbumin 
respectively. 
 
Hence, LPS-matured Anx-A1+/+ and Anx-A1-/- DC were pulsed with 
corresponding chicken ovalbumin peptides (OVA257-264 or OVA323-339) 
then co-cultured with transgenic TCR T cells form OT-I/RAG-1-/- (OT-I 
CD8) and OT-II/RAG-1-/- (OT-II CD4) mice. T cell proliferation was 
noted as a measure of DC stimulatory potential within antigen-
specific T-cell responses. The findings showed that peptide-pulsed, 
mature Anx-A1+/+ DC induced a strong, concentration-independent 
proliferative response in OT-I CD8 T cells and a strong, 
concentration-dependent proliferation of OT-II CD4 T cells during 
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both 5-day co-culture (Figure 3.12.1) and 7-day co-culture (Figure 
3.12.2) incubations. Whereas Anx-A1-/- DC demonstrated a 
significantly reduced ability to induce T cell proliferation in both OT-I 
CD8 and OT-II CD4 T cells during 5-day co-culture (Figure 3.12.1). 
Though the lack of proliferation was sustained in co-cultures with OT-
I CD8 T cells and Anx-A1-/- DC for 7-day co-cultures, this proliferative 
insufficiency, interestingly, was markedly abolished in similar 
incubations between Anx-A1-/- DC and OT-II CD4 T cells as seen in 
Figure 3.12.2. 
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Figure 3.12.1. Weakened stimulatory activity of peptide-pulsed, LPS-
matured Anx-A1-/- DC in 5-day co-cultures. 
3H-thymidine incorporation from mixed leukocyte reactions of OT-I CD8 T cells (upper 
panel) and OT-II CD4 T cells (lower panel) cultured with OVA-loaded, mature Anx-A1+/+ 
and Anx-A1-/- DC for 5 days. Values are mean radioactivity ± S.E.M. of 4 separate 
experiments with similar results. P values were determined by Student’s T-test and 
calculated from Anx-A1+\+ vs. Anx-A1-\- comparison of the respective data sets. 
**P<0.01, ***P<0.001. 
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Figure 3.12.2. Lessened Stimulatory effect in 7-day co-cultures of 
peptide-pulsed, LPS-matured Anx-A1-/- DC with OT-I CD8 T cells. 
3H-thymidine incorporation from mixed leukocyte reactions of OT-I CD8 T cells (upper 
panel) and OT-II CD4 T cells (lower panel) cultured with OVA-loaded, mature Anx-A1+/+ 
and Anx-A1-/- DC for 7 days. Values are mean radioactivity ± S.E.M. of 4 separate 
experiments with similar results. P values were determined by Student’s T-test and 
calculated from Anx-A1+\+ vs. Anx-A1-\- comparison of the respective data sets. *P<0.05, 
**P<0.01. 
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3.13. Reduced IL-2 Production in OT-I CD8 T 
cell co-cultures with Anx-A1-/- DC 
Observing the impaired ability of Anx-A1-/- DC to initiate OT-I CD8 T 
cell proliferation over 5-day and 7-day co-cultures and OT-II CD4 T 
cell expansion in 5-day cultures encouraged further scrutiny of T cell-
driven responses. Therefore, the supernatants of OVA-pulsed, LPS-
matured Anx-A1+/+ and Anx-A1-/- DC co-cultured with OT-I/RAG-1-/- 
(OT-I CD8) and OT-II/RAG-1-/- (OT-II CD4) transgenic TCR T cells 
were collected for cytokine analysis. The T-cell-specific mitogenic 
cytokine, IL-2, was tested as a measure of T-cell growth. 
 
OVA-pulsed, mature Anx-A1+/+ DC provoked a potent, concentration-
dependent increase in IL-2 co-culture levels containing both OT-I CD8 
T cells and OT-II CD4 T cells during 5-day co-culture as well as 7-day 
co-culture incubations (Figure 3.13.1 and Figure 3.13.2 respectively). 
Anx-A1-/- DC stimulated an abridged IL-2 production in both OT-I 
CD8 and OT-II CD4 T cell co-cultures, which were significant at 
certain concentrations, during 5-day co-culture incubations (Figure 
3.13.1). Although this suppression in IL-2 levels persisted in co-
cultures with Anx-A1-/- DC and OT-I CD8 T cells for 7-day co-cultures, 
this IL-2 deficiency was completely rescued in 7-day incubations 
between Anx-A1-/- DC and OT-II CD4 T cells (Figure 3.13.2). 
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Figure 3.13.1. Attenuated IL-2 content in 5-day co-cultures with OVA-
pulsed, LPS-matured Anx-A1-/- DC. 
Specific IL-2 ELISA analysis from mixed leukocyte reactions of OT-I CD8 T cells (upper 
panel) and OT-II CD4 T cells (lower panel) cultured with OVA-loaded, mature Anx-A1+/+ 
and Anx-A1-/- DC for 5 days. Values are mean concentration ± S.E.M. of 4 separate 
experiments with similar results. P values were calculated using Student’s T-test and 
statistical analysis was determined from Anx-A1+\+ vs. Anx-A1-\- data within the same 
sample group. *P<0.05, **P<0.01. 
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Figure 3.13.2. Suppressed IL-2 levels in 7-day co-cultures of OVA-pulsed, 
LPS-matured Anx-A1-/- DC with OT-I CD8 T cells. 
Specific IL-2 ELISA analysis from mixed leukocyte reactions of OT-I CD8 T cells (upper 
panel) and OT-II CD4 T cells (lower panel) cultured with OVA-loaded, mature Anx-A1+/+ 
and Anx-A1-/- DC for 7 days. Values are mean concentration ± S.E.M. of 4 separate 
experiments with similar results. P values were calculated using Student’s T-test and 
statistical analysis was determined from Anx-A1+\+ vs. Anx-A1-\- data within the same 
sample group. *P<0.05, **P<0.01. 
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3.14. Impaired IFN-γ Production in OT-I and 
OT-II T cell co-cultures with Anx-A1-/- DC 
Surveying the T cell proliferation and IL-2 production of OT-I and OT-
II T cells when incubated with Anx-A1+/+ DC and Anx-A1-/- DC during 
5-day and 7-day co-cultures revealed intricate data that suggest a 
varying extent of the role of DC-derived Anx-A1 in CD8 and CD4 T-
cell responses. Hence, additional exploration of this effect on a 
differentiating T-helper-like phenotype was pursued. Therefore, the 
supernatants of OVA-pulsed, LPS-matured Anx-A1+/+ DC and Anx-A1-
/- DC co-cultured with OT-I/RAG-1-/- (OT-I CD8) and OT-II/RAG-1-/- 
(OT-II CD4) transgenic TCR T cells used for the IL-2 investigations 
were also examined for their IFN-γ, IL-4, IL-17 and IL-10 content. 
 
Co-culture supernatants of OVA-pulsed, mature Anx-A1+/+ DC and 
Anx-A1-/- DC and both OT-I CD8 T cells and OT-II CD4 T cells during 
5-day as well as 7-day incubations did not trigger measurable levels 
of IL-4 and the IL-17 and IL-10 cytokine profiles were not 
reproducible and thus inconclusive. However, OVA-pulsed, mature 
Anx-A1+/+ DC elicited a profound IFN-γ release in co-cultures with OT-
I CD8 T cells, in a concentration-independent manner, and OT-II CD4 
T cells, in a concentration-dependent manner, during both 5-day co-
culture and 7-day co-culture incubations (Figure 3.14.1 and 3.14.2 
respectively). Meanwhile, Anx-A1-/- DC stimulated a significant deficit 
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in IFN-γ production in both OT-I CD8 and OT-II CD4 T cell co-cultures 
during both 5-day co-cultures (Figure 3.14.1) and 7-day co-cultures 
(Figure 3.14.2). 
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Figure 3.14.1. Diminutive IFN-γ concentrations in 5-day co-cultures of 
OVA-pulsed, LPS-matured Anx-A1-/- DC. 
IFN-γ production in co-cultures of OT-I CD8 T cells (upper panel) and OT-II CD4 T cells 
(lower panel) and OVA-loaded, mature Anx-A1+/+ and Anx-A1-/- DC for 5 days. Values 
are mean concentration ± S.E.M. of 4 separate experiments with similar results. P values 
were calculated using Student’s T-test and statistical analysis was determined from Anx-
A1+\+ vs. Anx-A1-\- data within the same sample group. **P<0.01, ***P<0.001. 
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Figure 3.14.2. Decreased IFN-γ production in 7-day co-cultures of OVA-
pulsed, LPS-matured Anx-A1-/- DC and OT-I CD8 T cells. 
IFN-γ content in co-cultures of OT-I CD8 T cells (upper panel) and OT-II CD4 T cells 
(lower panel) and OVA-loaded, mature Anx-A1+/+ and Anx-A1-/- DC for 7 days. Values 
are mean concentration ± S.E.M. of 4 separate experiments with similar results. P values 
were calculated using Student’s T-test and statistical analysis was determined from Anx-
A1+\+ vs. Anx-A1-\- data within the same sample group. *P<0.05, **P<0.01. 
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4. DISCUSSION 
Recent focus on the role of Anx-A1 in the adaptive immune response 
has revealed that this protein modulates T cell activation by fine-
tuning the strength of TCR signalling (D'Acquisto et al., 2008a, 
D'Acquisto et al., 2007a, D'Acquisto et al., 2007b). In this study, I 
sought to determine the role of endogenous Anx-A1 in DC biology 
examining events preceding T cell activation, but with a clear 
overspill on the consequential ability to activate T cells. To this aim, 
we generated bone marrow DC from Anx-A1-/- mice and compared 
them to their wild-type littermates. 
 
4.1. Anx-A1 Expression and Modulation in 
BMDC 
Prior to published data based on this thesis work, Anx-A1 had not 
been shown to be expressed in human and murine dendritic cells ex 
vivo nor in vitro. Extensive work had been performed, on very closely 
related cells, by focussing on the actions, the expression and 
distribution and the modulation of Anx-A1, in monocytes and more 
particularly, macrophages (Ambrose et al., 1992, Perretti et al., 
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1993b, Getting et al., 1997). Therefore, firstly, I examined if Anx-A1 
is present in bone marrow-derived dendritic cells and whether the 
protein was modulated during DC activation via TLR, and DC 
maturation. I found that Anx-A1 protein was preformed in the 
cytosolic compartment of terminally differentiated immature bone 
marrow-derived dendritic cells with the full-length protein at 
predominant levels compared to the N-terminal cleaved species, 
which was at minimal levels. In addition, the activation of TLR4 by 
LPS resulted in the secretion of the protein into the extracellular 
space with no detectable increase in protein cleavage. For the 
recorded time-points, the secretion peaked at 3h post-LPS 
stimulation and the protein was being resynthesized by 12h post-
stimulation and was completely restored to basal levels at 24h after 
activation. I also scrutinised the profile of messenger transcript levels 
during maturation process and the data complemented the protein 
modulation. 
4.2. Semi-mature Profile of Immature Anx-
A1-/- DC 
The first difference that I observed when I examined the classical 
phenotypical characteristics of immature BMDC was that immature 
Anx-A1-/- DC displayed an increased number of CD11c+ cells and, in 
addition, expressing high levels of CD40, CD54, CD80, reduced levels 
of CCR7 but similar levels of MHC II and CD86. One of the primary 
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functional attributes of immature DC is their ability to patrol and to 
endocytose foreign matter as potential danger-associated molecular 
patterns (DAMP). If DC stimulation does not occur in the periphery, 
DC remain immature and tissue-resident, expressing low levels of 
MHC class II (MHC-II) and co-stimulatory molecules. Therefore, the 
immature Anx-A1-/- DC exhibited the phenotypic features of DC that 
underwent a partial- or semi-maturation process. 
 
These semi-mature DC develop typically under steady-state 
conditions from immature, tissue-resident DC that encounter self-
antigens and commence a maturation process driven by TNF-α, which 
is expressed in considerable quantities in murine immature DC. 
Generation of semi-mature DC from either murine precursors or 
human peripheral blood monocytes possess a tolerogenic profile and 
induce either T cell anergy or, in most cases, a regulatory T cell pool 
(McGuirk et al., 2002, Akbari et al., 2001, Menges et al., 2002, 
Jonuleit et al., 2000). The characteristics of these DC are high 
expression of MHC-II and co-stimulatory molecules, but low or absent 
production of pro-inflammatory cytokines, such as IL-1β, IL-6, TNF-α, 
and in particular, IL-12p70 and some of cases production of anti-
inflammatory cytokines, such as IL-10 (Christensen et al., 2002). 
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4.3. Weakened Up-Regulation of Maturation 
Molecules on mature Anx-A1-/- DC 
To further compare the characteristics of semi-mature tolerogenic 
DC, I analyzed the surface receptors in LPS-matured Anx-A1-/- DC to 
observe if there would be a switch from tolerogenic to immunogenic 
functional profile (Granucci et al., 2001). Surprisingly, my 
observations uncovered an impaired capacity to up-regulate the 
expression of most of the receptors investigated and a virtual inability 
of MHC-II, CD80, CD54 and CCR7 up-regulation compared to Anx-
A1+/+ DC. 
 
This loss of plasticity in immature Anx-A1-/- DC to resume maturation 
from its arrested, semi-mature state to a fully mature, immunogenic 
DC when exposed to stimuli such as LPS was not expected. Immature 
Anx-A1-/- DC appeared to emerge from the DC differentiation process 
in a peculiar state of terminally matured DC and application of LPS 
only provoked a minor increase of up-regulation in a couple of 
receptors examined. Specifically, the most significant defect was the 
down-regulated expression of CCR7 and the failure of its upregulation 
upon exposure of Anx-A1-/- DC to LPS. I proceeded to question 
prominent and distinctive qualities of both immature DC, such as 
endocytosis, and mature DC, such as cytokine production and 
migration. 
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4.4 Reduced Endocytic Ability of Immature 
Anx-A1-/- DC 
One of the main functional characteristics of immature DC is 
endocytosis (Blander and Medzhitov, 2006, Silverstein et al., 1977). 
Considering that immature Anx-A1-/- DC display a semi-mature 
phenotypic profile and the intimate involvement of the annexins with 
actin and actin-dependent process such as phagocytosis (Gerke and 
Moss, 1997, Hayes et al., 2004), I, therefore, addressed the 
endocytic capacity of immature Anx-A1-/- DC. Immature Anx-A1-/- DC 
demonstrated an inhibition of endocytosis - a 34% reduction of mean 
fluorescence intensity of endocytosed FITC-dextran by immature Anx-
A1-/- DC compared to immature Anx-A1+/+ DC. DC maturation 
triggers a transformation process that converts immature, antigen-
processing DC into mature, antigen-presenting DC. As expected, 
endocytosis mechanisms are down-regulated in mature DC, upon LPS 
stimulation both mature Anx-A1+/+ DC and Anx-A1-/- DC endocytosed 
considerably less FITC-dextran compared to their immature 
counterparts. 
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4.5. Impaired Mature DC Functions displayed 
by Anx-A1-/- DC 
Stimulation of DC with microbial products - such as LPS - instigate a 
complex maturation process in immature DC characterized by their 
migration from tissues to secondary lymphoid organs (Reis e Sousa 
et al., 2003) and up-regulation of MHC as well as co-stimulatory 
molecules that are pivotal in T cell priming and the secretion of pro-
inflammatory cytokines including TNF-α and IL-1β as well as IL-12, a 
cytokine that is essential in driving Th1 cells polarization (Macagno et 
al., 2007). 
 
My investigations revealed that LPS-matured Anx-A1-/- DC failed to 
effectively migrate to the draining afferent lymph nodes in an 
adoptive transfer experimental protocol. This was conclusive by the 
lower percentage of migrated, CFSE-positive Anx-A1-/- DC present in 
the draining lymph nodes compared to the percentage of migrated, 
CFSE-positive Anx-A1+/+ DC present in similar tissues. 
 
The down-regulated expression of CCR7 in immature Anx-A1-/- DC, 
which ceased to increase its expression upon activation with LPS was 
a key indicator of a probable migratory deficiency. Inflammatory DC, 
as well as steady-state migratory DC, absolutely require the up-
regulation of surface CCR7 in order to initiate migration along 
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CCL19/CCL21 chemokine gradient to proximal lymph nodes for DC-T-
cell interactions (Randolph, 2001, Sallusto et al., 1999, Sallusto and 
Lanzavecchia, 2000, Ohl et al., 2004) 
 
Examining cytokine production, in my experiments, the strongest 
impairment was observed at the early time points (range from 0.5h 
to 6h) suggesting that the absence of Anx-A1 exerts a stronger 
influence on the first phase of LPS-induced DC activation and that this 
might be responsible for the ablated production of IL-1β, TNF-α and 
IL-12. 
 
Several studies have shown that cytokine production by DC is 
subjected to tight control (Reis e Sousa, 2004b, Reis e Sousa, 
2004a). In particular, it has been shown that the production of TNF-α 
and IL-1β occur in the first few hours post-stimulation and the 
production of IL-12 peak at later time points. These and other studies 
demonstrated that in response to LPS, the kinetics of DC activation is 
extremely important in regulating their capacity to prime T cells 
(Langenkamp et al., 2002, Langenkamp et al., 2000). 
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4.6. Defective oscillatory NF-κB activation in 
AnxA1-deficient DC 
To understand the mechanism responsible for decreased TNF-α, IL-1β 
and IL-12 production in Anx-A1-/- DC, I investigated early and late 
LPS signalling in these cells.  
 
LPS activates TLR4, a member of a family of innate receptors that 
sense microbial products and trigger DC maturation and cytokine 
production. Activation of TLR4 leads to the recruitment of adaptor 
proteins, which in turn lead to a cascade of events culminating in the 
activation of NF-κB (Reis e Sousa, 2004b). LPS signals through TLR4 
and activates two downstream pathways, each of which is thought to 
directly activate NF-κB (Kawasaki et al., 2003, Barton and Medzhitov, 
2003). The MyD88-dependent pathway recruits IRAK1 and IRAK4 
kinases, which phosphorylate TRAF6, and in turn leads to the 
activation of the IKK complex. The MyD88-independent cascade that 
results in NF-κB activation is yet to be fully elucidated. The pathway 
is dependent on the TRIF, TRAM, RIP1 and RIP3 have been identified 
as important factors in the pathway (Meylan et al., 2004, Yamamoto 
et al., 2003a, Yamamoto et al., 2003b). However, the end result of 
these pathways is the same as the end point of the TNFα-activated 
pathway: degradation of IκB, which is followed by activation of IκBα 
gene transcription (Ashall et al., 2009, Sun et al., 1993). NF-κB 
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activation through the MyD88-dependent pathway occurs earlier than 
activation by the MyD88-independent pathway (Yamamoto et al., 
2003a). This suggested that the non-oscillatory behaviour of NF-κB 
activation through TLR4 could be due to the interaction of the two 
pathways. 
 
I, first, investigated if the phenotype of Anx-A1-/- DC might be due to 
an impaired expression of this receptor and we did not find any 
difference. Thereafter I analyzed NF-κB activation over several time 
points. Stimulation of Anx-A1+/+ DC with LPS induced a strong 
sinusoidal pattern of NF-κB/DNA-binding activity, which is atypical of 
LPS-induced NF-κB activation pattern, even when compared with that 
of LPS-activated macrophages (Covert et al., 2005). In contrast, Anx-
A1-/- DC showed a delayed kinetics and marked decrease in NF-κB 
activation during the first 6h of stimulation and then a partial 
recovery at 12h. This impaired NF-κB activation coincided with the 
period where we observed a significantly decreased production of IL-
1β and TNF-α. 
 
The lag in NF-κB kinetics resultant from stimulation by LPS compared 
to that of TNFα could transpire through two modes: 
the MyD88-independent pathway could initiate much slower kinetics 
than that of the MyD88-dependent pathway; 
the MyD88-dependent and MyD88-independent pathways could 
display similar kinetics, in which case the initiation of the MyD88-
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independent pathway signalling must be delayed. 
 
The activation of NF-κB via the TRIF-dependent pathway occurs 
through a secondary response mediated by IRF-3 and NF-κB-
independent TNFα, establishing an autocrine feedback for a delayed 
NF-κB activation. The combination of two asynchronous oscillatory-
based responses appears to allow for the stable and consistent early 
NF-κB response to LPS. The temporally decreased production of TNF-
α in Anx-A1-/- DC probably accounts for the partial recovery of NF-κB 
activation. Unfortunately, I did not examine either IRF-3 or TNF-α 
mRNA, or intracellular TNF-α protein in Anx-A1-/- DC to confirm this 
hypothesis. 
 
4.7. Anx-A1/FPR cascade: synergism with 
TLR signalling? 
In order to elucidate why Anx-A1-/- DC showed this defect in NF-κB 
activation, I investigated classical ‘Anx-A1/FPR’ signalling events. 
Anx-A1 and its derived peptide Ac.2-26 are ligands for the FPRs, 
which are a family of seven transmembrane G protein coupled 
receptors with three members identified in humans to date: 
FPR/FPR1, FPR-like-1 (FPRL-1)/FPR2 and FPR-like-2 (FPRL-2)/FPR3 
(Wang and Ye, 2002, Ye et al., 2009, Walther et al., 2000). Upon 
binding of the ligands, heterotrimeric Gi proteins coupled to FPR 
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rapidly dissociate into α and βγ subunits, activating signalling 
molecules and pathways shared with most other leukocyte 
chemotactic receptors. The βγ subunit initiate a series of signal 
transduction events via phosphoinositide 3-kinase g (PI3Kγ) and 
phospholipase Cγ (PLCγ) where the former results in activation of 
Ras/Raf proteins and in turn, the mitogen-activated protein kinase 
(MAPK) pathway, particularly ERK1/2 and the latter causes Ca2+ 
mobilization and activation of protein kinase C (PKC) (Lopez-Ilasaca 
et al., 1997, Gripentrog and Miettinen, 2005, Le et al., 2002a, Le et 
al., 2002b). 
 
Previous studies have shown that immature monocyte-derived human 
DC express constitutive high basal levels of FPR1 and FPRL-2 but not 
FPRL-1. Upon maturation, DC lose FPR expression and maintain only 
FPRL-2 which is constitutively expressed on their plasmalemma (Yang 
et al., 2002). This study using murine bone marrow derived DC has 
shown that immature DC express message for Fpr1 and Fpr-rs2. 
Moreover, stimulation with LPS induced the upregulation of both Fpr1 
and Fpr-rs2, with little effect on Fpr-rs1 (Ye et al., 2009). It is highly 
likely that differences between the human and mouse cells exist with 
respect to receptor expression and, possibly also, in the mechanisms 
controlling their expression.  Most interestingly, I did not observe 
significant differences in the pattern of expression of these receptors 
in Anx-A1+/+ and Anx-A1-/- DC but I did find an impaired activation of 
classical FPR-initiated signalling pathways such as ERK1/2 and Akt. 
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These results allow two important considerations.  
 
First, the signalling cascade induced by LPS in immature DC includes 
the FPR/Anx-A1 system whose function is to integrate and contribute 
to the differentiation of mature DC. In fact, here I have shown that, 
in analogy with other cell types, activation of DC with LPS induced a 
time dependent release of Anx-A1 in the culture supernatant mirrored 
by a depletion of the intracellular stores. Most interestingly, I 
observed that the release of Anx-A1 peaked between 1-3h after LPS 
stimulation and then decline over the next 12-16h. Consistently, the 
intracellular levels decreased after 3h of stimulation and were 
subsequently restored. Cumulatively, these results suggest that the 
protein is promptly released soon after the activation of DC and that 
this might influence the signalling cascades activated by LPS. 
 
Second, considering the parallel up-regulation of both Fpr1 and Fpr-
rs2 upon LPS stimulation (the latter being the mouse ortholog of 
human FPRL-1/FPR2) it is not possible to fully associate the reduced 
activation of ERK1/2 and Akt to the lack of binding of Anx-A1 to only 
one of these two receptors. However, our and other research groups 
have demonstrated that most of the biological effects of Anx-A1 
occurs via the activation of its receptor FPRL-1 (Gavins et al., 2003, 
Hayhoe et al., 2006, Maderna et al., 2010, Maderna et al., 2005, 
Perretti et al., 2001, Renshaw et al., 2010, Chatterjee et al., 2005, 
Damazo et al., 2005, Gavins et al., 2005, Hannon et al., 2003, 
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Perretti et al., 1993a, Perretti et al., 2002, Babbin et al., 2006), 
therefore it is possible to hypothesize that lack of Fpr-rs2 signalling 
might be the main cause of the impaired phenotype of Anx-A1-/- DC. 
Further experiments adding other agonists to this receptor, e.g. 
serum amyloid protein A or lipoxin A4 or synthetic analogues such as 
Amgen compound 43 (Burli et al., 2006), would determine the 
validity of this hypothesis. 
4.8. Synergism at the level of Transcriptional 
Factors: A possible co-operation of TLR-induced 
NF-κB and FPR-activated ERK 
The transcription factor NF-κB is paramount in activating the 
inflammatory genes involved in the innate immune response. Recent 
studies have shown that NF-κB typically demonstrates a sinusoidal 
pattern of activation because NF-κB transcribes not only pro-
inflammatory genes but also transcribes the genes to its inhibitors, 
thus producing a regulatory feedback on its own activation (Ghosh 
and Karin, 2002, Thompson et al., 1995). Surprisingly, the pattern of 
NF-κB activation in Anx-A1-/- DC lacks this sinusoidal modulation. I 
was not able to determine the molecular mechanisms underlying this 
effects but it is tempting to speculate that the reduced degree of ERK 
activation, due to the lack of “Anx-A1/FPRL-1 signal”, might at least 
contribute to the impaired temporal control of NF-κB activation. To 
this regard, it would be also interesting to investigate whether FPR-
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deficient DC display the same phenotype or which member of the FPR 
family is responsible for these effects. 
 
4.9. T-cell stimulatory ability of Anx-A1-/- DC 
The up-regulated expression of co-stimulatory molecules together 
with MHC during maturation synergistically enhances the T cell 
stimulatory capacity of DC. In fact, the increased expression of MHC 
ensures the presentation of more epitopes of the antigens while the 
other co-stimulatory molecules engage with their respective co-
receptors on T cells and ensure an effective amplification of the 
signalling to T cells (Yoshimura et al., 2001, Cella et al., 1997a, Inaba 
et al., 2000, Kassiotis et al., 2003). When I analysed the allogeneic T 
cell stimulatory capacity of immature Anx-A1-/- DC, I observed an 
increase in T cell proliferation and IL-2 production compared to Anx-
A1+/+ DC. However, I noticed that with LPS-matured Anx-A1-/- DC I 
obtained the opposite results suggesting that stimulation of Anx-A1-/- 
DC induces a tolerogenic phenotype manifested as a reduced ability 
of these cells to elicit a robust T-cell response. 
 
Activated DC act as IL-12–producing APC for peripheral tissue-
homing NK cells and memory T cells at the site of infection. Beyond 
the role of a pro-inflammatory cytokine, IL-12 is integral in dictating 
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adaptive immune responses. IL-12 possesses T helper polarising 
properties thus maturing naïve T cells into effector Th1 cells. 
Engagement of CD28 by CD80 or CD86 is required for T cell priming 
by DC and the IL-12 produced by DC is a potent and obligatory 
inducer of differentiation of IFN-γ–producing T cells (Cella et al., 
1996, Schulz et al., 2000). Consistent with the IL-12 data, LPS-
matured Anx-A1-/- DC showed a reduced capability to induce Th1 
cytokine production compared to the mature Anx-A1+/+ DC. We can 
enticingly speculate from these findings that Anx-A1 plays a definitive 
role in DC differentiation, whereby its lack would favour 
differentiation to a ‘semi-mature’ DC status with a potential 
tolerogenic phenotype (Lutz and Schuler, 2002, van Duivenvoorde et 
al., 2006).  
 
Recent literature in the field of peripheral tolerance postulates that 
DC are paramount in deciphering the myriad of stimuli (self-antigens, 
harmless environmental agents or pathogens) encountered 
simultaneously in order to trigger the appropriate maturation status. 
The stage of DC maturation heavily influences the type of T cell 
response (Adler and Steinbrink, 2007, Steinman et al., 2003). 
 
Therefore, I pursued a specific system to monitor the influence of DC-
derived Anx-A1, or lack thereof, on particular T cell subset responses. 
I utilized two single-TCR transgenic mouse models – the OT-I/RAG-1-
/- mouse model and the OT-II/RAG-1-/- mouse model whereby only 
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CD8 T cells expressing a single TCR epitope and only CD4 T cells also 
expressing a single TCR epitope are generated respectfully. OT-
I/RAG-1-/- transgenic mice express a single T-cell receptor specific for 
chicken ovalbumin peptide 257-264 (OVA257-264; SIINFEKL) presented 
by the MHC class I molecule, H-2Kb. This is possible because of a 
MHC-I restriction of budding T cells in the thymus of these mice and 
mature naïve CD8+ T cells expressing only this specific receptor enter 
the periphery. OT-II/RAG-1-/- transgenic mice express a T-cell 
receptor specific for chicken ovalbumin peptide 323-339 (OVA323-339; 
ISQAVHAAHAEINEAGR) presented by the MHC class II molecule I-Ab. 
This is achieved by a MHC-II restriction of developing T cells in the 
thymus of these mice and mature naïve CD4+ T cells expressing only 
one receptor specific for this peptide emerge from the thymus. 
 
Hence, I incubated OVA257-264-pulsed Anx-A1+/+ DC and Anx-A1-/- DC 
with OT-I/RAG-1-/- T cells or OVA323-339-pulsed Anx-A1+/+ DC and 
Anx-A1-/- DC with OT-II/RAG-1-/- T cells in co-culture systems and 
assessed T-cell proliferation and cytokine production. Immature Anx-
A1-/- DC results were not fully reproducible and thus inconclusive. 
About one-third of experiments showed an expected, elevated cell 
proliferation level of both OT-I CD8 T cells and OT-II CD4 T cells co-
cultured with peptide-pulsed, immature Anx-A1-/- DC whilst, one-half 
of investigations with peptide-pulsed, immature Anx-A1-/- DC 
unpredictably illustrated opposing data, and the remaining results 
were questionable. On the other hand, peptide-pulsed, mature Anx-
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A1-/- DC consistently demonstrated that these cells are drastically 
defective in stimulating both OT-I CD8 T-cell and OT-II CD4 T-cell 
proliferation in 5-day cultures as well as OT-I CD8 T-cell proliferation 
but not OT-II CD4 T-cell proliferation in 7-day cultures when 
compared to T-cell proliferation in co-cultures with peptide-pulsed, 
mature Anx-A1+/+ DC. 
 
IL-2, the T-cell mitogenic cytokine, was also measured as an 
additional marker of T-cell activation. These results complemented 
the T-cell proliferation patterns whereby both OT-I CD8 T-cell and 
OT-II CD4 T-cell 5-day co-cultures as well as 7-day co-cultures with 
mature Anx-A1+/+ DC induced potent levels of IL-2. Whereas there 
was an abated IL-2 production in OT-I CD8 T-cell and OT-II CD4 T-
cell 5-day co-cultures as well as OT-I CD8 T-cell 7-day co-cultures 
with mature Anx-A1-/- DC but IL-2 levels were restored in OT-II CD4 
T-cell 7-day co-cultures  
 
These data compounded the aforementioned hypothesis that Anx-A1 
may have a prominent role in early events involved in fully maturing 
DC to an immunogenic state. This appears to have a knock-on effect 
in activating T cells and initiating T-cell proliferation during relatively 
early DC-T-cell interactions although while this impact seems to be 
maintained during DC interactions with certain T cell subsets, my 
observations suggest that this influence is less significant or probably 
even insignificant between DC-T-cell interactions of other T cell 
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subsets. 
 
Deciphering which were the likely effector T cells that would possibly 
result from these co-culture combinations, I scanned IFN-γ production 
within the co-cultures as an implication that the extent of IFN-γ-
producing cells may dictate effector subset classification. 
Fascinatingly, IFN-γ production was severely encumbered in all the 
OT-I CD8 T-cell and OT-II CD4 T-cell co-cultures with mature Anx-A1-
/- DC during both 5-day and 7-day incubation periods when compared 
to IFN-γ levels in co-cultures with mature Anx-A1+/+ DC. 
4.10. Synopsis: Proposed Role of Annexin-
A1 in Dendritic Cell Function. 
Annexin-A1 appears to have a clear influence on dendritic cell biology 
and this effect is noticeable from the point of the terminally 
differentiated immature dendritic cells; that is, the up-regulated 
expression of the maturation markers CD40 and CD80. This 
phenomenon may have even taken effect prior to the complete 
differentiation process. 
 
Immature Anx-A1-\- DC emerge from their developmental process in 
an advanced state of maturation; therefore, further maturation does 
not modify the phenotype and biology of these cells to any great 
extent. Once exposed to maturation stimuli, these Anx-A1-\- DC do 
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not function as expected of typical mature DC because when these 
cells become activated, they fail to undergo the ubiquitous DC 
maturation process: 
1. Anx-A1-\- DC fail to up-regulate MHC class II and co-stimulatory 
molecules proficiently. 
2. Anx-A1-\- DC fail to produce large amounts of inflammatory 
cytokines. 
3. Anx-A1-\- DC fail to effectively initiate and propagate T-cell 
activation and proliferation; and in the proportion of T-cell 
priming that occurs, a Treg phenotype may be induced due to 
the microenvironment created by these DC. 
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A summary of these interpretations is illustrated in Figure 4.10.2 
below. 
 
Figure 4.10.1. Overview of the effect of the absence of Annexin-A1 on 
dendritic cell biology. 
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CONCLUDING REMARKS 
In conclusion, this study provides the first evidence for an unexplored 
role of endogenous Anx-A1 in DC biology. It can be concluded that 
the role of Anx-A1 is strongly indicative of a positive modulator for 
DC maturation with immunogenic features. These findings 
complement our on-going research on the role of Anx-A1 in the 
adaptive immune response and further suggest that therapies 
targeting Anx-A1 function in DC might represent a novel way to limit 
uncontrolled adaptive immune response typical of autoimmune 
diseases. 
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5. FUTURE DIRECTIONS 
The first question I would pose is to investigate to what extent the 
role of DC-derived Annexin-A1 is involved in or influences CD4 T-cell 
and CD8 T-cell responses. And would the end product be similar if 
Annexin-A1-deficient, single-TCR transgenic T cells are co-cultured 
with ‘wild-type’ DC; that is, is the source of Anx-A1 vital to the 
immunological outcome? 
 
Another question to address would be to illuminate the exact murine 
FPR that mediates the effects of Annexin-A1 in mature DC and how 
this would reconcile with the role of Anx-A1/FPR signalling in human 
DC. 
 
To address these questions, I would pre-treat immature Anx-A1+\+ 
DC with selective FPR antagonists (cyclosporine H blocks FPR1 and 
WRW4 peptide blocks FPR2) followed by LPS stimulation. I would 
then again pre-treat the mature Anx-A1+\+ DC with selective FPR 
antagonists prior to establishing the co-cultures with the OT-I/RAG-1-
\- and OT-II/RAG-1-\- T cells in order to prevent modulation of DC 
effector functions by Annexin-A1 during T-cell-DC interactions. This 
would be a 2-fold approach examining the Anx-A1/FPR1 and Anx-
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A1/FPR2 signalling in DC and the effect of these two signalling 
cascades in DC biology – DC maturation and APC-stimulatory 
capacity. 
 
In addition, is this relationship between Annexin-A1 and dendritic cell 
activation and maturation unique to LPS/TLR4 signalling? Does 
Annexin-A1 acts in a similar manner in dendritic cells during other 
TLR signalling cascades? 
 
One final inquiry to tackle is the full dissection of the possible 
synergism between TLR signalling and Anx-A1/FPR signalling. 
 
 198 
BIBLIOGRAPHY 
ADLER, H. S. & STEINBRINK, K. 2007. Tolerogenic 
dendritic cells in health and disease: friend and 
foe! Eur J Dermatol, 17, 476-91. 
AKBARI, O., DEKRUYFF, R. H. & UMETSU, D. T. 2001. 
Pulmonary dendritic cells producing IL-10 mediate 
tolerance induced by respiratory exposure to 
antigen. Nat Immunol, 2, 725-31. 
AKIRA, S. 2004. Toll receptor families: structure and 
function. Semin Immunol, 16, 1-2. 
AKIRA, S. & HEMMI, H. 2003. Recognition of pathogen-
associated molecular patterns by TLR family. 
Immunol Lett, 85, 85-95. 
AKIRA, S. & TAKEDA, K. 2004. Toll-like receptor 
signalling. Nat Rev Immunol, 4, 499-511. 
AKIRA, S., YAMAMOTO, M. & TAKEDA, K. 2003. Role of 
adapters in Toll-like receptor signalling. Biochem 
Soc Trans, 31, 637-42. 
ALBEROLA-ILA, J., TAKAKI, S., KERNER, J. D. & 
PERLMUTTER, R. M. 1997. Differential signaling by 
lymphocyte antigen receptors. Annu Rev Immunol, 
15, 125-54. 
ALLDRIDGE, L. C., HARRIS, H. J., PLEVIN, R., HANNON, 
R. & BRYANT, C. E. 1999. The annexin protein 
 199 
lipocortin 1 regulates the MAPK/ERK pathway. J 
Biol Chem, 274, 37620-8. 
ALVAREZ-MARTINEZ, M. T., MANI, J. C., PORTE, F., 
FAIVRE-SARRAILH, C., LIAUTARD, J. P. & SRI 
WIDADA, J. 1996. Characterization of the 
interaction between annexin I and profilin. Eur J 
Biochem, 238, 777-84. 
ALVAREZ-MARTINEZ, M. T., PORTE, F., LIAUTARD, J. P. 
& SRI WIDADA, J. 1997. Effects of profilin-annexin 
I association on some properties of both profilin 
and annexin I: modification of the inhibitory 
activity of profilin on actin polymerization and 
inhibition of the self-association of annexin I and 
its interactions with liposomes. Biochim Biophys 
Acta, 1339, 331-40. 
AMBROSE, M. P., BAHNS, C. L. & HUNNINGHAKE, G. W. 
1992. Lipocortin I production by human alveolar 
macrophages. Am J Respir Cell Mol Biol, 6, 17-21. 
ANNUNZIATO, F. & ROMAGNANI, S. 2009. 
Heterogeneity of human effector CD4+ T cells. 
Arthritis Res Ther, 11, 257. 
ARDAVIN, C. 2003. Origin, precursors and 
differentiation of mouse dendritic cells. Nat Rev 
Immunol, 3, 582-90. 
ASHALL, L., HORTON, C. A., NELSON, D. E., PASZEK, 
P., HARPER, C. V., SILLITOE, K., RYAN, S., 
SPILLER, D. G., UNITT, J. F., BROOMHEAD, D. S., 
KELL, D. B., RAND, D. A., SEE, V. & WHITE, M. R. 
2009. Pulsatile stimulation determines timing and 
specificity of NF-kappaB-dependent transcription. 
Science, 324, 242-6. 
 200 
BABBIN, B. A., LEE, W. Y., PARKOS, C. A., WINFREE, L. 
M., AKYILDIZ, A., PERRETTI, M. & NUSRAT, A. 
2006. Annexin I regulates SKCO-15 cell invasion 
by signaling through formyl peptide receptors. J 
Biol Chem, 281, 19588-99. 
BAEUERLE, P. A. & BALTIMORE, D. 1988a. Activation of 
DNA-binding activity in an apparently cytoplasmic 
precursor of the NF-kappa B transcription factor. 
Cell, 53, 211-7. 
BAEUERLE, P. A. & BALTIMORE, D. 1988b. I kappa B: a 
specific inhibitor of the NF-kappa B transcription 
factor. Science, 242, 540-6. 
BAEUERLE, P. A. & BALTIMORE, D. 1989. A 65-kappaD 
subunit of active NF-kappaB is required for 
inhibition of NF-kappaB by I kappaB. Genes Dev, 
3, 1689-98. 
BAICHWAL, V. R. & BAEUERLE, P. A. 1997. Activate NF-
kappa B or die? Curr Biol, 7, R94-6. 
BALDWIN, A. S., JR. 2001. Series introduction: the 
transcription factor NF-kappaB and human disease. 
J Clin Invest, 107, 3-6. 
BANCHEREAU, J., BRIERE, F., CAUX, C., DAVOUST, J., 
LEBECQUE, S., LIU, Y. J., PULENDRAN, B. & 
PALUCKA, K. 2000. Immunobiology of dendritic 
cells. Annu Rev Immunol, 18, 767-811. 
BANCHEREAU, J. & STEINMAN, R. M. 1998. Dendritic 
cells and the control of immunity. Nature, 392, 
245-52. 
BAR-SHAVIT, R., KAHN, A., FENTON, J. W., 2ND & 
WILNER, G. D. 1983a. Receptor-mediated 
 201 
chemotactic response of a macrophage cell line 
(J774) to thrombin. Lab Invest, 49, 702-7. 
BAR-SHAVIT, R., KAHN, A., MUDD, M. S., WILNER, G. 
D., MANN, K. G. & FENTON, J. W., 2ND 1984. 
Localization of a chemotactic domain in human 
thrombin. Biochemistry, 23, 397-400. 
BAR-SHAVIT, R., KAHN, A., WILNER, G. D. & FENTON, 
J. W., 2ND 1983b. Monocyte chemotaxis: 
stimulation by specific exosite region in thrombin. 
Science, 220, 728-31. 
BARCHET, W., CELLA, M. & COLONNA, M. 2005. 
Plasmacytoid dendritic cells--virus experts of 
innate immunity. Semin Immunol, 17, 253-61. 
BARNES, P. J. 1997. Nuclear factor-kappa B. Int J 
Biochem Cell Biol, 29, 867-70. 
BARTON, G. M. & MEDZHITOV, R. 2003. Linking Toll-
like receptors to IFN-alpha/beta expression. Nat 
Immunol, 4, 432-3. 
BELZ, G. T., BEDOUI, S., KUPRESANIN, F., CARBONE, 
F. R. & HEATH, W. R. 2007. Minimal activation of 
memory CD8+ T cell by tissue-derived dendritic 
cells favors the stimulation of naive CD8+ T cells. 
Nat Immunol, 8, 1060-6. 
BELZ, G. T., SHORTMAN, K., BEVAN, M. J. & HEATH, W. 
R. 2005. CD8alpha+ dendritic cells selectively 
present MHC class I-restricted noncytolytic viral 
and intracellular bacterial antigens in vivo. J 
Immunol, 175, 196-200. 
BELZ, G. T., SMITH, C. M., EICHNER, D., SHORTMAN, 
K., KARUPIAH, G., CARBONE, F. R. & HEATH, W. 
R. 2004. Cutting edge: conventional CD8 alpha+ 
 202 
dendritic cells are generally involved in priming 
CTL immunity to viruses. J Immunol, 172, 1996-
2000. 
BENSON, R. A., PATAKAS, A., CONIGLIARO, P., RUSH, 
C. M., GARSIDE, P., MCINNES, I. B. & BREWER, J. 
M. 2010. Identifying the cells breaching self-
tolerance in autoimmunity. J Immunol, 184, 6378-
85. 
BENSON, R. A., PATAKAS, A., MCQUEENIE, R., ROSS, 
K., MCINNES, I. B., BREWER, J. M. & GARSIDE, P. 
2011. Arthritis in space and time - To boldly go! 
FEBS Lett. 
BERG, E. L., MULLOWNEY, A. T., ANDREW, D. P., 
GOLDBERG, J. E. & BUTCHER, E. C. 1998. 
Complexity and differential expression of 
carbohydrate epitopes associated with L-selectin 
recognition of high endothelial venules. Am J 
Pathol, 152, 469-77. 
BHATIA, S., EDIDIN, M., ALMO, S. C. & NATHENSON, 
S. G. 2006. B7-1 and B7-2: similar costimulatory 
ligands with different biochemical, oligomeric and 
signaling properties. Immunol Lett, 104, 70-5. 
BIANCHI, M. E. 2007. DAMPs, PAMPs and alarmins: all 
we need to know about danger. J Leukoc Biol, 81, 
1-5. 
BLANCO, P., PALUCKA, A. K., PASCUAL, V. & 
BANCHEREAU, J. 2008. Dendritic cells and 
cytokines in human inflammatory and autoimmune 
diseases. Cytokine Growth Factor Rev, 19, 41-52. 
BLANDER, J. M. & MEDZHITOV, R. 2006. On regulation 
of phagosome maturation and antigen 
presentation. Nat Immunol, 7, 1029-35. 
 203 
BOMAN, H. G. 1995. Peptide antibiotics and their role in 
innate immunity. Annu Rev Immunol, 13, 61-92. 
BORREGAARD, N., LOLLIKE, K., KJELDSEN, L., 
SENGELØV, H., BASTHOLM, L., NIELSEN, M. H. & 
BAINTON, D. F. 1993. Human neutrophil granules 
and secretory vesicles. European Journal of 
Haematology, 51, 187-198. 
BRODELL, L. A. & ROSENTHAL, K. S. 2008. Skin 
Structure and Function: The Body's Primary 
Defense Against Infection. Infectious Diseases in 
Clinical Practice, 16, 113-117 
10.1097/IPC.0b013e3181660bf4. 
BROWN, K., PARK, S., KANNO, T., FRANZOSO, G. & 
SIEBENLIST, U. 1993. Mutual regulation of the 
transcriptional activator NF-kappa B and its 
inhibitor, I kappa B-alpha. Proc Natl Acad Sci U S 
A, 90, 2532-6. 
BRUNNER, M. C., CHAMBERS, C. A., CHAN, F. K., 
HANKE, J., WINOTO, A. & ALLISON, J. P. 1999. 
CTLA-4-Mediated inhibition of early events of T cell 
proliferation. J Immunol, 162, 5813-20. 
BUCKINGHAM, J. C. & FLOWER, R. J. 1997. Lipocortin 
1: a second messenger of glucocorticoid action in 
the hypothalamo-pituitary-adrenocortical axis. Mol 
Med Today, 3, 296-302. 
BURLI, R. W., XU, H., ZOU, X., MULLER, K., GOLDEN, 
J., FROHN, M., ADLAM, M., PLANT, M. H., WONG, 
M., MCELVAIN, M., REGAL, K., VISWANADHAN, V. 
N., TAGARI, P. & HUNGATE, R. 2006. Potent 
hFPRL1 (ALXR) agonists as potential anti-
inflammatory agents. Bioorg Med Chem Lett, 16, 
3713-8. 
 204 
BURTENSHAW, J. M. 1942. The mechanism of self-
disinfection of the human skin and its appendages. 
J Hyg (Lond), 42, 184-210. 
BURTENSHAW, J. M. L. 1945. SELF-DISINFECTION OF 
THE SKIN: A SHORT REVIEW AND SOME 
ORIGINAL OBSERVATIONS. Br Med Bull, 3, 161-
164. 
BUTCHER, E. C. & PICKER, L. J. 1996. Lymphocyte 
homing and homeostasis. Science, 272, 60-6. 
CARBONE, F. R., BELZ, G. T. & HEATH, W. R. 2004. 
Transfer of antigen between migrating and lymph 
node-resident DCs in peripheral T-cell tolerance 
and immunity. Trends Immunol, 25, 655-8. 
CARTER, L., FOUSER, L. A., JUSSIF, J., FITZ, L., DENG, 
B., WOOD, C. R., COLLINS, M., HONJO, T., 
FREEMAN, G. J. & CARRENO, B. M. 2002. PD-1:PD-
L inhibitory pathway affects both CD4(+) and 
CD8(+) T cells and is overcome by IL-2. Eur J 
Immunol, 32, 634-43. 
CAUX, C., DEZUTTER-DAMBUYANT, C., SCHMITT, D. & 
BANCHEREAU, J. 1992. GM-CSF and TNF-alpha 
cooperate in the generation of dendritic 
Langerhans cells. Nature, 360, 258-61. 
CAUX, C., VANBERVLIET, B., MASSACRIER, C., 
DEZUTTER-DAMBUYANT, C., DE SAINT-VIS, B., 
JACQUET, C., YONEDA, K., IMAMURA, S., 
SCHMITT, D. & BANCHEREAU, J. 1996. CD34+ 
hematopoietic progenitors from human cord blood 
differentiate along two independent dendritic cell 
pathways in response to GM-CSF+TNF alpha. J Exp 
Med, 184, 695-706. 
 205 
CELLA, M., ENGERING, A., PINET, V., PIETERS, J. & 
LANZAVECCHIA, A. 1997a. Inflammatory stimuli 
induce accumulation of MHC class II complexes on 
dendritic cells. Nature, 388, 782-7. 
CELLA, M., SALLUSTO, F. & LANZAVECCHIA, A. 1997b. 
Origin, maturation and antigen presenting function 
of dendritic cells. Curr Opin Immunol, 9, 10-6. 
CELLA, M., SCHEIDEGGER, D., PALMER-LEHMANN, K., 
LANE, P., LANZAVECCHIA, A. & ALBER, G. 1996. 
Ligation of CD40 on dendritic cells triggers 
production of high levels of interleukin-12 and 
enhances T cell stimulatory capacity: T-T help via 
APC activation. J Exp Med, 184, 747-52. 
CERWENKA, A. & LANIER, L. L. 2001. Natural killer 
cells, viruses and cancer. Nat Rev Immunol, 1, 41-
49. 
CHAMBERS, C. A. & ALLISON, J. P. 1997. Co-
stimulation in T cell responses. Curr Opin 
Immunol, 9, 396-404. 
CHATTERJEE, B. E., YONA, S., ROSIGNOLI, G., YOUNG, 
R. E., NOURSHARGH, S., FLOWER, R. J. & 
PERRETTI, M. 2005. Annexin 1-deficient 
neutrophils exhibit enhanced transmigration in 
vivo and increased responsiveness in vitro. J 
Leukoc Biol, 78, 639-46. 
CHEESMAN, S. E. & GUILLEMIN, K. 2007. We know you 
are in there: Conversing with the indigenous gut 
microbiota. Research in Microbiology, 158, 2-9. 
CHEN, Y., VALLEE, S., WU, J., VU, D., SONDEK, J. & 
GHOSH, G. 2004. Inhibition of NF-kappaB activity 
by IkappaBbeta in association with kappaB-Ras. 
Mol Cell Biol, 24, 3048-56. 
 206 
CHEN, Y., WU, J. & GHOSH, G. 2003. KappaB-Ras binds 
to the unique insert within the ankyrin repeat 
domain of IkappaBbeta and regulates cytoplasmic 
retention of IkappaBbeta x NF-kappaB complexes. 
J Biol Chem, 278, 23101-6. 
CHRISTENSEN, H. R., FROKIAER, H. & PESTKA, J. J. 
2002. Lactobacilli differentially modulate 
expression of cytokines and maturation surface 
markers in murine dendritic cells. J Immunol, 168, 
171-8. 
CHRISTMAS, P., CALLAWAY, J., FALLON, J., JONES, J. & 
HAIGLER, H. T. 1991. Selective secretion of 
annexin 1, a protein without a signal sequence, by 
the human prostate gland. J Biol Chem, 266, 
2499-507. 
CICALA, C. & CIRINO, G. 1998. Linkage between 
inflammation and coagulation: An update on the 
molecular basis of the crosstalk. Life Sci, 62, 1817-
1824. 
CIRINO, G., CICALA, C., SORRENTINO, L., CILIBERTO, 
G., ARPAIA, G., PERRETTI, M. & FLOWER, R. J. 
1993. Anti-inflammatory actions of an N-terminal 
peptide from human lipocortin 1. Br J Pharmacol, 
108, 573-4. 
COBAN, C., ISHII, K. J., KAWAI, T., HEMMI, H., SATO, 
S., UEMATSU, S., YAMAMOTO, M., TAKEUCHI, O., 
ITAGAKI, S., KUMAR, N., HORII, T. & AKIRA, S. 
2005. Toll-like receptor 9 mediates innate immune 
activation by the malaria pigment hemozoin. J Exp 
Med, 201, 19-25. 
COVERT, M. W., LEUNG, T. H., GASTON, J. E. & 
BALTIMORE, D. 2005. Achieving stability of 
 207 
lipopolysaccharide-induced NF-kappaB activation. 
Science, 309, 1854-7. 
COYLE, A. J. & GUTIERREZ-RAMOS, J. C. 2001. The 
expanding B7 superfamily: increasing complexity 
in costimulatory signals regulating T cell function. 
Nat Immunol, 2, 203-9. 
CROWLEY, M., INABA, K., WITMER-PACK, M. & 
STEINMAN, R. M. 1989. The cell surface of mouse 
dendritic cells: FACS analyses of dendritic cells 
from different tissues including thymus. Cell 
Immunol, 118, 108-25. 
CURTSINGER, J. M., SCHMIDT, C. S., MONDINO, A., 
LINS, D. C., KEDL, R. M., JENKINS, M. K. & 
MESCHER, M. F. 1999. Inflammatory cytokines 
provide a third signal for activation of naive CD4+ 
and CD8+ T cells. J Immunol, 162, 3256-62. 
D'ACQUISTO, F. 2009. On the adaptive nature of 
Annexin-A1. Curr Opin Pharmacol. 
D'ACQUISTO, F., MERGHANI, A., LECONA, E., 
ROSIGNOLI, G., RAZA, K., BUCKLEY, C. D., 
FLOWER, R. J. & PERRETTI, M. 2007a. Annexin-1 
modulates T-cell activation and differentiation. 
Blood, 109, 1095-102. 
D'ACQUISTO, F., PASCHALIDIS, N., RAZA, K., 
BUCKLEY, C. D., FLOWER, R. J. & PERRETTI, M. 
2008a. Glucocorticoid treatment inhibits annexin-1 
expression in rheumatoid arthritis CD4+ T cells. 
Rheumatology (Oxford), 47, 636-9. 
D'ACQUISTO, F., PASCHALIDIS, N., SAMPAIO, A. L., 
MERGHANI, A., FLOWER, R. J. & PERRETTI, M. 
2007b. Impaired T cell activation and increased 
 208 
Th2 lineage commitment in Annexin-1-deficient T 
cells. Eur J Immunol, 37, 3131-42. 
D'ACQUISTO, F., PERRETTI, M. & FLOWER, R. J. 2008b. 
Annexin-A1: a pivotal regulator of the innate and 
adaptive immune systems. Br J Pharmacol. 
DAHLGREN, C., CHRISTOPHE, T., BOULAY, F., 
MADIANOS, P. N., RABIET, M. J. & KARLSSON, A. 
2000. The synthetic chemoattractant Trp-Lys-Tyr-
Met-Val-DMet activates neutrophils preferentially 
through the lipoxin A(4) receptor. Blood, 95, 1810-
8. 
DALE, D. C., BOXER, L. & LILES, W. C. 2008. The 
phagocytes: neutrophils and monocytes. Blood, 
112, 935-945. 
DALOD, M., SALAZAR-MATHER, T. P., MALMGAARD, L., 
LEWIS, C., ASSELIN-PATUREL, C., BRIERE, F., 
TRINCHIERI, G. & BIRON, C. A. 2002. Interferon 
alpha/beta and interleukin 12 responses to viral 
infections: pathways regulating dendritic cell 
cytokine expression in vivo. J Exp Med, 195, 517-
28. 
DAMAZO, A. S., YONA, S., D'ACQUISTO, F., FLOWER, 
R. J., OLIANI, S. M. & PERRETTI, M. 2005. Critical 
protective role for annexin 1 gene expression in 
the endotoxemic murine microcirculation. Am J 
Pathol, 166, 1607-17. 
DE CATERINA, R., SICARI, R., GIANNESSI, D., 
PAGGIARO, P. L., PAOLETTI, P., LAZZERINI, G., 
BERNINI, W., SOLITO, E. & PARENTE, L. 1993. 
Macrophage-specific eicosanoid synthesis inhibition 
and lipocortin-1 induction by glucocorticoids. J 
Appl Physiol, 75, 2368-75. 
 209 
DE JONG, E. C., SMITS, H. H. & KAPSENBERG, M. L. 
2005. Dendritic cell-mediated T cell polarization. 
Springer Semin Immunopathol, 26, 289-307. 
DE NORONHA, S., HARDY, S., SINCLAIR, J., BLUNDELL, 
M. P., STRID, J., SCHULZ, O., ZWIRNER, J., 
JONES, G. E., KATZ, D. R., KINNON, C. & 
THRASHER, A. J. 2005. Impaired dendritic-cell 
homing in vivo in the absence of Wiskott-Aldrich 
syndrome protein. Blood, 105, 1590-7. 
DEL HOYO, G. M., MARTIN, P., VARGAS, H. H., RUIZ, 
S., ARIAS, C. F. & ARDAVIN, C. 2002. 
Characterization of a common precursor population 
for dendritic cells. Nature, 415, 1043-7. 
DEN HAAN, J. M., LEHAR, S. M. & BEVAN, M. J. 2000. 
CD8(+) but not CD8(-) dendritic cells cross-prime 
cytotoxic T cells in vivo. J Exp Med, 192, 1685-96. 
DHODAPKAR, M. V. & STEINMAN, R. M. 2002. Antigen-
bearing immature dendritic cells induce peptide-
specific CD8(+) regulatory T cells in vivo in 
humans. Blood, 100, 174-7. 
DI ROSA, M., FLOWER, R. J., HIRATA, F., PARENTE, L. 
& RUSSO-MARIE, F. 1984. Anti-phospholipase 
proteins. Prostaglandins, 28, 441-2. 
DIEBOLD, S. S., KAISHO, T., HEMMI, H., AKIRA, S. & 
REIS E SOUSA, C. 2004. Innate antiviral responses 
by means of TLR7-mediated recognition of single-
stranded RNA. Science, 303, 1529-31. 
DONALDSON, D. M., ROBERTS, R. R., LARSEN, H. S. & 
TEW, J. G. 1974. Interrelationship between serum 
beta-lysin, lysozyme, and the antibody-
complement system in killing Escherichia coli. 
Infect Immun, 10, 657-66. 
 210 
DONALDSON, D. M. & TEW, J. G. 1977. beta-Lysin of 
platelet origin. Bacteriol Rev, 41, 501-13. 
DONNELLY, S. R. & MOSS, S. E. 1997. Annexins in the 
secretory pathway. Cell Mol Life Sci, 53, 533-8. 
DORNER, B. G., DORNER, M. B., ZHOU, X., OPITZ, C., 
MORA, A., GUTTLER, S., HUTLOFF, A., MAGES, H. 
W., RANKE, K., SCHAEFER, M., JACK, R. S., HENN, 
V. & KROCZEK, R. A. 2009. Selective expression of 
the chemokine receptor XCR1 on cross-presenting 
dendritic cells determines cooperation with CD8+ T 
cells. Immunity, 31, 823-33. 
DOYLE, H. A. & MAMULA, M. J. 2001. Post-translational 
protein modifications in antigen recognition and 
autoimmunity. Trends Immunol, 22, 443-9. 
DRANOFF, G. 2004. Cytokines in cancer pathogenesis 
and cancer therapy. Nat Rev Cancer, 4, 11-22. 
DU PRÉ, M. F. & SAMSOM, J. N. 2011. Adaptive T-cell 
responses regulating oral tolerance to protein 
antigen. Allergy, 66, 478-90. 
DZIONEK, A., FUCHS, A., SCHMIDT, P., CREMER, S., 
ZYSK, M., MILTENYI, S., BUCK, D. W. & SCHMITZ, 
J. 2000. BDCA-2, BDCA-3, and BDCA-4: three 
markers for distinct subsets of dendritic cells in 
human peripheral blood. J Immunol, 165, 6037-
46. 
EKSIOGLU, E. A., MAHMOOD, S. S., CHANG, M. & 
REDDY, V. 2007. GM-CSF promotes differentiation 
of human dendritic cells and T lymphocytes toward 
a predominantly type 1 proinflammatory response. 
Exp Hematol, 35, 1163-71. 
 211 
ELGERT, K. D. 2009. Immunology: understanding the 
immune system. 726. 
ERNST, S., LANGE, C., WILBERS, A., GOEBELER, V., 
GERKE, V. & RESCHER, U. 2004. An annexin 1 N-
terminal peptide activates leukocytes by triggering 
different members of the formyl peptide receptor 
family. J Immunol, 172, 7669-76. 
FARRAR, J. D., ASNAGLI, H. & MURPHY, K. M. 2002. T 
helper subset development: roles of instruction, 
selection, and transcription. J Clin Invest, 109, 
431-5. 
FAURSCHOU, M. & BORREGAARD, N. 2003. Neutrophil 
granules and secretory vesicles in inflammation. 
Microbes and Infection, 5, 1317-1327. 
FAZEKAS DE ST GROTH, B. 1998. The evolution of self-
tolerance: a new cell arises to meet the challenge 
of self-reactivity. Immunol Today, 19, 448-54. 
FEILI-HARIRI, M., FALKNER, D. H. & MOREL, P. A. 
2005. Polarization of naive T cells into Th1 or Th2 
by distinct cytokine-driven murine dendritic cell 
populations: implications for immunotherapy. J 
Leukoc Biol, 78, 656-64. 
FELLERMANN, K. & STANGE, E. F. 2001. Defensins - 
innate immunity at the epithelial frontier. 
European Journal of Gastroenterology & 
Hepatology, 13, 771-776. 
FERRY, H., LEUNG, J. C., LEWIS, G., NIJNIK, A., 
SILVER, K., LAMBE, T. & CORNALL, R. J. 2006. B-
cell tolerance. Transplantation, 81, 308-15. 
 212 
FILIPENKO, N. R. & WAISMAN, D. M. 2001. The C 
terminus of annexin II mediates binding to F-actin. 
J Biol Chem, 276, 5310-5. 
FITZGERALD, K. A., MCWHIRTER, S. M., FAIA, K. L., 
ROWE, D. C., LATZ, E., GOLENBOCK, D. T., 
COYLE, A. J., LIAO, S. M. & MANIATIS, T. 2003a. 
IKKepsilon and TBK1 are essential components of 
the IRF3 signaling pathway. Nat Immunol, 4, 491-
6. 
FITZGERALD, K. A., ROWE, D. C., BARNES, B. J., 
CAFFREY, D. R., VISINTIN, A., LATZ, E., MONKS, 
B., PITHA, P. M. & GOLENBOCK, D. T. 2003b. LPS-
TLR4 signaling to IRF-3/7 and NF-kappaB involves 
the toll adapters TRAM and TRIF. J Exp Med, 198, 
1043-55. 
FLAVELL, R. A., LI, B., DONG, C., LU, H. T., YANG, D. 
D., ENSLEN, H., TOURNIER, C., WHITMARSH, A., 
WYSK, M., CONZE, D., RINCON, M. & DAVIS, R. J. 
1999. Molecular basis of T-cell differentiation. Cold 
Spring Harb Symp Quant Biol, 64, 563-71. 
FLOWER, R. J. 1988. Eleventh Gaddum memorial 
lecture. Lipocortin and the mechanism of action of 
the glucocorticoids. Br J Pharmacol, 94, 987-1015. 
FLUHR, J. W., KAO, J., JAIN, M., AHN, S. K., FEINGOLD, 
K. R. & ELIAS, P. M. 2001. Generation of free fatty 
acids from phospholipids regulates stratum 
corneum acidification and integrity. J Invest 
Dermatol, 117, 44-51. 
FORSTER, R., DAVALOS-MISSLITZ, A. C. & ROT, A. 
2008. CCR7 and its ligands: balancing immunity 
and tolerance. Nat Rev Immunol, 8, 362-71. 
 213 
FOSSIEZ, F., DJOSSOU, O., CHOMARAT, P., FLORES-
ROMO, L., AIT-YAHIA, S., MAAT, C., PIN, J. J., 
GARRONE, P., GARCIA, E., SAELAND, S., 
BLANCHARD, D., GAILLARD, C., DAS MAHAPATRA, 
B., ROUVIER, E., GOLSTEIN, P., BANCHEREAU, J. 
& LEBECQUE, S. 1996. T cell interleukin-17 
induces stromal cells to produce proinflammatory 
and hematopoietic cytokines. J Exp Med, 183, 
2593-603. 
FRANCHIMONT, D., MARTENS, H., HAGELSTEIN, M. T., 
LOUIS, E., DEWE, W., CHROUSOS, G. P., 
BELAICHE, J. & GEENEN, V. 1999. Tumor necrosis 
factor alpha decreases, and interleukin-10 
increases, the sensitivity of human monocytes to 
dexamethasone: potential regulation of the 
glucocorticoid receptor. J Clin Endocrinol Metab, 
84, 2834-9. 
FREEMAN, G. J., LONG, A. J., IWAI, Y., BOURQUE, K., 
CHERNOVA, T., NISHIMURA, H., FITZ, L. J., 
MALENKOVICH, N., OKAZAKI, T., BYRNE, M. C., 
HORTON, H. F., FOUSER, L., CARTER, L., LING, V., 
BOWMAN, M. R., CARRENO, B. M., COLLINS, M., 
WOOD, C. R. & HONJO, T. 2000. Engagement of 
the PD-1 immunoinhibitory receptor by a novel B7 
family member leads to negative regulation of 
lymphocyte activation. J Exp Med, 192, 1027-34. 
FURNESS, S. G. & MCNAGNY, K. 2006. Beyond mere 
markers: functions for CD34 family of sialomucins 
in hematopoiesis. Immunologic research, 34, 13-
32. 
GANZ, T. 2003. Defensins: antimicrobial peptides of 
innate immunity. Nat Rev Immunol, 3, 710-20. 
GAVINS, F. N., SAWMYNADEN, P., CHATTERJEE, B. E. & 
PERRETTI, M. 2005. A twist in anti-inflammation: 
 214 
annexin 1 acts via the lipoxin A4 receptor. 
Prostaglandins Leukot Essent Fatty Acids, 73, 211-
9. 
GAVINS, F. N., YONA, S., KAMAL, A. M., FLOWER, R. J. 
& PERRETTI, M. 2003. Leukocyte antiadhesive 
actions of annexin 1: ALXR- and FPR-related anti-
inflammatory mechanisms. Blood, 101, 4140-7. 
GERKE, V., CREUTZ, C. E. & MOSS, S. E. 2005. 
Annexins: linking Ca2+ signalling to membrane 
dynamics. Nat Rev Mol Cell Biol, 6, 449-61. 
GERKE, V. & MOSS, S. E. 1997. Annexins and 
membrane dynamics. Biochim Biophys Acta, 1357, 
129-54. 
GERKE, V. & MOSS, S. E. 2002. Annexins: from 
structure to function. Physiol Rev, 82, 331-71. 
GETTING, S. J., FLOWER, R. J. & PERRETTI, M. 1997. 
Inhibition of neutrophil and monocyte recruitment 
by endogenous and exogenous lipocortin 1. Br J 
Pharmacol, 120, 1075-82. 
GHOSH, S. & KARIN, M. 2002. Missing pieces in the NF-
kappaB puzzle. Cell, 109 Suppl, S81-96. 
GHOSH, S., MAY, M. J. & KOPP, E. B. 1998. NF-kappa B 
and Rel proteins: evolutionarily conserved 
mediators of immune responses. Annu Rev 
Immunol, 16, 225-60. 
GIMMI, C. D., FREEMAN, G. J., GRIBBEN, J. G., GRAY, 
G. & NADLER, L. M. 1993. Human T-cell clonal 
anergy is induced by antigen presentation in the 
absence of B7 costimulation. Proc Natl Acad Sci U 
S A, 90, 6586-90. 
 215 
GLEICH, G. J., FRIGAS, E., LOEGERING, D. A., 
WASSOM, D. L. & STEINMULLER, D. 1979. 
Cytotoxic Properties of the Eosinophil Major Basic 
Protein. J Immunol, 123, 2925-2927. 
GLIMCHER, L. H. & MURPHY, K. M. 2000. Lineage 
commitment in the immune system: the T helper 
lymphocyte grows up. Genes Dev, 14, 1693-711. 
GOLDYNE, M. E. 1975. PROSTAGLANDINS AND 
CUTANEOUS INFLAMMATION. J Investig Dermatol, 
64, 377-385. 
GONDEK, D. C., LU, L. F., QUEZADA, S. A., 
SAKAGUCHI, S. & NOELLE, R. J. 2005. Cutting 
edge: contact-mediated suppression by 
CD4+CD25+ regulatory cells involves a granzyme 
B-dependent, perforin-independent mechanism. J 
Immunol, 174, 1783-6. 
GOODNOW, C. C. 1992. B-cell tolerance. Curr Opin 
Immunol, 4, 703-10. 
GOULDING, N. J. 2004. The molecular complexity of 
glucocorticoid actions in inflammation - a four-ring 
circus. Curr Opin Pharmacol, 4, 629-36. 
GOULDING, N. J., GODOLPHIN, J. L., SAMPSON, M. B., 
MADDISON, P. J. & FLOWER, R. J. 1990a. 
Hydrocortisone induces lipocortin 1 production by 
peripheral blood mononuclear cells in vivo in man. 
Biochem Soc Trans, 18, 306-7. 
GOULDING, N. J., GODOLPHIN, J. L., SHARLAND, P. R., 
PEERS, S. H., SAMPSON, M., MADDISON, P. J. & 
FLOWER, R. J. 1990b. Anti-inflammatory lipocortin 
1 production by peripheral blood leucocytes in 
response to hydrocortisone. Lancet, 335, 1416-8. 
 216 
GOULDING, N. J. & GUYRE, P. M. 1992. Regulation of 
inflammation by lipocortin 1. Immunol Today, 13, 
295-7. 
GOULDING, N. J., LUYING, P. & GUYRE, P. M. 1990c. 
Characteristics of lipocortin 1 binding to the 
surface of human peripheral blood leucocytes. 
Biochem Soc Trans, 18, 1237-8. 
GRANUCCI, F., VIZZARDELLI, C., VIRZI, E., RESCIGNO, 
M. & RICCIARDI-CASTAGNOLI, P. 2001. 
Transcriptional reprogramming of dendritic cells by 
differentiation stimuli. Eur J Immunol, 31, 2539-
46. 
GRIFFITH, T. S., BRUNNER, T., FLETCHER, S. M., 
GREEN, D. R. & FERGUSON, T. A. 1995. Fas 
ligand-induced apoptosis as a mechanism of 
immune privilege. Science, 270, 1189-92. 
GRIFFITH, T. S. & FERGUSON, T. A. 1997. The role of 
FasL-induced apoptosis in immune privilege. 
Immunol Today, 18, 240-4. 
GRIPENTROG, J. M. & MIETTINEN, H. M. 2005. 
Activation and nuclear translocation of ERK1/2 by 
the formyl peptide receptor is regulated by G 
protein and is not dependent on beta-arrestin 
translocation or receptor endocytosis. Cell Signal, 
17, 1300-11. 
GRIPENTROG, J. M. & MIETTINEN, H. M. 2008. Formyl 
peptide receptor-mediated ERK1/2 activation 
occurs through G(i) and is not dependent on beta-
arrestin1/2. Cell Signal, 20, 424-31. 
GROUARD, G., DURAND, I., FILGUEIRA, L., 
BANCHEREAU, J. & LIU, Y. J. 1996. Dendritic cells 
 217 
capable of stimulating T cells in germinal centres. 
Nature, 384, 364-7. 
GUERIN, L. R., PRINS, J. R. & ROBERTSON, S. A. 2009. 
Regulatory T-cells and immune tolerance in 
pregnancy: a new target for infertility treatment? 
Hum Reprod Update, 15, 517-35. 
GUTCHER, I. & BECHER, B. 2007. APC-derived 
cytokines and T cell polarization in autoimmune 
inflammation. J Clin Invest, 117, 1119-27. 
GUTTRIDGE, D. C., ALBANESE, C., REUTHER, J. Y., 
PESTELL, R. G. & BALDWIN, A. S., JR. 1999. NF-
kappaB controls cell growth and differentiation 
through transcriptional regulation of cyclin D1. Mol 
Cell Biol, 19, 5785-99. 
GUYRE, P. M., BODWELL, J. E. & MUNCK, A. 1981. 
Glucocorticoid actions on the immune system: 
inhibition of production of an Fc-receptor 
augmenting factor. J Steroid Biochem, 15, 35-9. 
GUYRE, P. M., BODWELL, J. E. & MUNCK, A. 1984. 
Glucocorticoid actions on lymphoid tissue and the 
immune system: physiologic and therapeutic 
implications. Prog Clin Biol Res, 142, 181-94. 
HAIGLER, H. T. & CHRISTMAS, P. 1990. Annexin 1 is 
secreted by the human prostate. Biochem Soc 
Trans, 18, 1104-6. 
HAJJAR, K. A., JACOVINA, A. T. & CHACKO, J. 1994. An 
endothelial cell receptor for plasminogen/tissue 
plasminogen activator. I. Identity with annexin II. 
J Biol Chem, 269, 21191-7. 
HAMANN, K. J., BARKER, R. L., LOEGERING, D. A. & 
GLEICH, G. J. 1987. Comparative Toxicity of 
 218 
Purified Human Eosinophil Granule Proteins for 
Newborn Larvae of Trichinella spiralis. The Journal 
of Parasitology, 73, 523-529. 
HANNON, R., CROXTALL, J. D., GETTING, S. J., 
ROVIEZZO, F., YONA, S., PAUL-CLARK, M. J., 
GAVINS, F. N., PERRETTI, M., MORRIS, J. F., 
BUCKINGHAM, J. C. & FLOWER, R. J. 2003. 
Aberrant inflammation and resistance to 
glucocorticoids in annexin 1-/- mouse. Faseb J, 17, 
253-5. 
HARRIS, J. G., FLOWER, R. J. & PERRETTI, M. 1995. 
Alteration of neutrophil trafficking by a lipocortin 1 
N-terminus peptide. Eur J Pharmacol, 279, 149-57. 
HAWIGER, D., INABA, K., DORSETT, Y., GUO, M., 
MAHNKE, K., RIVERA, M., RAVETCH, J. V., 
STEINMAN, R. M. & NUSSENZWEIG, M. C. 2001. 
Dendritic cells induce peripheral T cell 
unresponsiveness under steady state conditions in 
vivo. J Exp Med, 194, 769-79. 
HAYES, M. J., RESCHER, U., GERKE, V. & MOSS, S. E. 
2004. Annexin-actin interactions. Traffic, 5, 571-6. 
HAYHOE, R. P., KAMAL, A. M., SOLITO, E., FLOWER, R. 
J., COOPER, D. & PERRETTI, M. 2006. Annexin 1 
and its bioactive peptide inhibit neutrophil-
endothelium interactions under flow: indication of 
distinct receptor involvement. Blood, 107, 2123-
30. 
HEASMAN, S. J., GILES, K. M., WARD, C., ROSSI, A. G., 
HASLETT, C. & DRANSFIELD, I. 2003. 
Glucocorticoid-mediated regulation of granulocyte 
apoptosis and macrophage phagocytosis of 
apoptotic cells: implications for the resolution of 
inflammation. J Endocrinol, 178, 29-36. 
 219 
HEIL, F., HEMMI, H., HOCHREIN, H., AMPENBERGER, 
F., KIRSCHNING, C., AKIRA, S., LIPFORD, G., 
WAGNER, H. & BAUER, S. 2004. Species-specific 
recognition of single-stranded RNA via toll-like 
receptor 7 and 8. Science, 303, 1526-9. 
HEINO, M., PETERSON, P., KUDOH, J., NAGAMINE, K., 
LAGERSTEDT, A., OVOD, V., RANKI, A., RANTALA, 
I., NIEMINEN, M., TUUKKANEN, J., SCOTT, H. S., 
ANTONARAKIS, S. E., SHIMIZU, N. & KROHN, K. 
1999. Autoimmune regulator is expressed in the 
cells regulating immune tolerance in thymus 
medulla. Biochem Biophys Res Commun, 257, 
821-5. 
HENRI, S., VREMEC, D., KAMATH, A., WAITHMAN, J., 
WILLIAMS, S., BENOIST, C., BURNHAM, K., 
SAELAND, S., HANDMAN, E. & SHORTMAN, K. 
2001. The dendritic cell populations of mouse 
lymph nodes. J Immunol, 167, 741-8. 
HIRATA, A. & HIRATA, F. 1999. Lipocortin (Annexin) I 
heterotetramer binds to purine RNA and pyrimidine 
DNA. Biochem Biophys Res Commun, 265, 200-4. 
HIROTA, K., MARTIN, B. & VELDHOEN, M. 2010. 
Development, regulation and functional capacities 
of Th17 cells. Semin Immunopathol, 32, 3-16. 
HOCHREIN, H., SCHLATTER, B., O'KEEFFE, M., 
WAGNER, C., SCHMITZ, F., SCHIEMANN, M., 
BAUER, S., SUTER, M. & WAGNER, H. 2004. 
Herpes simplex virus type-1 induces IFN-alpha 
production via Toll-like receptor 9-dependent and -
independent pathways. Proc Natl Acad Sci U S A, 
101, 11416-21. 
HOCHREIN, H., SHORTMAN, K., VREMEC, D., SCOTT, 
B., HERTZOG, P. & O'KEEFFE, M. 2001. Differential 
 220 
production of IL-12, IFN-alpha, and IFN-gamma by 
mouse dendritic cell subsets. J Immunol, 166, 
5448-55. 
HOFFMANN, A. & BALTIMORE, D. 2006. Circuitry of 
nuclear factor kappaB signaling. Immunol Rev, 
210, 171-86. 
HOFFMANN, A., LEVCHENKO, A., SCOTT, M. L. & 
BALTIMORE, D. 2002. The IkappaB-NF-kappaB 
signaling module: temporal control and selective 
gene activation. Science, 298, 1241-5. 
HOFFMANN, A., NATOLI, G. & GHOSH, G. 2006. 
Transcriptional regulation via the NF-kappaB 
signaling module. Oncogene, 25, 6706-16. 
HONJO, T., ALT, F. W. & RABBITTS, T. H. 1989. 
Immunoglobulin genes, London ; San Diego, 
Academic Press. 
HORI, S. & SAKAGUCHI, S. 2004. Foxp3: a critical 
regulator of the development and function of 
regulatory T cells. Microbes Infect, 6, 745-51. 
HORI, S., TAKAHASHI, T. & SAKAGUCHI, S. 2003. 
Control of autoimmunity by naturally arising 
regulatory CD4+ T cells. Adv Immunol, 81, 331-
71. 
HORNG, T., BARTON, G. M., FLAVELL, R. A. & 
MEDZHITOV, R. 2002. The adaptor molecule TIRAP 
provides signalling specificity for Toll-like 
receptors. Nature, 420, 329-33. 
HU, N. J., BRADSHAW, J., LAUTER, H., BUCKINGHAM, 
J., SOLITO, E. & HOFMANN, A. 2008. Membrane-
induced folding and structure of membrane-bound 
annexin A1 N-terminal peptides: implications for 
 221 
annexin-induced membrane aggregation. Biophys 
J, 94, 1773-81. 
HUANG, F. P., PLATT, N., WYKES, M., MAJOR, J. R., 
POWELL, T. J., JENKINS, C. D. & MACPHERSON, G. 
G. 2000. A discrete subpopulation of dendritic cells 
transports apoptotic intestinal epithelial cells to T 
cell areas of mesenteric lymph nodes. J Exp Med, 
191, 435-44. 
INABA, K., INABA, M., ROMANI, N., AYA, H., DEGUCHI, 
M., IKEHARA, S., MURAMATSU, S. & STEINMAN, R. 
M. 1992. Generation of large numbers of dendritic 
cells from mouse bone marrow cultures 
supplemented with granulocyte/macrophage 
colony-stimulating factor. J Exp Med, 176, 1693-
702. 
INABA, K., METLAY, J. P., CROWLEY, M. T., WITMER-
PACK, M. & STEINMAN, R. M. 1990. Dendritic cells 
as antigen presenting cells in vivo. Int Rev 
Immunol, 6, 197-206. 
INABA, K., PACK, M., INABA, M., SAKUTA, H., ISDELL, 
F. & STEINMAN, R. M. 1997. High levels of a major 
histocompatibility complex II-self peptide complex 
on dendritic cells from the T cell areas of lymph 
nodes. J Exp Med, 186, 665-72. 
INABA, K., TURLEY, S., IYODA, T., YAMAIDE, F., 
SHIMOYAMA, S., REIS E SOUSA, C., GERMAIN, R. 
N., MELLMAN, I. & STEINMAN, R. M. 2000. The 
formation of immunogenic major histocompatibility 
complex class II-peptide ligands in lysosomal 
compartments of dendritic cells is regulated by 
inflammatory stimuli. J Exp Med, 191, 927-36. 
INTO, T., KIURA, K., YASUDA, M., KATAOKA, H., 
INOUE, N., HASEBE, A., TAKEDA, K., AKIRA, S. & 
 222 
SHIBATA, K. 2004. Stimulation of human Toll-like 
receptor (TLR) 2 and TLR6 with membrane 
lipoproteins of Mycoplasma fermentans induces 
apoptotic cell death after NF-kappa B activation. 
Cell Microbiol, 6, 187-99. 
IP, W. K. & LAU, Y. L. 2004. Distinct maturation of, but 
not migration between, human monocyte-derived 
dendritic cells upon ingestion of apoptotic cells of 
early or late phases. J Immunol, 173, 189-96. 
ISHITSUKA, R., KOJIMA, K., UTSUMI, H., OGAWA, H. & 
MATSUMOTO, I. 1998. Glycosaminoglycan binding 
properties of annexin IV, V, and VI. J Biol Chem, 
273, 9935-41. 
ITO, T., INABA, M., INABA, K., TOKI, J., SOGO, S., 
IGUCHI, T., ADACHI, Y., YAMAGUCHI, K., 
AMAKAWA, R., VALLADEAU, J., SAELAND, S., 
FUKUHARA, S. & IKEHARA, S. 1999. A 
CD1a+/CD11c+ subset of human blood dendritic 
cells is a direct precursor of Langerhans cells. J 
Immunol, 163, 1409-19. 
JANEWAY, C. 2005. Immunobiology : the immune 
system in health and disease, New York ; London, 
Garland Science. 
JEGO, G., PASCUAL, V., PALUCKA, A. K. & 
BANCHEREAU, J. 2005. Dendritic cells control B 
cell growth and differentiation. Curr Dir 
Autoimmun, 8, 124-39. 
JIANG, W., SWIGGARD, W. J., HEUFLER, C., PENG, M., 
MIRZA, A., STEINMAN, R. M. & NUSSENZWEIG, M. 
C. 1995. The receptor DEC-205 expressed by 
dendritic cells and thymic epithelial cells is 
involved in antigen processing. Nature, 375, 151-
5. 
 223 
JOHN, M., LIM, S., SEYBOLD, J., JOSE, P., ROBICHAUD, 
A., O'CONNOR, B., BARNES, P. J. & CHUNG, K. F. 
1998. Inhaled corticosteroids increase interleukin-
10 but reduce macrophage inflammatory protein-
1alpha, granulocyte-macrophage colony-
stimulating factor, and interferon-gamma release 
from alveolar macrophages in asthma. American 
Journal of Respiratory and Critical Care Medicine, 
157, 256-62. 
JONULEIT, H., SCHMITT, E., SCHULER, G., KNOP, J. & 
ENK, A. H. 2000. Induction of interleukin 10-
producing, nonproliferating CD4(+) T cells with 
regulatory properties by repetitive stimulation with 
allogeneic immature human dendritic cells. J Exp 
Med, 192, 1213-22. 
JORRITSMA, P. J., BROGDON, J. L. & BOTTOMLY, K. 
2003. Role of TCR-induced extracellular signal-
regulated kinase activation in the regulation of 
early IL-4 expression in naive CD4+ T cells. J 
Immunol, 170, 2427-34. 
JOSE, P. J. 1987. Complement-derived peptide 
mediators of inflammation. Br Med Bull, 43, 336-
349. 
KABARA, J., VRABLE, R. & LIE KEN JIE, M. 1977. 
Antimicrobial lipids: Natural and synthetic fatty 
acids and monoglycerides. Lipids, 12, 753-759. 
KADOWAKI, N., HO, S., ANTONENKO, S., MALEFYT, R. 
W., KASTELEIN, R. A., BAZAN, F. & LIU, Y. J. 
2001. Subsets of human dendritic cell precursors 
express different toll-like receptors and respond to 
different microbial antigens. J Exp Med, 194, 863-
9. 
 224 
KADOWAKI, N. & LIU, Y. J. 2002. Natural type I 
interferon-producing cells as a link between innate 
and adaptive immunity. Hum Immunol, 63, 1126-
32. 
KAHAN, B. D. 2003. Individuality: the barrier to optimal 
immunosuppression. Nat Rev Immunol, 3, 831-8. 
KAMAL, A. M., FLOWER, R. J. & PERRETTI, M. 2005. An 
overview of the effects of annexin 1 on cells 
involved in the inflammatory process. Mem Inst 
Oswaldo Cruz, 100 Suppl 1, 39-47. 
KAMATH, A. T., HENRI, S., BATTYE, F., TOUGH, D. F. & 
SHORTMAN, K. 2002. Developmental kinetics and 
lifespan of dendritic cells in mouse lymphoid 
organs. Blood, 100, 1734-41. 
KAPSENBERG, M. L. 2003. Dendritic-cell control of 
pathogen-driven T-cell polarization. Nat Rev 
Immunol, 3, 984-93. 
KARIN, M. & LIN, A. 2002. NF-kappaB at the crossroads 
of life and death. Nat Immunol, 3, 221-7. 
KASSIOTIS, G., ZAMOYSKA, R. & STOCKINGER, B. 
2003. Involvement of avidity for major 
histocompatibility complex in homeostasis of naive 
and memory T cells. J Exp Med, 197, 1007-16. 
KAWASAKI, K., NOGAWA, H. & NISHIJIMA, M. 2003. 
Identification of mouse MD-2 residues important 
for forming the cell surface TLR4-MD-2 complex 
recognized by anti-TLR4-MD-2 antibodies, and for 
conferring LPS and taxol responsiveness on mouse 
TLR4 by alanine-scanning mutagenesis. J 
Immunol, 170, 413-20. 
 225 
KEARNEY, J. F., RADBRUCH, A., LIESEGANG, B. & 
RAJEWSKY, K. 1979. A new mouse myeloma cell 
line that has lost immunoglobulin expression but 
permits the construction of antibody-secreting 
hybrid cell lines. J Immunol, 123, 1548-50. 
KHATTRI, R., AUGER, J. A., GRIFFIN, M. D., SHARPE, A. 
H. & BLUESTONE, J. A. 1999. Lymphoproliferative 
disorder in CTLA-4 knockout mice is characterized 
by CD28-regulated activation of th2 response. 
Journal of Immunology, 162, 5784-5791. 
KHURANA 2006. Textbook Of Medical Physiology. 
KIRBY, A. C., YRLID, U. & WICK, M. J. 2002. The innate 
immune response differs in primary and secondary 
Salmonella infection. J Immunol, 169, 4450-9. 
KNOWLES, M. R. & BOUCHER, R. C. 2002. Mucus 
clearance as a primary innate defense mechanism 
for mammalian airways. J Clin Invest, 109, 571-
577. 
KOCH, N. & STOCKINGER, B. 1991. Molecules that 
modify antigen recognition. Curr Opin Immunol, 3, 
10-5. 
KRONIN, V., FITZMAURICE, C. J., CAMINSCHI, I., 
SHORTMAN, K., JACKSON, D. C. & BROWN, L. E. 
2001. Differential effect of CD8(+) and CD8(-) 
dendritic cells in the stimulation of secondary 
CD4(+) T cells. Int Immunol, 13, 465-73. 
KRONIN, V., SUSS, G., WINKEL, K. & SHORTMAN, K. 
1997a. The regulation of T cell responses by a 
subpopulation of CD8+DEC205+ murine dendritic 
cells. Adv Exp Med Biol, 417, 239-48. 
 226 
KRONIN, V., VREMEC, D., WINKEL, K., CLASSON, B. J., 
MILLER, R. G., MAK, T. W., SHORTMAN, K. & 
SUSS, G. 1997b. Are CD8+ dendritic cells (DC) 
veto cells? The role of CD8 on DC in DC 
development and in the regulation of CD4 and CD8 
T cell responses. Int Immunol, 9, 1061-4. 
KRUG, A., LUKER, G. D., BARCHET, W., LEIB, D. A., 
AKIRA, S. & COLONNA, M. 2004. Herpes simplex 
virus type 1 activates murine natural interferon-
producing cells through toll-like receptor 9. Blood, 
103, 1433-7. 
LAMMERMANN, T. & SIXT, M. 2008. The microanatomy 
of T-cell responses. Immunol Rev, 221, 26-43. 
LANGENKAMP, A., CASORATI, G., GARAVAGLIA, C., 
DELLABONA, P., LANZAVECCHIA, A. & SALLUSTO, 
F. 2002. T cell priming by dendritic cells: 
thresholds for proliferation, differentiation and 
death and intraclonal functional diversification. Eur 
J Immunol, 32, 2046-54. 
LANGENKAMP, A., MESSI, M., LANZAVECCHIA, A. & 
SALLUSTO, F. 2000. Kinetics of dendritic cell 
activation: impact on priming of TH1, TH2 and 
nonpolarized T cells. Nat Immunol, 1, 311-6. 
LE, Y., MURPHY, P. M. & WANG, J. M. 2002a. Formyl-
peptide receptors revisited. Trends Immunol, 23, 
541-8. 
LE, Y., YANG, Y., CUI, Y., YAZAWA, H., GONG, W., QIU, 
C. & WANG, J. M. 2002b. Receptors for 
chemotactic formyl peptides as pharmacological 
targets. Int Immunopharmacol, 2, 1-13. 
LEE, K. R., BETZ, A. L., KIM, S., KEEP, R. F. & HOFF, J. 
T. 1996. The role of the coagulation cascade in 
 227 
brain edema formation after intracerebral 
hemorrhage. Acta Neurochirurgica, 138, 396-401. 
LEON, B., MARTINEZ DEL HOYO, G., PARRILLAS, V., 
VARGAS, H. H., SANCHEZ-MATEOS, P., LONGO, 
N., LOPEZ-BRAVO, M. & ARDAVIN, C. 2004. 
Dendritic cell differentiation potential of mouse 
monocytes: monocytes represent immediate 
precursors of CD8- and CD8+ splenic dendritic 
cells. Blood, 103, 2668-76. 
LEVY, D. E., MARIE, I., SMITH, E. & PRAKASH, A. 2002. 
Enhancement and diversification of IFN induction 
by IRF-7-mediated positive feedback. J Interferon 
Cytokine Res, 22, 87-93. 
LEY, K., SMITH, E. & STARK, M. A. 2006. IL-17A-
producing neutrophil-regulatory Tn lymphocytes. 
Immunol Res, 34, 229-42. 
LIEW, F. Y. 2002. T(H)1 and T(H)2 cells: a historical 
perspective. Nat Rev Immunol, 2, 55-60. 
LING, Q., JACOVINA, A. T., DEORA, A., FEBBRAIO, M., 
SIMANTOV, R., SILVERSTEIN, R. L., HEMPSTEAD, 
B., MARK, W. H. & HAJJAR, K. A. 2004. Annexin II 
regulates fibrin homeostasis and neoangiogenesis 
in vivo. J Clin Invest, 113, 38-48. 
LINK, E., KERR, L. D., SCHRECK, R., ZABEL, U., 
VERMA, I. & BAEUERLE, P. A. 1992. Purified I 
kappa B-beta is inactivated upon 
dephosphorylation. J Biol Chem, 267, 239-46. 
LIU, Y. J. 2001. Dendritic cell subsets and lineages, and 
their functions in innate and adaptive immunity. 
Cell, 106, 259-62. 
 228 
LIU, Y. J., KANZLER, H., SOUMELIS, V. & GILLIET, M. 
2001. Dendritic cell lineage, plasticity and cross-
regulation. Nat Immunol, 2, 585-9. 
LIU, Y. J., SOUMELIS, V., WATANABE, N., ITO, T., 
WANG, Y. H., MALEFYT RDE, W., OMORI, M., 
ZHOU, B. & ZIEGLER, S. F. 2007. TSLP: an 
epithelial cell cytokine that regulates T cell 
differentiation by conditioning dendritic cell 
maturation. Annu Rev Immunol, 25, 193-219. 
LODOEN, M. B. & LANIER, L. L. 2005. Viral modulation 
of NK cell immunity. Nat Rev Micro, 3, 59-69. 
LOPEZ-ILASACA, M., CRESPO, P., PELLICI, P. G., 
GUTKIND, J. S. & WETZKER, R. 1997. Linkage of G 
protein-coupled receptors to the MAPK signaling 
pathway through PI 3-kinase gamma. Science, 
275, 394-7. 
LUND, J., SATO, A., AKIRA, S., MEDZHITOV, R. & 
IWASAKI, A. 2003. Toll-like receptor 9-mediated 
recognition of Herpes simplex virus-2 by 
plasmacytoid dendritic cells. J Exp Med, 198, 513-
20. 
LUNDIE, R. J., DE KONING-WARD, T. F., DAVEY, G. M., 
NIE, C. Q., HANSEN, D. S., LAU, L. S., MINTERN, 
J. D., BELZ, G. T., SCHOFIELD, L., CARBONE, F. 
R., VILLADANGOS, J. A., CRABB, B. S. & HEATH, 
W. R. 2008. Blood-stage Plasmodium infection 
induces CD8+ T lymphocytes to parasite-
expressed antigens, largely regulated by 
CD8alpha+ dendritic cells. Proc Natl Acad Sci U S 
A, 105, 14509-14. 
LUTZ, M. B., KUKUTSCH, N., OGILVIE, A. L., ROSSNER, 
S., KOCH, F., ROMANI, N. & SCHULER, G. 1999. 
An advanced culture method for generating large 
 229 
quantities of highly pure dendritic cells from mouse 
bone marrow. J Immunol Methods, 223, 77-92. 
LUTZ, M. B. & SCHULER, G. 2002. Immature, semi-
mature and fully mature dendritic cells: which 
signals induce tolerance or immunity? Trends 
Immunol, 23, 445-9. 
MA, C. S., TANGYE, S. G. & DEENICK, E. K. 2010. 
Human Th9 cells: inflammatory cytokines 
modulate IL-9 production through the induction of 
IL-21. Immunol Cell Biol. 
MACAGNO, A., NAPOLITANI, G., LANZAVECCHIA, A. & 
SALLUSTO, F. 2007. Duration, combination and 
timing: the signal integration model of dendritic 
cell activation. Trends Immunol, 28, 227-33. 
MACATONIA, S. E., HOSKEN, N. A., LITTON, M., 
VIEIRA, P., HSIEH, C. S., CULPEPPER, J. A., 
WYSOCKA, M., TRINCHIERI, G., MURPHY, K. M. & 
O'GARRA, A. 1995. Dendritic cells produce IL-12 
and direct the development of Th1 cells from naive 
CD4+ T cells. J Immunol, 154, 5071-9. 
MACKAY, I. R., ROSEN, F. S. & WALPORT, M. J. 2001. 
Complement. New England Journal of Medicine, 
344, 1058-1066. 
MADERNA, P., COTTELL, D. C., TOIVONEN, T., DUFTON, 
N., DALLI, J., PERRETTI, M. & GODSON, C. 2010. 
FPR2/ALX receptor expression and internalization 
are critical for lipoxin A4 and annexin-derived 
peptide-stimulated phagocytosis. Faseb J. 
MADERNA, P., YONA, S., PERRETTI, M. & GODSON, C. 
2005. Modulation of phagocytosis of apoptotic 
neutrophils by supernatant from dexamethasone-
 230 
treated macrophages and annexin-derived peptide 
Ac(2-26). J Immunol, 174, 3727-33. 
MAHNKE, K., KNOP, J. & ENK, A. H. 2003. Induction of 
tolerogenic DCs: 'you are what you eat'. Trends 
Immunol, 24, 646-51. 
MAILLIARD, W. S., HAIGLER, H. T. & SCHLAEPFER, D. 
D. 1996. Calcium-dependent binding of S100C to 
the N-terminal domain of annexin I. J Biol Chem, 
271, 719-25. 
MAJKA, D. S., DEANE, K. D., PARRISH, L. A., LAZAR, A. 
A., BAR√≥N, A. E., WALKER, C. W., RUBERTONE, 
M. V., GILLILAND, W. R., NORRIS, J. M. & 
HOLERS, V. M. 2008. Duration of preclinical 
rheumatoid arthritis-related autoantibody positivity 
increases in subjects with older age at time of 
disease diagnosis. Annals of the Rheumatic 
Diseases, 67, 801-7. 
MALE, D., BROSTOFF, J., ROTH, D. & ROITT, I. 2006. 
Immunology, Mosby Elsevier. 
MANICKASINGHAM, S. P., EDWARDS, A. D., SCHULZ, 
O. & REIS E SOUSA, C. 2003. The ability of murine 
dendritic cell subsets to direct T helper cell 
differentiation is dependent on microbial signals. 
Eur J Immunol, 33, 101-7. 
MCCAUGHTRY, T. M. & HOGQUIST, K. A. 2008. Central 
tolerance: what have we learned from mice? 
Semin Immunopathol, 30, 399-409. 
MCGILVRAY, I. D. & ROTSTEIN, O. D. 1998. Role of the 
Coagulation System in the Local and Systemic 
Inflammatory Response. World Journal of Surgery, 
22, 179-186. 
 231 
MCGUIRK, P., MCCANN, C. & MILLS, K. H. 2002. 
Pathogen-specific T regulatory 1 cells induced in 
the respiratory tract by a bacterial molecule that 
stimulates interleukin 10 production by dendritic 
cells: a novel strategy for evasion of protective T 
helper type 1 responses by Bordetella pertussis. J 
Exp Med, 195, 221-31. 
MEDZHITOV, R. 2008. Origin and physiological roles of 
inflammation. Nature, 454, 428-35. 
MEDZHITOV, R. & JANEWAY, C., JR. 2000. Innate 
immune recognition: mechanisms and pathways. 
Immunol Rev, 173, 89-97. 
MEDZHITOV, R., PRESTON-HURLBURT, P., KOPP, E., 
STADLEN, A., CHEN, C., GHOSH, S. & JANEWAY, 
C. A., JR. 1998. MyD88 is an adaptor protein in the 
hToll/IL-1 receptor family signaling pathways. Mol 
Cell, 2, 253-8. 
MENGES, M., ROSSNER, S., VOIGTLANDER, C., 
SCHINDLER, H., KUKUTSCH, N. A., BOGDAN, C., 
ERB, K., SCHULER, G. & LUTZ, M. B. 2002. 
Repetitive injections of dendritic cells matured with 
tumor necrosis factor alpha induce antigen-specific 
protection of mice from autoimmunity. J Exp Med, 
195, 15-21. 
MENKE, M., GERKE, V. & STEINEM, C. 2005. 
Phosphatidylserine membrane domain clustering 
induced by annexin A2/S100A10 heterotetramer. 
Biochemistry, 44, 15296-303. 
METLAY, J. P., WITMER-PACK, M. D., AGGER, R., 
CROWLEY, M. T., LAWLESS, D. & STEINMAN, R. M. 
1990. The distinct leukocyte integrins of mouse 
spleen dendritic cells as identified with new 
 232 
hamster monoclonal antibodies. J Exp Med, 171, 
1753-71. 
MEYLAN, E., BURNS, K., HOFMANN, K., BLANCHETEAU, 
V., MARTINON, F., KELLIHER, M. & TSCHOPP, J. 
2004. RIP1 is an essential mediator of Toll-like 
receptor 3-induced NF-kappa B activation. Nat 
Immunol, 5, 503-7. 
MIGEOTTE, I., COMMUNI, D. & PARMENTIER, M. 2006. 
Formyl peptide receptors: a promiscuous subfamily 
of G protein-coupled receptors controlling immune 
responses. Cytokine Growth Factor Rev, 17, 501-
19. 
MILLER, J., LEVITSKY, J., MATHEW, J. & CIANCIO, G. 
2009. Tolerance versus immunosuppression: a 
perspective. Am J Transplant, 9, 434. 
MILLINGTON, O., GIBSON, V., RUSH, C., 
ZINSELMEYER, B., PHILLIPS, R. S., GARSIDE, P. & 
BREWER, J. 2007. Malaria impairs T cell clustering 
and immune priming despite normal signal 1 from 
dendritic cells. PLoS Pathogens, 3, 1380-7. 
MILLINGTON, O. R., DI LORENZO, C., PHILLIPS, R. S., 
GARSIDE, P. & BREWER, J. M. 2006. Suppression 
of adaptive immunity to heterologous antigens 
during Plasmodium infection through hemozoin-
induced failure of dendritic cell function. J Biol, 5, 
5. 
MOGENSEN, T. H. 2009. Pathogen recognition and 
inflammatory signaling in innate immune defenses. 
Clin Microbiol Rev, 22, 240-73, Table of Contents. 
MOHAMADZADEH, M., POLTORAK, A. N., 
BERGSTRESSOR, P. R., BEUTLER, B. & 
TAKASHIMA, A. 1996. Dendritic cells produce 
 233 
macrophage inflammatory protein-1 gamma, a 
new member of the CC chemokine family. J 
Immunol, 156, 3102-6. 
MOLINA, H. A., KIERSZENBAUM, F., HAMANN, K. J. & 
GLEICH, G. J. 1988. Toxic Effects Produced or 
Mediated by Human Eosinophil Granule 
Components on Trypanosoma cruzi. Am J Trop 
Med Hyg, 38, 327-334. 
MORAND, E. F., HUTCHINSON, P., HARGREAVES, A., 
GOULDING, N. J., BOYCE, N. W. & HOLDSWORTH, 
S. R. 1995. Detection of intracellular lipocortin 1 in 
human leukocyte subsets. Clin Immunol 
Immunopathol, 76, 195-202. 
MULLA, A., LEROUX, C., SOLITO, E. & BUCKINGHAM, J. 
C. 2005. Correlation between the antiinflammatory 
protein annexin 1 (lipocortin 1) and serum cortisol 
in subjects with normal and dysregulated adrenal 
function. J Clin Endocrinol Metab, 90, 557-62. 
MUNOZ-SUANO, A., HAMILTON, A. B. & BETZ, A. G. 
2011. Gimme shelter: the immune system during 
pregnancy. Immunol Rev, 241, 20-38. 
MURPHY, K. M., TRAVERS, P., WALPORT, M. & 
JANEWAY, C. 2008. Janeway's immunobiology, 
New York, Garland Science ; London : Taylor & 
Francis [distributor]. 
NAGL, M., KACANI, L., MULLAUER, B., LEMBERGER, E.-
M., STOIBER, H., SPRINZL, G. M., SCHENNACH, H. 
& DIERICH, M. P. 2002. Phagocytosis and Killing of 
Bacteria by Professional Phagocytes and Dendritic 
Cells. Clin. Diagn. Lab. Immunol., 9, 1165-1168. 
NARBUTT, J., LESIAK, A., ZAK-PRELICH, M., 
WOZNIACKA, A., SYSA-JEDRZEJOWSKA, A., 
 234 
TYBURA, M., ROBAK, T. & SMOLEWSKI, P. 2004. 
The distribution of peripheral blood dendritic cells 
assayed by a new panel of anti-BDCA monoclonal 
antibodies in healthy representatives of the polish 
population. Cell Mol Biol Lett, 9, 497-509. 
NEL, A. E. & SLAUGHTER, N. 2002. T-cell activation 
through the antigen receptor. Part 2: role of 
signaling cascades in T-cell differentiation, anergy, 
immune senescence, and development of 
immunotherapy. J Allergy Clin Immunol, 109, 901-
15. 
NEWTON, R. 2000. Molecular mechanisms of 
glucocorticoid action: what is important? Thorax, 
55, 603-13. 
NI, K. & O'NEILL, H. C. 1997. The role of dendritic cells 
in T cell activation. Immunol Cell Biol, 75, 223-30. 
NIELEN, M. M., VAN DER HORST, A. R., VAN 
SCHAARDENBURG, D., VAN DER HORST-
BRUINSMA, I. E., VAN DE STADT, R. J., AARDEN, 
L., DIJKMANS, B. A. & HAMANN, D. 2005. 
Antibodies to citrullinated human fibrinogen (ACF) 
have diagnostic and prognostic value in early 
arthritis. Annals of the Rheumatic Diseases, 64, 
1199-204. 
NIELSEN, J. S. & MCNAGNY, K. M. 2008. Novel 
functions of the CD34 family. Journal of Cell 
Science, 121, 3683-92. 
NIEMAN, C. 1954. Influence of trace amounts of fatty 
acids on the growth of microorganisms. Bacteriol 
Rev, 18, 147-63. 
NIJMAN, H. W., KLEIJMEER, M. J., OSSEVOORT, M. A., 
OORSCHOT, V. M., VIERBOOM, M. P., VAN DE 
 235 
KEUR, M., KENEMANS, P., KAST, W. M., GEUZE, H. 
J. & MELIEF, C. J. 1995. Antigen capture and 
major histocompatibility class II compartments of 
freshly isolated and cultured human blood dendritic 
cells. J Exp Med, 182, 163-74. 
NOSSAL, G. J. 1993. Tolerance and ways to break it. 
Ann N Y Acad Sci, 690, 34-41. 
OGURA, H., MURAKAMI, M., OKUYAMA, Y., TSURUOKA, 
M., KITABAYASHI, C., KANAMOTO, M., 
NISHIHARA, M., IWAKURA, Y. & HIRANO, T. 2008. 
Interleukin-17 promotes autoimmunity by 
triggering a positive-feedback loop via interleukin-
6 induction. Immunity, 29, 628-36. 
OHL, L., MOHAUPT, M., CZELOTH, N., HINTZEN, G., 
KIAFARD, Z., ZWIRNER, J., BLANKENSTEIN, T., 
HENNING, G. & FORSTER, R. 2004. CCR7 governs 
skin dendritic cell migration under inflammatory 
and steady-state conditions. Immunity, 21, 279-
88. 
OLIANI, S. M., CHRISTIAN, H. C., MANSTON, J., 
FLOWER, R. J. & PERRETTI, M. 2000. An 
immunocytochemical and in situ hybridization 
analysis of annexin 1 expression in rat mast cells: 
modulation by inflammation and dexamethasone. 
Lab Invest, 80, 1429-38. 
OOSTERWEGEL, M. A., GREENWALD, R. J., 
MANDELBROT, D. A., LORSBACH, R. B. & SHARPE, 
A. H. 1999a. CTLA-4 and T cell activation. Curr 
Opin Immunol, 11, 294-300. 
OOSTERWEGEL, M. A., MANDELBROT, D. A., BOYD, S. 
D., LORSBACH, R. B., JARRETT, D. Y., ABBAS, A. 
K. & SHARPE, A. H. 1999b. The role of CTLA-4 in 
 236 
regulating Th2 differentiation. J Immunol, 163, 
2634-9. 
PAIN, A., URBAN, B. C., KAI, O., CASALS-PASCUAL, C., 
SHAFI, J., MARSH, K. & ROBERTS, D. J. 2001. A 
non-sense mutation in Cd36 gene is associated 
with protection from severe malaria. Lancet, 357, 
1502-3. 
PALMER, E. 2003. Negative selection--clearing out the 
bad apples from the T-cell repertoire. Nat Rev 
Immunol, 3, 383-91. 
PARDOLL, D. 2002. Spinning molecular immunology 
into successful immunotherapy. Nature Reviews 
Immunology, 2, 227-38. 
PASCHALIDIS, N., IQBAL, A. J., MAIONE, F., WOOD, E. 
G., PERRETTI, M., FLOWER, R. J. & D'ACQUISTO, 
F. 2009. Modulation of experimental autoimmune 
encephalomyelitis by endogenous annexin A1. J 
Neuroinflammation, 6, 33. 
PERRETTI, M. 2003. The annexin 1 receptor(s): is the 
plot unravelling? Trends Pharmacol Sci, 24, 574-9. 
PERRETTI, M., AHLUWALIA, A., HARRIS, J. G., 
GOULDING, N. J. & FLOWER, R. J. 1993a. 
Lipocortin-1 fragments inhibit neutrophil 
accumulation and neutrophil-dependent edema in 
the mouse. A qualitative comparison with an anti-
CD11b monoclonal antibody. J Immunol, 151, 
4306-14. 
PERRETTI, M., CHIANG, N., LA, M., FIERRO, I. M., 
MARULLO, S., GETTING, S. J., SOLITO, E. & 
SERHAN, C. N. 2002. Endogenous lipid- and 
peptide-derived anti-inflammatory pathways 
generated with glucocorticoid and aspirin 
 237 
treatment activate the lipoxin A4 receptor. Nat 
Med, 8, 1296-302. 
PERRETTI, M., CHRISTIAN, H., WHELLER, S. K., 
AIELLO, I., MUGRIDGE, K. G., MORRIS, J. F., 
FLOWER, R. J. & GOULDING, N. J. 2000. Annexin I 
is stored within gelatinase granules of human 
neutrophil and mobilized on the cell surface upon 
adhesion but not phagocytosis. Cell Biol Int, 24, 
163-74. 
PERRETTI, M., CROXTALL, J. D., WHELLER, S. K., 
GOULDING, N. J., HANNON, R. & FLOWER, R. J. 
1996. Mobilizing lipocortin 1 in adherent human 
leukocytes downregulates their transmigration. Nat 
Med, 2, 1259-62. 
PERRETTI, M. & D'ACQUISTO, F. 2009. Annexin A1 and 
glucocorticoids as effectors of the resolution of 
inflammation. Nat Rev Immunol, 9, 62-70. 
PERRETTI, M. & FLOWER, R. J. 1995. Anti-inflammatory 
lipocortin-derived peptides. Agents Actions Suppl, 
46, 131-8. 
PERRETTI, M. & FLOWER, R. J. 1996. Measurement of 
lipocortin 1 levels in murine peripheral blood 
leukocytes by flow cytometry: modulation by 
glucocorticoids and inflammation. Br J Pharmacol, 
118, 605-10. 
PERRETTI, M. & FLOWER, R. J. 2004. Annexin 1 and the 
biology of the neutrophil. J Leukoc Biol, 76, 25-9. 
PERRETTI, M., FLOWER, R. J. & GOULDING, N. J. 
1993b. The ability of murine leukocytes to bind 
lipocortin 1 is lost during acute inflammation. 
Biochem Biophys Res Commun, 192, 345-50. 
 238 
PERRETTI, M. & GAVINS, F. N. 2003. Annexin 1: an 
endogenous anti-inflammatory protein. News 
Physiol Sci, 18, 60-4. 
PERRETTI, M., GETTING, S. J., SOLITO, E., MURPHY, P. 
M. & GAO, J. L. 2001. Involvement of the receptor 
for formylated peptides in the in vivo anti-
migratory actions of annexin 1 and its mimetics. 
Am J Pathol, 158, 1969-73. 
PERRETTI, M., WHELLER, S. K., FLOWER, R. J., WAHID, 
S. & PITZALIS, C. 1999. Modulation of cellular 
annexin I in human leukocytes infiltrating DTH skin 
reactions. J Leukoc Biol, 65, 583-9. 
PFAFFL, M. W. 2001. A new mathematical model for 
relative quantification in real-time RT-PCR. Nucleic 
Acids Res, 29, e45. 
PIERRE, P., TURLEY, S. J., GATTI, E., HULL, M., 
MELTZER, J., MIRZA, A., INABA, K., STEINMAN, R. 
M. & MELLMAN, I. 1997. Developmental regulation 
of MHC class II transport in mouse dendritic cells. 
Nature, 388, 787-92. 
POOLEY, J. L., HEATH, W. R. & SHORTMAN, K. 2001. 
Cutting edge: intravenous soluble antigen is 
presented to CD4 T cells by CD8- dendritic cells, 
but cross-presented to CD8 T cells by CD8+ 
dendritic cells. J Immunol, 166, 5327-30. 
PRUD'HOMME, G. J. 2004. Altering immune tolerance 
therapeutically: the power of negative thinking. J 
Leukoc Biol, 75, 586-99. 
PULENDRAN, B., LINGAPPA, J., KENNEDY, M. K., 
SMITH, J., TEEPE, M., RUDENSKY, A., 
MALISZEWSKI, C. R. & MARASKOVSKY, E. 1997. 
Developmental pathways of dendritic cells in vivo: 
 239 
distinct function, phenotype, and localization of 
dendritic cell subsets in FLT3 ligand-treated mice. J 
Immunol, 159, 2222-31. 
RAMSEY, C., HASSLER, S., MARITS, P., KAMPE, O., 
SURH, C. D., PELTONEN, L. & WINQVIST, O. 2006. 
Increased antigen presenting cell-mediated T cell 
activation in mice and patients without the 
autoimmune regulator. Eur J Immunol, 36, 305-
17. 
RANDOLPH, G. J. 2001. Dendritic cell migration to 
lymph nodes: cytokines, chemokines, and lipid 
mediators. Semin Immunol, 13, 267-74. 
RANDOLPH, G. J., BEAULIEU, S., LEBECQUE, S., 
STEINMAN, R. M. & MULLER, W. A. 1998. 
Differentiation of monocytes into dendritic cells in 
a model of transendothelial trafficking. Science, 
282, 480-3. 
RANDOLPH, G. J., INABA, K., ROBBIANI, D. F., 
STEINMAN, R. M. & MULLER, W. A. 1999. 
Differentiation of phagocytic monocytes into lymph 
node dendritic cells in vivo. Immunity, 11, 753-61. 
RANDOLPH, G. J., SANCHEZ-SCHMITZ, G., LIEBMAN, R. 
M. & SCHAKEL, K. 2002. The CD16(+) 
(FcgammaRIII(+)) subset of human monocytes 
preferentially becomes migratory dendritic cells in 
a model tissue setting. J Exp Med, 196, 517-27. 
RANTAPÄÄ-DAHLQVIST, S., DE JONG, B. A., BERGLIN, 
E., HALLMANS, G., WADELL, G., STENLUND, H., 
SUNDIN, U. & VAN VENROOIJ, W. J. 2003. 
Antibodies against cyclic citrullinated peptide and 
IgA rheumatoid factor predict the development of 
rheumatoid arthritis. Arthritis & Rheumatism, 48, 
2741-9. 
 240 
RAYNAL, P. & POLLARD, H. B. 1994. Annexins: the 
problem of assessing the biological role for a gene 
family of multifunctional calcium- and 
phospholipid-binding proteins. Biochim Biophys 
Acta, 1197, 63-93. 
REIS E SOUSA, C. 2004a. Activation of dendritic cells: 
translating innate into adaptive immunity. Curr 
Opin Immunol, 16, 21-5. 
REIS E SOUSA, C. 2004b. Toll-like receptors and 
dendritic cells: for whom the bug tolls. Semin 
Immunol, 16, 27-34. 
REIS E SOUSA, C., DIEBOLD, S. D., EDWARDS, A. D., 
ROGERS, N., SCHULZ, O. & SPORRI, R. 2003. 
Regulation of dendritic cell function by microbial 
stimuli. Pathol Biol (Paris), 51, 67-8. 
RENSHAW, D., MONTERO-MELENDEZ, T., DALLI, J., 
KAMAL, A., BRANCALEONE, V., D'ACQUISTO, F., 
CIRINO, G. & PERRETTI, M. 2010. Downstream 
gene activation of the receptor ALX by the agonist 
annexin A1. PLoS ONE, 5. 
RESCHER, U., GOEBELER, V., WILBERS, A. & GERKE, V. 
2006. Proteolytic cleavage of annexin 1 by human 
leukocyte elastase. Biochim Biophys Acta, 1763, 
1320-4. 
RHEN, T. & CIDLOWSKI, J. A. 2005. Antiinflammatory 
action of glucocorticoids--new mechanisms for old 
drugs. N Engl J Med, 353, 1711-23. 
RIZZITELLI, A., HAWKINS, E., TODD, H., HODGKIN, P. 
D. & SHORTMAN, K. 2006. The proliferative 
response of CD4 T cells to steady-state CD8+ 
dendritic cells is restricted by post-activation 
death. Int Immunol, 18, 415-23. 
 241 
RODRÍGUEZ-PINTO, D. 2005. B cells as antigen 
presenting cells. Cell Immunol, 238, 67-75. 
ROSE, A. J., VEGIOPOULOS, A. & HERZIG, S. 2010. 
Role of glucocorticoids and the glucocorticoid 
receptor in metabolism: insights from genetic 
manipulations. J Steroid Biochem Mol Biol, 122, 
10-20. 
ROSENGARTH, A. & LUECKE, H. 2003. A calcium-driven 
conformational switch of the N-terminal and core 
domains of annexin A1. J Mol Biol, 326, 1317-25. 
RUDD, C. E. 2009. CTLA-4 co-receptor impacts on the 
function of Treg and CD8+ T-cell subsets. Eur J 
Immunol, 39, 687-90. 
RUTELLA, S., DANESE, S. & LEONE, G. 2006. 
Tolerogenic dendritic cells: cytokine modulation 
comes of age. Blood, 108, 1435-40. 
SAITO, S., SHIOZAKI, A., SASAKI, Y., NAKASHIMA, A., 
SHIMA, T. & ITO, M. 2007. Regulatory T cells and 
regulatory natural killer (NK) cells play important 
roles in feto-maternal tolerance. Semin 
Immunopathol, 29, 115-22. 
SAKAGUCHI, S. 2003. Regulatory T cells: mediating 
compromises between host and parasite. Nat 
Immunol, 4, 10-1. 
SAKAGUCHI, S., SAKAGUCHI, N., ASANO, M., ITOH, M. 
& TODA, M. 1995. Immunologic self-tolerance 
maintained by activated T cells expressing IL-2 
receptor alpha-chains (CD25). Breakdown of a 
single mechanism of self-tolerance causes various 
autoimmune diseases. J Immunol, 155, 1151-64. 
 242 
SAKAGUCHI, S., SAKAGUCHI, N., SHIMIZU, J., 
YAMAZAKI, S., SAKIHAMA, T., ITOH, M., 
KUNIYASU, Y., NOMURA, T., TODA, M. & 
TAKAHASHI, T. 2001. Immunologic tolerance 
maintained by CD25+ CD4+ regulatory T cells: 
their common role in controlling autoimmunity, 
tumor immunity, and transplantation tolerance. 
Immunol Rev, 182, 18-32. 
SAKAGUCHI, S., TAKAHASHI, T. & NISHIZUKA, Y. 
1982. Study on cellular events in post-thymectomy 
autoimmune oophoritis in mice. II. Requirement of 
Lyt-1 cells in normal female mice for the 
prevention of oophoritis. J Exp Med, 156, 1577-86. 
SAKAGUCHI, S., YAMAGUCHI, T., NOMURA, T. & ONO, 
M. 2008. Regulatory T cells and immune tolerance. 
Cell, 133, 775-87. 
SALLUSTO, F., CELLA, M., DANIELI, C. & 
LANZAVECCHIA, A. 1995. Dendritic cells use 
macropinocytosis and the mannose receptor to 
concentrate macromolecules in the major 
histocompatibility complex class II compartment: 
downregulation by cytokines and bacterial 
products. J Exp Med, 182, 389-400. 
SALLUSTO, F. & LANZAVECCHIA, A. 1994. Efficient 
presentation of soluble antigen by cultured human 
dendritic cells is maintained by 
granulocyte/macrophage colony-stimulating factor 
plus interleukin 4 and downregulated by tumor 
necrosis factor alpha. J Exp Med, 179, 1109-18. 
SALLUSTO, F. & LANZAVECCHIA, A. 2000. 
Understanding dendritic cell and T-lymphocyte 
traffic through the analysis of chemokine receptor 
expression. Immunol Rev, 177, 134-40. 
 243 
SALLUSTO, F., PALERMO, B., LENIG, D., MIETTINEN, 
M., MATIKAINEN, S., JULKUNEN, I., FORSTER, R., 
BURGSTAHLER, R., LIPP, M. & LANZAVECCHIA, A. 
1999. Distinct patterns and kinetics of chemokine 
production regulate dendritic cell function. Eur J 
Immunol, 29, 1617-25. 
SALOMON, B., LENSCHOW, D. J., RHEE, L., 
ASHOURIAN, N., SINGH, B., SHARPE, A. & 
BLUESTONE, J. A. 2000. B7/CD28 costimulation is 
essential for the homeostasis of the CD4+CD25+ 
immunoregulatory T cells that control autoimmune 
diabetes. Immunity, 12, 431-40. 
SANCHEZ-SANCHEZ, N., RIOL-BLANCO, L. & 
RODRIGUEZ-FERNANDEZ, J. L. 2006. The multiple 
personalities of the chemokine receptor CCR7 in 
dendritic cells. J Immunol, 176, 5153-9. 
SATO, K. & FUJITA, S. 2007. Dendritic cells: nature and 
classification. Allergol Int, 56, 183-91. 
SATO, S., SUGIYAMA, M., YAMAMOTO, M., WATANABE, 
Y., KAWAI, T., TAKEDA, K. & AKIRA, S. 2003. 
Toll/IL-1 receptor domain-containing adaptor 
inducing IFN-beta (TRIF) associates with TNF 
receptor-associated factor 6 and TANK-binding 
kinase 1, and activates two distinct transcription 
factors, NF-kappa B and IFN-regulatory factor-3, in 
the Toll-like receptor signaling. J Immunol, 171, 
4304-10. 
SATTERTHWAITE, A. B., BURN, T. C., LE BEAU, M. M. & 
TENEN, D. G. 1992. Structure of the gene 
encoding CD34, a human hematopoietic stem cell 
antigen. Genomics, 12, 788-94. 
SAWMYNADEN, P. & PERRETTI, M. 2006. Glucocorticoid 
upregulation of the annexin-A1 receptor in 
 244 
leukocytes. Biochem Biophys Res Commun, 349, 
1351-5. 
SCHEINECKER, C., MCHUGH, R., SHEVACH, E. M. & 
GERMAIN, R. N. 2002. Constitutive presentation of 
a natural tissue autoantigen exclusively by 
dendritic cells in the draining lymph node. J Exp 
Med, 196, 1079-90. 
SCHMIDT, K. N., AMSTAD, P., CERUTTI, P. & 
BAEUERLE, P. A. 1995a. The roles of hydrogen 
peroxide and superoxide as messengers in the 
activation of transcription factor NF-kappa B. 
Chem Biol, 2, 13-22. 
SCHMIDT, K. N., TRAENCKNER, E. B., MEIER, B. & 
BAEUERLE, P. A. 1995b. Induction of oxidative 
stress by okadaic acid is required for activation of 
transcription factor NF-kappa B. J Biol Chem, 270, 
27136-42. 
SCHULZ, O., EDWARDS, A. D., SCHITO, M., ALIBERTI, 
J., MANICKASINGHAM, S., SHER, A. & REIS E 
SOUSA, C. 2000. CD40 triggering of heterodimeric 
IL-12 p70 production by dendritic cells in vivo 
requires a microbial priming signal. Immunity, 13, 
453-62. 
SCOTT, M. L., FUJITA, T., LIOU, H. C., NOLAN, G. P. & 
BALTIMORE, D. 1993. The p65 subunit of NF-
kappa B regulates I kappa B by two distinct 
mechanisms. Genes Dev, 7, 1266-76. 
SERHAN, C. N., BRAIN, S. D., BUCKLEY, C. D., GILROY, 
D. W., HASLETT, C., O'NEILL L, A., PERRETTI, M., 
ROSSI, A. G. & WALLACE, J. L. 2006. Resolution of 
inflammation: state of the art, definitions and 
terms. Faseb J. 
 245 
SERHAN, C. N. & SAVILL, J. 2005. Resolution of 
inflammation: the beginning programs the end. 
Nat Immunol, 6, 1191-1197. 
SHANKAR, G., BADER, R. & LODGE, P. A. 2004. The 
COSTIM bioassay: a novel potency test for 
dendritic cells. J Immunol Methods, 285, 293-9. 
SHARMA, S., TENOEVER, B. R., GRANDVAUX, N., 
ZHOU, G. P., LIN, R. & HISCOTT, J. 2003. 
Triggering the interferon antiviral response 
through an IKK-related pathway. Science, 300, 
1148-51. 
SHEVACH, E. M. 2002. CD4+ CD25+ suppressor T 
cells: more questions than answers. Nat Rev 
Immunol, 2, 389-400. 
SHORTMAN, K. 2000. Burnet oration: dendritic cells: 
multiple subtypes, multiple origins, multiple 
functions. Immunol Cell Biol, 78, 161-5. 
SHORTMAN, K. & LIU, Y. J. 2002. Mouse and human 
dendritic cell subtypes. Nat Rev Immunol, 2, 151-
61. 
SIEBENLIST, U., FRANZOSO, G. & BROWN, K. 1994. 
Structure, regulation and function of NF-kappa B. 
Annual review of cell biology, 10, 405-55. 
SILVERSTEIN, S. C., STEINMAN, R. M. & COHN, Z. A. 
1977. Endocytosis. Annu Rev Biochem, 46, 669-
722. 
SIMMONS, D. L., SATTERTHWAITE, A. B., TENEN, D. G. 
& SEED, B. 1992. Molecular cloning of a cDNA 
encoding CD34, a sialomucin of human 
hematopoietic stem cells. Journal of immunology 
(Baltimore, Md : 1950), 148, 267-71. 
 246 
SINGH, P. K., PARSEK, M. R., GREENBERG, E. P. & 
WELSH, M. J. 2002. A component of innate 
immunity prevents bacterial biofilm development. 
Nature, 417, 552-555. 
SIXT, M., KANAZAWA, N., SELG, M., SAMSON, T., 
ROOS, G., REINHARDT, D. P., PABST, R., LUTZ, M. 
B. & SOROKIN, L. 2005. The conduit system 
transports soluble antigens from the afferent 
lymph to resident dendritic cells in the T cell area 
of the lymph node. Immunity, 22, 19-29. 
SMITH, E., ZARBOCK, A., STARK, M. A., BURCIN, T. L., 
BRUCE, A. C., FOLEY, P. & LEY, K. 2007. IL-23 is 
required for neutrophil homeostasis in normal and 
neutrophilic mice. J Immunol, 179, 8274-9. 
SMITS, H. H., DE JONG, E. C., WIERENGA, E. A. & 
KAPSENBERG, M. L. 2005. Different faces of 
regulatory DCs in homeostasis and immunity. 
Trends Immunol, 26, 123-9. 
SOLITO, E., KAMAL, A., RUSSO-MARIE, F., 
BUCKINGHAM, J. C., MARULLO, S. & PERRETTI, M. 
2003. A novel calcium-dependent proapoptotic 
effect of annexin 1 on human neutrophils. FASEB 
J, 17, 1544-6. 
SPONAAS, A. M., CADMAN, E. T., VOISINE, C., 
HARRISON, V., BOONSTRA, A., O'GARRA, A. & 
LANGHORNE, J. 2006. Malaria infection changes 
the ability of splenic dendritic cell populations to 
stimulate antigen-specific T cells. J Exp Med, 203, 
1427-33. 
SPURR, L., NADKARNI, S., PEDERZOLI-RIBEIL, M., 
GOULDING, N. J., PERRETTI, M. & D'ACQUISTO, F. 
2011. Comparative analysis of Annexin A1-formyl 
peptide receptor 2/ALX expression in human 
 247 
leukocyte subsets. Int Immunopharmacol, 11, 55-
66. 
STARK, M. A., HUO, Y., BURCIN, T. L., MORRIS, M. A., 
OLSON, T. S. & LEY, K. 2005. Phagocytosis of 
apoptotic neutrophils regulates granulopoiesis via 
IL-23 and IL-17. Immunity, 22, 285-94. 
STEINMAN, R. M. 1991. The dendritic cell system and 
its role in immunogenicity. Annu Rev Immunol, 9, 
271-96. 
STEINMAN, R. M. & COHN, Z. A. 1973. Identification of 
a novel cell type in peripheral lymphoid organs of 
mice. I. Morphology, quantitation, tissue 
distribution. J Exp Med, 137, 1142-62. 
STEINMAN, R. M., HAWIGER, D. & NUSSENZWEIG, M. 
C. 2003. Tolerogenic dendritic cells. Annu Rev 
Immunol, 21, 685-711. 
STEINMAN, R. M. & HEMMI, H. 2006. Dendritic cells: 
translating innate to adaptive immunity. Curr Top 
Microbiol Immunol, 311, 17-58. 
STEINMAN, R. M., TURLEY, S., MELLMAN, I. & INABA, 
K. 2000. The induction of tolerance by dendritic 
cells that have captured apoptotic cells. J Exp Med, 
191, 411-6. 
STEINMAN, R. M., WITMER, M. D., NUSSENZWEIG, M. 
C., CHEN, L. L., SCHLESINGER, S. & COHN, Z. A. 
1980. Dendritic cells of the mouse: identification 
and characterization. J Invest Dermatol, 75, 14-6. 
STOCKINGER, B. 1999. T lymphocyte tolerance: from 
thymic deletion to peripheral control mechanisms. 
Adv Immunol, 71, 229-65. 
 248 
STOCKINGER, B., VELDHOEN, M. & MARTIN, B. 2007. 
Th17 T cells: linking innate and adaptive 
immunity. Semin Immunol, 19, 353-61. 
STROBL, H., RIEDL, E., SCHEINECKER, C., BELLO-
FERNANDEZ, C., PICKL, W. F., RAPPERSBERGER, 
K., MAJDIC, O. & KNAPP, W. 1996. TGF-beta 1 
promotes in vitro development of dendritic cells 
from CD34+ hemopoietic progenitors. J Immunol, 
157, 1499-507. 
SUN, S., GANCHI, P., BALLARD, D. & GREENE, W. 
1993. NF-kappa B controls expression of inhibitor I 
kappa B alpha: evidence for an inducible 
autoregulatory pathway. Science, 259, 1912-1915. 
SUSS, G. & SHORTMAN, K. 1996. A subclass of 
dendritic cells kills CD4 T cells via Fas/Fas-ligand-
induced apoptosis. J Exp Med, 183, 1789-96. 
SUYANG, H., PHILLIPS, R., DOUGLAS, I. & GHOSH, S. 
1996. Role of unphosphorylated, newly 
synthesized I kappa B beta in persistent activation 
of NF-kappa B. Mol Cell Biol, 16, 5444-9. 
SVENSSON, M., STOCKINGER, B. & WICK, M. J. 1997. 
Bone marrow-derived dendritic cells can process 
bacteria for MHC-I and MHC-II presentation to T 
cells. J Immunol, 158, 4229-36. 
TAKEDA, K. & AKIRA, S. 2004. Microbial recognition by 
Toll-like receptors. J Dermatol Sci, 34, 73-82. 
TAKEDA, K. & AKIRA, S. 2005. Toll-like receptors in 
innate immunity. Int Immunol, 17, 1-14. 
THANOS, D. & MANIATIS, T. 1995. NF-kappa B: a 
lesson in family values. Cell, 80, 529-32. 
 249 
THOMPSON, J. E., PHILLIPS, R. J., ERDJUMENT-
BROMAGE, H., TEMPST, P. & GHOSH, S. 1995. I 
kappa B-beta regulates the persistent response in 
a biphasic activation of NF-kappa B. Cell, 80, 573-
82. 
THORNTON, A. M., DONOVAN, E. E., PICCIRILLO, C. A. 
& SHEVACH, E. M. 2004. Cutting edge: IL-2 is 
critically required for the in vitro activation of 
CD4+CD25+ T cell suppressor function. J 
Immunol, 172, 6519-23. 
TRAENCKNER, E. B., PAHL, H. L., HENKEL, T., 
SCHMIDT, K. N., WILK, S. & BAEUERLE, P. A. 
1995. Phosphorylation of human I kappa B-alpha 
on serines 32 and 36 controls I kappa B-alpha 
proteolysis and NF-kappa B activation in response 
to diverse stimuli. Embo J, 14, 2876-83. 
TRAVERSO, V., CHRISTIAN, H. C., MORRIS, J. F. & 
BUCKINGHAM, J. C. 1999. Lipocortin 1 (annexin 
1): a candidate paracrine agent localized in 
pituitary folliculo-stellate cells. Endocrinology, 140, 
4311-9. 
URBAN, B. C., FERGUSON, D. J., PAIN, A., WILLCOX, 
N., PLEBANSKI, M., AUSTYN, J. M. & ROBERTS, D. 
J. 1999. Plasmodium falciparum-infected 
erythrocytes modulate the maturation of dendritic 
cells. Nature, 400, 73-7. 
URBAN, B. C., MWANGI, T., ROSS, A., KINYANJUI, S., 
MOSOBO, M., KAI, O., LOWE, B., MARSH, K. & 
ROBERTS, D. J. 2001. Peripheral blood dendritic 
cells in children with acute Plasmodium falciparum 
malaria. Blood, 98, 2859-61. 
 250 
VABULAS, R. M., WAGNER, H. & SCHILD, H. 2002. Heat 
shock proteins as ligands of toll-like receptors. 
Curr Top Microbiol Immunol, 270, 169-84. 
VAN DER AAR, A. M., SYLVA-STEENLAND, R. M., BOS, 
J. D., KAPSENBERG, M. L., DE JONG, E. C. & 
TEUNISSEN, M. B. 2007. Loss of TLR2, TLR4, and 
TLR5 on Langerhans cells abolishes bacterial 
recognition. J Immunol, 178, 1986-90. 
VAN DUIVENVOORDE, L. M., VAN MIERLO, G. J., 
BOONMAN, Z. F. & TOES, R. E. 2006. Dendritic 
cells: vehicles for tolerance induction and 
prevention of autoimmune diseases. 
Immunobiology, 211, 627-32. 
VERMAELEN, K. Y., CARRO-MUINO, I., LAMBRECHT, B. 
N. & PAUWELS, R. A. 2001. Specific migratory 
dendritic cells rapidly transport antigen from the 
airways to the thoracic lymph nodes. J Exp Med, 
193, 51-60. 
VILLADANGOS, J. A. & SHORTMAN, K. 2010. Found in 
translation: the human equivalent of mouse CD8+ 
dendritic cells. J Exp Med, 207, 1131-4. 
VOIGTLANDER, C., ROSSNER, S., CIERPKA, E., 
THEINER, G., WIETHE, C., MENGES, M., SCHULER, 
G. & LUTZ, M. B. 2006. Dendritic cells matured 
with TNF can be further activated in vitro and after 
subcutaneous injection in vivo which converts their 
tolerogenicity into immunogenicity. J Immunother, 
29, 407-15. 
VOLKMANN, A., NEEFJES, J. & STOCKINGER, B. 1996. 
A conditionally immortalized dendritic cell line 
which differentiates in contact with T cells or T 
cell-derived cytokines. Eur J Immunol, 26, 2565-
72. 
 251 
VOLKMANN, A., ZAL, T. & STOCKINGER, B. 1997. 
Antigen-presenting cells in the thymus that can 
negatively select MHC class II-restricted T cells 
recognizing a circulating self antigen. J Immunol, 
158, 693-706. 
VONG, L., D'ACQUISTO, F., PEDERZOLI-RIBEIL, M., 
LAVAGNO, L., FLOWER, R. J., WITKO-SARSAT, V. 
& PERRETTI, M. 2007. Annexin 1 cleavage in 
activated neutrophils: a pivotal role for proteinase 
3. J Biol Chem, 282, 29998-30004. 
VREMEC, D., POOLEY, J., HOCHREIN, H., WU, L. & 
SHORTMAN, K. 2000. CD4 and CD8 expression by 
dendritic cell subtypes in mouse thymus and 
spleen. J Immunol, 164, 2978-86. 
WAGNER, H. 2001. Toll meets bacterial CpG-DNA. 
Immunity, 14, 499-502. 
WAGNER, H. 2004. The immunobiology of the TLR9 
subfamily. Trends Immunol, 25, 381-6. 
WALTHER, A., RIEHEMANN, K. & GERKE, V. 2000. A 
novel ligand of the formyl peptide receptor: 
annexin I regulates neutrophil extravasation by 
interacting with the FPR. Mol Cell, 5, 831-40. 
WANG, Y. H., ITO, T., HOMEY, B., WATANABE, N., 
MARTIN, R., BARNES, C. J., MCINTYRE, B. W., 
GILLIET, M., KUMAR, R., YAO, Z. & LIU, Y. J. 2006. 
Maintenance and polarization of human TH2 
central memory T cells by thymic stromal 
lymphopoietin-activated dendritic cells. Immunity, 
24, 827-38. 
WANG, Z. G. & YE, R. D. 2002. Characterization of two 
new members of the formyl peptide receptor gene 
family from 129S6 mice. Gene, 299, 57-63. 
 252 
WEINER, H. L., DA CUNHA, A. P., QUINTANA, F. & WU, 
H. 2011. Oral tolerance. Immunol Rev, 241, 241-
59. 
WEISS, A. & LITTMAN, D. R. 1994. Signal transduction 
by lymphocyte antigen receptors. Cell, 76, 263-74. 
WEISSMANN, G., SMOLEN, J. E. & HOFFSTEIN, S. 
1978. Polymorphonuclear Leukocytes as Secretory 
Organs of Inflammation. J Investig Dermatol, 71, 
95-99. 
WILCKENS, T. 1995. Glucocorticoids and immune 
function: physiological relevance and pathogenic 
potential of hormonal dysfunction. Trends 
Pharmacol Sci, 16, 193-7. 
WILCKENS, T. & DE RIJK, R. 1997. Glucocorticoids and 
immune function: unknown dimensions and new 
frontiers. Immunol Today, 18, 418-24. 
WILLE, J. J. & KYDONIEUS, A. 2003. Palmitoleic acid 
isomer (C16:1delta6) in human skin sebum is 
effective against gram-positive bacteria. Skin 
Pharmacol Appl Skin Physiol, 16, 176-87. 
WILSON, N. S., EL-SUKKARI, D., BELZ, G. T., SMITH, 
C. M., STEPTOE, R. J., HEATH, W. R., SHORTMAN, 
K. & VILLADANGOS, J. A. 2003. Most lymphoid 
organ dendritic cell types are phenotypically and 
functionally immature. Blood, 102, 2187-94. 
WINKEL, K., SOTZIK, F., VREMEC, D., CAMERON, P. U. 
& SHORTMAN, K. 1994. CD4 and CD8 expression 
by human and mouse thymic dendritic cells. 
Immunol Lett, 40, 93-9. 
WINKEL, K. D., KRONIN, V., KRUMMEL, M. F. & 
SHORTMAN, K. 1997. The nature of the signals 
 253 
regulating CD8 T cell proliferative responses to 
CD8alpha+ or CD8alpha- dendritic cells. Eur J 
Immunol, 27, 3350-9. 
WINZLER, C., ROVERE, P., RESCIGNO, M., GRANUCCI, 
F., PENNA, G., ADORINI, L., ZIMMERMANN, V. S., 
DAVOUST, J. & RICCIARDI-CASTAGNOLI, P. 1997. 
Maturation stages of mouse dendritic cells in 
growth factor-dependent long-term cultures. J Exp 
Med, 185, 317-28. 
WU, L. & DAKIC, A. 2004. Development of dendritic cell 
system. Cell Mol Immunol, 1, 112-8. 
YAMAMOTO, M. & AKIRA, S. 2005. TIR domain-
containing adaptors regulate TLR signaling 
pathways. Adv Exp Med Biol, 560, 1-9. 
YAMAMOTO, M., SATO, S., HEMMI, H., HOSHINO, K., 
KAISHO, T., SANJO, H., TAKEUCHI, O., 
SUGIYAMA, M., OKABE, M., TAKEDA, K. & AKIRA, 
S. 2003a. Role of adaptor TRIF in the MyD88-
independent toll-like receptor signaling pathway. 
Science, 301, 640-3. 
YAMAMOTO, M., SATO, S., HEMMI, H., UEMATSU, S., 
HOSHINO, K., KAISHO, T., TAKEUCHI, O., 
TAKEDA, K. & AKIRA, S. 2003b. TRAM is 
specifically involved in the Toll-like receptor 4-
mediated MyD88-independent signaling pathway. 
Nat Immunol, 4, 1144-50. 
YAMAZAKI, S., DUDZIAK, D., HEIDKAMP, G. F., 
FIORESE, C., BONITO, A. J., INABA, K., 
NUSSENZWEIG, M. C. & STEINMAN, R. M. 2008. 
CD8+ CD205+ splenic dendritic cells are 
specialized to induce Foxp3+ regulatory T cells. J 
Immunol, 181, 6923-33. 
 254 
YANG, D., CHEN, Q., GERTZ, B., HE, R., 
PHULSUKSOMBATI, M., YE, R. D. & OPPENHEIM, J. 
J. 2002. Human dendritic cells express functional 
formyl peptide receptor-like-2 (FPRL2) throughout 
maturation. J Leukoc Biol, 72, 598-607. 
YAROVINSKY, F., KANZLER, H., HIENY, S., COFFMAN, 
R. L. & SHER, A. 2006. Toll-like receptor 
recognition regulates immunodominance in an 
antimicrobial CD4+ T cell response. Immunity, 25, 
655-64. 
YAROVINSKY, F., ZHANG, D., ANDERSEN, J. F., 
BANNENBERG, G. L., SERHAN, C. N., HAYDEN, M. 
S., HIENY, S., SUTTERWALA, F. S., FLAVELL, R. A., 
GHOSH, S. & SHER, A. 2005. TLR11 activation of 
dendritic cells by a protozoan profilin-like protein. 
Science, 308, 1626-9. 
YE, R. D., BOULAY, F., WANG, J. M., DAHLGREN, C., 
GERARD, C., PARMENTIER, M., SERHAN, C. N. & 
MURPHY, P. M. 2009. International Union of Basic 
and Clinical Pharmacology. LXXIII. Nomenclature 
for the formyl peptide receptor (FPR) family. 
Pharmacol Rev, 61, 119-61. 
YEAGER, M. P., GUYRE, P. M. & MUNCK, A. U. 2004. 
Glucocorticoid regulation of the inflammatory 
response to injury. Acta Anaesthesiol Scand, 48, 
799-813. 
YOSHIMURA, S., BONDESON, J., FOXWELL, B. M., 
BRENNAN, F. M. & FELDMANN, M. 2001. Effective 
antigen presentation by dendritic cells is NF-
kappaB dependent: coordinate regulation of MHC, 
co-stimulatory molecules and cytokines. Int 
Immunol, 13, 675-83. 
 255 
ZEUTHEN, L. H., FINK, L. N. & FROKIAER, H. 2008. 
Toll-like receptor 2 and nucleotide-binding 
oligomerization domain-2 play divergent roles in 
the recognition of gut-derived lactobacilli and 
bifidobacteria in dendritic cells. Immunology, 124, 
489-502. 
ZHOU, L. J. & TEDDER, T. F. 1995. A distinct pattern of 
cytokine gene expression by human CD83+ blood 
dendritic cells. Blood, 86, 3295-301. 
 
 
